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ABSTRACT
SNFing Glucose to PASs Mitochondrial Mitochondrial Dysfunction: The Role
of Two Sensory Protein Kinases
in Metabolic Diseases
Kai Li Ong
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
Mitochondria is no longer viewed as merely a powerhouse of the cell. It is now apparent
that mitochondria play a central role in signaling, maintaining cellular homeostasis and cell fate.
Mitochondrial dysfunction has been linked to many human diseases caused by cellular metabolic
deregulation, such as obesity, diabetes, neurodegenerative disease, cardiovascular disease and
cancer. Eukaryotic organisms have evolved an efficient way in sensing, communicating and
responding to cellular stress and regulating mitochondrial activity correspondingly through a
complex network of intercommunicating protein kinases and their downstream effectors. This
dissertation focuses on the interplay of two of the master metabolic regulators in the cell: AMPK
and PASK, and characterization of the functions of their downstream substrates: OSBP and
MED13. AMPK is an energy sensing kinase that maintains energy homeostasis in the cell,
whereas PASK is a nutrient sensing kinase that regulates glucose partitioning and respiration in
the cell. Both kinases play important roles in mitochondrial function and regulation, and
deficiency in either kinase has been found to associate with various human pathologies. Further
characterization of the cross-talk and molecular mechanisms of both kinases in controlling
mitochondrial health and function may aid in the identification of new targets for treating
metabolic diseases.

Keywords: AMP-activated Kinase; SNF1; Oxysterol binding protein; OSBP; Osh6; Osh7;
ORP5; ORP8; PAS Kinase; Med13; cyclin C; mitochondria function; mitochondria dynamic;
mitophagy

ACKNOWLEDGMENTS
I would like to thank my advisor, Julianne Grose, who believed in my ability and gave
me the opportunity to come and work with her back in September 2014, which has permanently
changed my life. Without her faith in me, I would not be here today. Together we have been
through thick and thin, the good times and the hard times, the laughter, the sweat, the blood and
the tears. I have learned and grown so much from being in her lab and am forever grateful for
her. I also want to give a big thank you to all my amazing committee members, for all their
patience, support and guidance; for cheering me on for 5 years and helping me become the
scientist I am today. I could not ask for a better committee. I also want to give special thanks to
Kim O’Neill, for lifting my spirit whenever I felt discouraged and getting me through hard times
from the very beginning. I am forever thankful to all the people that have supported me along the
way, either physically, mentally or both—my husband, my mom, my brother, my mentors at
BYUH: Shane Gold and Mark Cannon, all the wonderful friends that have been there for me—
Evita Weagel, Edwin Velazquez, Stewart Morley, Deborah Johnson, Kiara Vaden, Nidhi Choksi,
Ruchira Sharma, Denise Ng, Elise Melhado, Trevor Thurgood, Brooke Cozzens and all the
present and past Grose lab members, O’Neill lab members, and the collaborators. I am thankful
for everyone in the MMBIO Department who have let me borrow reagents/ instruments here and
there in times of need. I am forever grateful for our friendships and grateful that we crossed paths
during this time in our lives.
The list of people I would like to thank goes on. I would like to dedicate this work to all
of you, because my life would not be the same without you.

TABLE OF CONTENTS
TITLE PAGE ................................................................................................................................... i
ABSTRACT.................................................................................................................................... ii
ACKNOWLEDGMENTS ............................................................................................................. iii
TABLE OF CONTENTS............................................................................................................... iv
LIST OF FIGURES ........................................................................................................................ x
LIST OF TABLES ....................................................................................................................... xiii
CHAPTER 1: Role of Mitochondrial Dysfunction and Metabolic Diseases .................................. 1
1.1 Introduction ........................................................................................................................... 1
1.1.1 Role of AMPK in mitochondrial function and metabolic diseases ................................ 3
1.1.2 Conserved signaling of AMPK-PASK from yeast to man ............................................. 7
1.2 Conclusion ........................................................................................................................... 10
CHAPTER 2: Differential Regulation and Function Support Paralogous Evolution of Yeast Osh6
and Osh7 ....................................................................................................................................... 11
2.1 Author information .............................................................................................................. 11
2.2 Abbreviations ...................................................................................................................... 12
2.3 Abstract ............................................................................................................................... 13
2.4 Introduction ......................................................................................................................... 13
2.5 Results ................................................................................................................................. 15

iv

2.5.1 Evolutionary relationships of OSBP families supports a close relationship between
Osh6 and Osh7....................................................................................................................... 15
2.5.2 AMPK/ Snf1 phosphorylates ORP8/ Osh7 directly but not Osh6................................ 15
2.5.3 Evidence for the direct interaction and stabilization of Osh7 by SNF1 ....................... 18
2.5.4 Osh7, but not Osh6, co-localizes with mdm34; Snf1 does not affect Osh7 localization
............................................................................................................................................... 21
2.5.5 Both Osh6 and Osh7 plays a role in mitochondrial function; with Osh6 playing a more
prominent role........................................................................................................................ 23
2.6 Conclusions ......................................................................................................................... 27
2.7 Experimental procedures ..................................................................................................... 28
2.7.1 Yeast Strains, plasmids and primers ............................................................................. 28
2.7.2 Growth media ............................................................................................................... 32
2.7.3 In vitro kinase assays .................................................................................................... 33
2.7.4 Yeast-2-hybrid assays ................................................................................................... 35
2.7.5 Co-IP of Osh6/ Osh7 with Snf1.................................................................................... 35
2.7.6 Stability assays ............................................................................................................. 36
2.7.7 Microscopy for Osh6-YFP and Osh7-YFP localization ............................................... 36
2.7.8 Florescent microscopy mitochondria morphology ....................................................... 37
2.7.9 Plate testing for respiration ........................................................................................... 37
2.7.10 Whole yeast seahorse respiration assay ...................................................................... 37

v

2.7.11 Mitophagy assays ....................................................................................................... 38
2.8 Supplementary methods ...................................................................................................... 39
2.8.1 Cell culturing and culture plate preparation ................................................................. 39
2.8.2 Sensor cartridge and drug preparation .......................................................................... 40
2.8.3 OCR normalization and XFp analyzer settings ............................................................ 41
CHAPTER 3: PAS kinase Regulates Cyclin C Localization in Yeast Through Direct
Phosphorylation ............................................................................................................................ 42
3.1 Author information .............................................................................................................. 42
3.2 Abbreviations ...................................................................................................................... 43
3.3 Abstract ............................................................................................................................... 44
3.4 Introduction ......................................................................................................................... 44
3.5 Results ................................................................................................................................. 46
3.5.1 PAS kinase 1 (Psk1) interacts with Med13 in vivo ...................................................... 46
3.5.2 Psk1 phosphorylates Med13 in vitro ............................................................................ 46
3.5.3 Psk1 is required for Med13 degradation in response to carbon stress.......................... 48
3.5.4 Psk1 affects localization of cyclin C and its nuclear release upon oxidative stress ..... 50
3.6 Conclusions ......................................................................................................................... 51
3.7 Experimental procedure ...................................................................................................... 54
3.7.1 In vitro kinase assay ..................................................................................................... 54
3.7.2 Cyclin C-YFP nuclear release microscopy ................................................................... 55
vi

3.7.3 Yeast-2-Hybrid Assay .................................................................................................. 56
CHAPTER 4: Concluding Remarks ............................................................................................. 57
APPENDIX 1: Snf1 Cooperates with the CWI MAPK Pathway to Mediate the Degradation of
Med13 Following Oxidative Stress .............................................................................................. 60
A1.1 Author information ........................................................................................................... 60
A1.2 Abbreviations ................................................................................................................... 61
A1.3 Keywords.......................................................................................................................... 61
A1.4 Abstract ............................................................................................................................ 62
A1.5 Introduction ...................................................................................................................... 62
A1.6 Results .............................................................................................................................. 66
A1.6.1 Med13 contains two SCFGrr1 phospho-degrons ......................................................... 66
A1.6.2 Snf1 is required for stress-induced degradation of Med13 ........................................ 67
A1.6.3 Snf1 activation alone is not sufficient to mediate Med13 degradation ..................... 70
A1.6.4 The CWI pathway sensors proteins are not required for Snf1 activation .................. 70
A1.6.5 The Snf1 degron lies within the IDR of Med13 ........................................................ 71
A1.6.6 Other potential Snf1 sites on Med13 are not needed for its degradation following
H2O2 stress ............................................................................................................................. 74
A1.6.7 Snf1 is necessary for cyclin C nuclear release and stress-induced mitochondrial
fission..................................................................................................................................... 75
A1.6.8 Med13-degron571-650 is not required for the degradation of Med13 following H2O2
stress ...................................................................................................................................... 78
vii

A1.7 Discussion ........................................................................................................................ 78
A1.8 Materials and methods...................................................................................................... 82
A1.8.1 Yeast strains and plasmids ......................................................................................... 82
A1.8.2 Cell growth ................................................................................................................ 83
A1.8.3 Western blot analysis and co-immunoprecipitation .................................................. 84
A1.8.4 Snf1 activation and kinase assays .............................................................................. 84
A1.8.5 Fluorescence microscopy........................................................................................... 85
A1.9 Acknowledgments ............................................................................................................ 86
APPENDIX 2: A Complex Molecular Switch Directs Stress-induced Cyclin C Nuclear Release
Through SCFGrr1 Mediated Degradation of Med13.................................................................... 90
A2.1 Author information ........................................................................................................... 90
A2.2 Abbreviations ................................................................................................................... 91
A2.3 Abstract ............................................................................................................................ 92
A2.4 Introduction ...................................................................................................................... 92
A2.5 Results .............................................................................................................................. 95
A2.5.1 SCFGrr1 is required for Med13 H2O2-mediated degradation ...................................... 95
A2.5.2 The intrinsic disordered region of Med13 interacts with Grr1 .................................. 97
A2.5.3 The Med13 IDR binds cyclin C ................................................................................. 99
A2.5.4 The Med13 IDR is sufficient to retain cyclin C in the nucleus ............................... 101
A2.5.5 Cdk8 phosphorylation primes Med13 for destruction ............................................. 101
viii

A2.5.6 The CWI pathway is required for ROS-mediated destruction of Med13 ................ 105
A2.5.7 Slt2 and Cdk8 phosphorylation of the IDR region is required for Med13 destruction
............................................................................................................................................. 107
A2.6 Discussion ...................................................................................................................... 109
A2.6.1 The Med13 phospho-degron activation requires a three-step process..................... 110
A2.6.2 Med13 Intrinsic disordered Region (IDR) is a communication hub ....................... 112
A2.6.3 Role of SCFFbw7 and Med13 in higher eukaryotes following stress ........................ 114
A2.7 Materials and methods.................................................................................................... 115
A2.7.1 Yeast strains and plasmids ....................................................................................... 115
A2.7.2 Cell growth .............................................................................................................. 116
A2.7.3 Western blot analysis ............................................................................................... 117
A2.7.4 Fluorescence microscopy......................................................................................... 118
A2.7.5 Pull down assays and kinase assays......................................................................... 119
A2.8 Acknowledgments .......................................................................................................... 121
A2.9 Supplementary materials ................................................................................................ 122
REFERENCES ........................................................................................................................... 130

ix

LIST OF FIGURES
Figure 1-1 Crystal structure of AMPK complex ............................................................................ 5
(A) Schematic representation of the construct used for crystallization of AMPK α1β1γ1
(AMPKxtal), α (purple), β (cyan), and γ (pink). (B) Topology of near-full length AMPK α1β1γ1.
......................................................................................................................................................... 5
Figure 1-2 Crystal structure of SNF1 complex .............................................................................. 9
Figure 2-1 Evolutionary history and relationships of OSBP families in S. cerevisiae, H. sapiens,
C. elegans, and D. melanogaster .................................................................................................. 16
Figure 2-2 Evidence supporting the direct phosphorylation of Osh7 by Snf1 and direct
phosphorylation of ORP8 by AMPK ............................................................................................ 17
Figure 2-3 Evidence that direct interaction with SNF1 maintains the intracellular stability of
Osh7 .............................................................................................................................................. 20
Figure 2-4 Osh7, but not Osh6, localizes to ER-mitochondrial contact sites in a Snf1
independent manner, and its stable expression is affected by Snf1 .............................................. 22
Figure 2-5 Both Osh6 and Osh7 plays a role in mitochondria function with Osh6 playing a more
prominent role ............................................................................................................................... 25
Figure 2-6 Osh6-deficient cells display mitophagy defects ......................................................... 26
Figure 3-1 PAS kinase directly binds to Med13 as found in a yeast two-hyrid assay ................. 47
Figure 3-2 Psk1 phosphorylates Med13 in vitro .......................................................................... 48
Figure 3-3 PAS kinase is required for Med13 degradation in response to carbon stress ............ 49
Figure 3-4 PAS kinase plays an important role in cyclin C nuclear release upon oxidative stress
....................................................................................................................................................... 51

x

Figure 3-5 A model for the regulation of cyclin C localization through a cascade including PAS
kinase (Psk1) ................................................................................................................................. 53
Figure A1-1 Cdk8 module regulation by the CWI MAPK pathway ........................................... 64
Figure A1-2 Med13 contains two H2O2 stress responsive degrons ............................................. 66
Figure A1-3 Snf1, Sak1 and at least one β subunit are required for degradation of Med13
following H2O2 stress .................................................................................................................. 69
Figure A1-4 Snf1 activation does not mediate Med13 degradation ............................................ 71
Figure A1-5 Snf1 phosphorylates degron571-650 ........................................................................... 73
Figure A1-6 Other potential Snf1 sites in Med13 are not required for its degradation following
H2O2 stress..................................................................................................................................... 76
Figure A1-7 Cyclin C remains predominantly nuclear following H2O2 stress in snf1∆ .............. 77
Figure A1-8 Either Med13 degron is sufficient for Med13 degradation ..................................... 79
Figure A2-1 Cdk8 module (Cd8, cyclin C, Med12 and Med13) regulation by the CWI MAPK
pathway ......................................................................................................................................... 94
Figure A2-2 SCFGrr1 mediates Med13 degradation following H2O2 stress ................................. 96
Figure A2-3 The unstructured domain of Med13 binds Grr1 ..................................................... 98
Figure A2-4 The Med13 IDR binds cyclin C ............................................................................ 100
Figure A2-5 The unstructured domain of Med13 retains cyclin C in the nucleus ..................... 102
Figure A2-6 Cyclin C-Cdk8 directly stimulate Med13 proteolysis ........................................... 103
Figure A2-7 Slt2 directly stimulates Med13 destruction ........................................................... 106
Figure A2-8 The Med13 IDR contains the phospho-degron ..................................................... 108
Figure A2-9 Three-step model of cyclin C release from Med13 following H2O2 stress ........... 112
Figure A2-S1 The human Fbw7 degron on Med13 is not required for Med13 degradation ..... 125

xi

Figure A2-S2 Fluorescence microscopy of mid-log phase med13∆ cells (Y1701) harboring the
GalAD-Med13 fusion constructs shown and cyclin C-YFP (pBK38) ......................................... 126
Figure A2-S3 PKA mediated phosphorylation of Med13 is not required for its degradation
following H2O2 stress.................................................................................................................. 127
Figure A2-S4 (A) Quantification of Med13-HA degradation following 0.4mM H2O2 stress for
the experiments shown in Figure A2-6 (A) and Figure A2-7 (B)............................................... 128
Figure A2-S5 (A) IUPred and ANCHOR plot analysis of Med13 ............................................ 129

xii

LIST OF TABLES
Table 2-1 List of yeast strain used ............................................................................................... 29
Table 2-2 List of plasmids used ................................................................................................... 30
Table 2-3 List of primers used ..................................................................................................... 31
Supplemental Table A1-1 Yeast strains used in this study......................................................... 87
Supplemental Table A1-2 Plasmid used in this study ................................................................ 88
Supplemental Table A2-1 Yeast strains used in this study....................................................... 122
Supplemental Table A2-2 Plasmids used in this study............................................................. 123

xiii

CHAPTER 1: Role of Mitochondrial Dysfunction and Metabolic Diseases
1.1 Introduction
Mitochondria are powerhouses of the cell that generate the energy necessary for all
cellular activity in the form of adenosine triphosphate (ATP), a high energy carrying molecule
[1]. Although some ATP can be obtained through anaerobic glycolysis, most ATP derives from
oxidation of carbohydrates and fatty acids in the mitochondria through a series of reactions in the
Kreb cycle and the Electron transport chain (ETC). In addition to generation of cellular energy,
mitochondria have also been recognized as an important signaling hub and a critical regulator of
apoptosis about 2 decades ago due to two major discoveries: 1) cytochrome c, a protein
previously known as only an electron transporter, was found to initiate apoptosis once it is
released into the cytosol through association with apoptotic protease activating factors (Apaf)
and activating signaling cascade of caspases [2]. 2) The discovery of Bcl-2 family’s involvement
in apoptotic signaling through controlling the release of cytochrome c into the cytosol [3]. It is
now established (and still under rigorous, active research) that mitochondria communicate to the
rest of the cells regarding its fitness through many pathways such as the release of metabolites,
mitochondrial peptides, reactive oxygen species (ROS), activation of AMPK, changes in inner
mitochondria membrane potential, calcium signaling and communication through mitochondria
associated membrane (MAMs) [4-7]. Changes in mitochondria dynamic (fission and fusion)
ensure delivery of appropriate signal to proper location in the cell, allow mitochondria fitness
assessment by quality control mechanisms such as mitophagy and cellular stress adaptation [8,
9]. These mechanisms may function jointly—for instance, decreases in mitochondrial respiratory
flux can result in reduced mitochondrial membrane potential, decreased output of ATP (and the
corresponding increase in the AMP:ATP ratio), decreased ROS production, and alterations in
1

other TCA metabolites. These signals can activate AMPK and cause a switch from anabolic
metabolism to a catabolic state; AMPK activation promotes mitochondria fission [10], hence
mitochondria without adequate membrane potential are dissociated from healthy mitochondria
and destroyed through mitophagy [11, 12]; decreases ROS levels thus reducing signaling
pathway activation necessary for cell proliferation and metabolic adaptation [4]; decreases TCA
metabolites which output may cause reduction in lipid production necessary for cell growth and
reduced protein acetylation [5]; and inadequate mitochondria membrane potential also causes a
decrease in Ca+ uptake hence improper calcium signaling [13]. Under starvation conditions, cells
ensure adequate supply of substrates such as amino acids to the TCA cycle through autophagy in
an effort to maintain mitochondria membrane potential or risk the release of cytochrome c. With
mitochondria’s importance to the overall cell health and role in many essential cellular processes,
it is not surprising that mitochondrial dysfunction can lead to many diseases at the tissue and
organismal level. Mitochondrial dysfunction has been associated with many diseases such as
sarcopenia, type 2 diabetes mellitus (T2DM), neurodegenerative disease, cardiovascular disease,
liver and kidney disease and cancer [14-17]. Furthermore, their regulation has been shown to be
important in longevity in many different organisms from yeast to man [18, 19]. With
mitochondria being at the center of cellular metabolism and signaling pathways, the difficulty in
understanding and treating human diseases caused by mitochondrial dysfunction arises from the
complex relationships between mitochondria and other cellular processes. Understanding of
mitochondrial protein-protein signaling network, types of mitochondrial stressors, their interplay
with mitochondrial dynamics and the mechanisms that orchestrate how cells respond to them is
critical in better understanding the transition between health and disease.
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1.1.1 Role of AMPK in mitochondrial function and metabolic diseases
AMP-activated kinase (AMPK) is an evolutionarily conserved protein kinase that
regulates energy homeostasis in the cell. Cells need to manage their energy consumption
depending on nutrient availability and on their capacity to produce ATP constantly by changing
their metabolism, and AMPK is the key player in this process. AMPK is a heterotrimeric
complex composed of a catalytic α-subunit and two regulatory subunits, β and γ (Figure 1-1
[20]). Humans possess multiple genes that encode for each subunit which results in different
isoforms of AMPK complexes: two α-subunits, α1 and α2 encoded by the gene PRKAA1 and
PRKAA2 [21]; two β-subunits, β1 an β2 encoded by the gene PRKAB1 and PRKAB2 [22]; and
three γ-subunits, γ1, γ2 and γ3, encoded by the gene PRKAG1, PRKAG2 and PRKAG3 [23].
Each AMPK complex is only composed of one α, one β and one γ subunit at any given time,
which gives rise to 12 possible combinations of AMPK complexes. Different complexes of
AMPK seem to be functionally redundant with differences in tissue/ organ dependent expression
levels [24]. When ATP is used in cellular processes, it is broken down into ADP and can be
further broken down into AMP. AMPK senses changes in cellular AMP/ADP: ATP ratio by the
binding of AMP, and to a lesser extent ADP to the γ subunit, which stimulates AMPK activity
[25-27]. Binding of AMP/ ADP to the γ subunit promotes Thr172 phosphorylation in the
activation loop in the kinase domain by upstream kinases such as LKB1 and protects Thr172
from dephosphorylation by protein phosphatases. Activation of AMPK can also be achieved in a
non-AMP/ ADP sensitive fashion, by the phosphorylation of calcium-sensitive kinase CAMKK2
at Thr172.
AMPK has been identified as a central integrator of mitochondrial homeostasis by
controlling multiple aspects of the mitochondrial life cycle: from mitochondrial biogenesis and
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dynamics, to healthy removal by mitophagy [28]. Almost every mitochondrial insult or defect
activates AMPK and given the function of mitochondria as the major source of ATP production
in the cell, it makes perfect sense that AMPK, an energy homeostasis regulator in the cell would
engage downstream effectors to ensure optimal mitochondrial function. AMPK promotes
mitochondrial biogenesis through direct and indirect regulation of the peroxisome proliferatoractivated receptor-γ co-activator 1 (PGC1) family— by affecting expression level of PGC1α
[29], direct phosphorylation [30] or through AMPK-dependent modulation of p38 MAPK1 [31],
HDAC5 [32, 33] or SIRT1 [34]. Understanding the effect of AMPK on mitochondrial biogenesis
has important implications in multiple pathological states and processes, including Duchenne
muscular dystrophy [35], mitochondrial myopathy[36], exercise capacity [37], muscle
regeneration after injury [38] and protection from age-related myopathies [39]. AMPK is also a
direct and crucial regulator of mitochondrial dynamics. As mentioned above, AMPK regulates a
core component of the mitochondria fission pathway—mitochondrial fission factor (MFF) [40]
through direct phosphorylation at Ser155 and Ser172 of MFF and promote DRP1 (a protein that
mediates constriction of mitochondria during fission [41]) localization at mitochondria [10].
Therefore, AMPK controls the shape of the mitochondrial network in response to stress, in which
fusion of mitochondria maximizes generation of ATP [42], distributes lipids and protects
mitochondria from mitophagy [12, 43]; fission of mitochondria facilitates mitophagy of
mitochondrial fragments lacking proper membrane potential, as well as allows timely apoptosis
when necessary [44]. AMPK also regulates other pathways that control autophagy/ mitophagy
through multiple downstream substrates such as mTORC1, ULK1, ATG9 and VPS34 to remove
damaged/ depolarized mitochondria [45-48]. With AMPK’s essential role in regulating energy
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metabolism and mitochondria function, AMPK is currently at the center stage of interests in
studies of diabetes and related metabolic diseases, as well as cancer [49, 50].

Figure 1-1 Crystal structure of AMPK complex (A) Schematic representation of the construct used for
crystallization of AMPK α1β1γ1 (AMPKxtal), α (purple), β (cyan), and γ (pink). (B) Topology of near-full length
AMPK α1β1γ1. Arrows indicate the location of the CBM-KD interface, αC-helix and C-interacting helix, ATP site,
activation loop, and highest affinity AMP site (site 4). (C) Close-up view of the CBM-KD interface illustrating
intersubunit electrostatics. (D) Surface representation of the structure shown in (B). The disordered segment
between the β1 CBM and the C-terminal domain is shown as dotted lines. Adapted from Calabrese, M. F., et al.
(2014). Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from
Opposite Poles by Different Molecular Mechanisms. Structure 22(8): 1161-1172.

The yeast ortholog of AMPK—SNF1 was identified in Saccharomyces cerevisiae
(baker’s yeast) in 1981 when the snf1 mutation was found in a search for mutants unable to
utilize sucrose (snf, sucrose-nonfermenting) [51]. SNF1/ AMPK pathways are highly conserved,
5

in which upstream kinases of AMPK— LKB1, CAMKK2, TAK1 were first identified in yeast
[52-54]. Much like mammalian AMPK, SNF1 complex is a heterotrimeric protein kinase
composed of one catalytic α subunit, one β subunit and one γ subunit. Saccharomyces cerevisiae
genome possesses one gene that encodes for the catalytic α subunit Snf1, three genes encode for
alternate β subunits Gal83, Sip1 and Sip2, and one gene encodes for the γ subunit Snf4 [55].
Crystal structure of SNF1 complexes are shown in Figure 1-2 [56]. The constitutively expressed
α subunit Snf1is a 633 amino acid protein that phosphorylates its downstream targets. The α
subunit consists of a N-terminal catalytic domain and a C-terminal regulatory region [57-59].
The regulatory region consists of a short autoinhibitory sequence (AIS) (380—415aa) and a
region which facilitates the interactions with the β subunits of the complex (515—633aa) as
sufficient for interaction with Sip2 [60]. The autoinhibitory domain interacts with both the
regulatory subunit Snf4 and the kinase domain of Snf1 [61]. The interaction with Snf4 relieves
the inhibition of the AIS allowing phosphorylation of Thr210 residue of Snf1 that results in
activation of the catalytic subunit [62]. The β subunits direct the localization of α subunit, and
exhibit overlapping function as each subunit alone is sufficient for growth under conditions in
which SNF1 activity is required [63-65]. Under normal conditions, all three β subunits are
cytosolic; however, the different N-termini of β subunits allows unique subcellular localization
upon glucose depletion: Sip1 re-localizes to the vacuolar membrane, Gal83 re-localizes to the
nucleus, and Sip2 remains cytosolic [64]. Sip1 is a 863 amino acids protein, Sip2 is a 415 amino
acids protein and Gal83 is a 417 amino acids protein [55]. The β subunits contain conserved Cterminal sequences that mediate their interaction with the SNF1 complex [66]. Amino acids
residue 198 to 350 of Gal83 and residues 154 to 335 of Sip2 are sufficient for interaction with
Snf1; while residues 771 to 863 of Sip1 and residues 332 to 415 of Sip2 mediates interaction
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with Snf4 [60, 66]. The sequence of glycogen binding domain (GBD) in Gal83 (161-243) and
Sip2 (163-245) is conserved in the mammalian AMPK β1 subunit [67]. However, studies
showed that GBD may affect SNF1 function through mechanisms independent of glycogen
binding [67]. Despite all three β subunits having overlapping functions, the abundance of each
beta subunit is differently regulated by glucose availability. Gal83 is the main beta subunit
during glucose growth, while the level of Sip2 increases when switched to non-fermenting
carbon sources. Sip1 is the least abundant amongst the three β subunits and its cellular level
remained constant regardless of carbon sources [64]. Gal83 contributes the most to SNF1 activity
in response to glucose depletion, while Sip2 has been implicated in aging [68]. SNF1 complexes
with different β subunits also display preference for activation by Sak1, Tos3, and Elm1 in a
stress-dependent manner [69]. Snf4 contains a Bateman domain that binds adenosine derivatives;
however several studies showed that unlike AMPK, SNF1 is not allosterically activated by AMP
in vitro [70-73].
1.1.2 Conserved signaling of AMPK-PASK from yeast to man
Like mammalian AMPK, SNF1 plays a central role in energy sensing, metabolism and
stress response [74]. Per-Arnt-Sim kinase (PAS kinase) is a highly conserved nutrient sensing
kinase that has recently been identified as being a downstream substrate of Snf1 in yeast [75].
PAS kinase is an emerging regulator of mammalian glucose and lipid metabolism, as shown by a
wide range of studies [76]. Mice with PAS kinase deficiency display a hypermetabolic
phenotype and are protected from high fat diet-induced obesity and insulin resistance [77]; PAS
kinase is found to promote energy production by shifting metabolism towards respiration in both
yeast and mammalian systems, through regulation of its substrate Cbf1/USF1 and perhaps
through activation of AMPK pathways [78, 79] because the presence of PAS kinase is necessary
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for AMPK activation in the nerve cells of the hypothalamus (N2A), as well as normal glucosestimulated insulin production in cultured β-cells [78]. PASK also controls insulin secretion as it
enhanced PDX-1 stability through inactivating glycogen synthase kinase 3β (GSK-3β); hence
reducing blood glucose [80]. PAS kinase was also found to regulate glucose partitioning through
phosphorylation of UDP-glucose pyrophosphorylase (Ugp1) [81]. With a large number of yeast
PAS kinase (Psk1) interacting partners that are involved in cell growth (gene/ protein expression,
replication/ cell division, and protein modification and degradation), vacuole function and stress
tolerance identified [82], functions and regulation of PAS kinase remain to be explored.
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Figure 1-2 Crystal structure of SNF1 complex (A) Domain organization of SNF1 subunits. Residues that are
included in the co-expression construct are shown in color, and the others are shown in grey or black. KD, protein
kinase domain; RS, regulatory sequence. (B) Schematic representation (stereo view) of the heterotrimer core of
SNF1. The regulatory sequence of the α-subunit (Snf1) is shown in red and the rest is in yellow; the GBD of the βsubunit (Sip2) is shown in cyan and the rest is in magenta; and the γ-subunit (Snf4) is shown in green. The positions
of AMP (stick model in black), as observed from the S. pombe enzyme as well as that of β-cyclodextrin (in grey) as
bound in the rat GBD10, are shown for reference. (C) Superposition of the structures of S. cerevisiae SNF1 (colored
as in b) and S. pombe AMPK (in grey). The superposition is based on the γ-subunits only. Red arrows point to new
features in the SNF1 structure, and blue arrows point to differences between the two structures. Produced with
Ribbons30. Adapted from Amodeo, G. A., et al. (2007). Crystal structure of the heterotrimer core of Saccharomyces
cerevisiae AMPK homologue SNF1. Nature 449: 492.
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1.2 Conclusion
AMPK acts as the caretaker of mitochondria and this role is conserved from yeast to man
[83]. Given the important role of mitochondria functions in cellular energetics, metabolism and
survival, it is not surprising that there are more substrates dedicated to restoring mitochondria
health waiting to be identified. Understanding the cross-talk of AMPK with other protein kinases
and identifying new downstream targets of AMPK will help to unravel novel aspects of
regulation in mitochondrial health and functions, which is of immerse therapeutic potential for
metabolic diseases, neurodegenerative disorders and cancer. In Chapter 2, we report a novel
downstream substrate of yeast AMPK (SNF1)—Osh7 and the regulation of mitochondrial
function through this signaling pathway; in Chapter 3, we report a novel signaling pathway in
which SNF1 regulates Med13 degradation and mitochondrial dynamic through PAS kinase.
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2.2 Abbreviations
ORP- Oxysterol binding protein related protein
OSBP- Oxysterol binding protein
LTP- Lipid transfer protein
ORD- OSBP-related protein domain
PI(4)P-Phosphatidylinositol 4-phosphate
PS- Phosphatidylserine
ESCRT- Endosomal sorting complexes required for transport
Vps4- Vacuolar protein sorting-associated protein 4
Osh- Oxysterol binding protein homolog
AMPK- AMP-activated protein kinase
AMP- Adenosine monophosphate
ADP- Adenosine diphosphate
ATP- Adenosine triphosphate
SNF1- Sucrose non-fermenting 1
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2.3 Abstract
Gene evolution through duplication and divergence appears to be a common strategy for
producing proteins with related but unique function. Herein we explore the evolution of two
homologous oxysterol binding proteins (OSBPs) in yeast, Osh6 and Osh7. These proteins were
previously found to have overlapping function, but evidence is provided herein for their
differential regulation and function. First, Osh7, but not Osh6, is phosphorylated by the nutrient
sensing protein kinase Snf1. This phosphorylation is required for Osh7 stability within the cell.
Second, Osh7, but not Osh6, localizes to ER-mitochondrial contact sites. OSH6-deficient yeast,
on the other hand, display a more pronounced respiratory-defect as well as a mitophagy defect.
In addition, a double osh6osh7 mutant suppresses the respiratory defect of OSH6-deficient yeast.
These findings support differential but overlapping function for these OSBPs, explaining the
selective pressures in the maintenance of both genes and providing pathways for the study of
their mammalian homolog.
2.4 Introduction
Oxysterol binding proteins (OSBP) and OSBP-related proteins (ORP) are a large family
of lipid transfer proteins (LTPs) conserved from yeast to man. The human genome encodes 12
ORP genes and a total of 16 ORP protein products generated from alternative splicing, whereas
the Saccharomyces cerevisiae (baker’s yeast) genome encodes seven ORP genes: Osh1-Osh7
[84, 85]. OSBP and ORP contain a conserved OSBP-related protein domain (ORD) at the Cterminal and were first discovered in the 1980’s as the intracellular receptors of oxysterols [86].
Recent advances in the understanding of cellular OSBP revealed many lipids in addition to
oxysterols may occupy the ORD, such as phosphatidylserine (PS), phosphoinositides, cholesterol
and other anionic lipids [85, 87-90]. OSBP and ORP have been implicated in many cellular
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functions such as sterol and lipid metabolism, cell cycle, calcium signaling, vesicular transport
and apoptosis [91], with roles as lipid or signaling regulators at different membrane contact sites
(MCS) [92-97]. OSBPs/ ORPs were also reported to play roles in various human diseases
including dyslipidemia, amyotrophic lateral sclerosis (ALS) and many types of cancer [91].
Despite this importance, there is still much unknown about their individual functions and
regulation.
Yeast Osh proteins collectively play a role in sterol homeostasis and share at least one
essential function [84], however the unique functions of each Osh protein remain elusive.
Together with their human homologs ORP5 and ORP8, respectively, Osh6 and Osh7 have been
reported to mediate the counter transport of PI(4)P/PS between the endoplasmic reticulum (ER)
and plasma membrane (PM) [98, 99]. Osh6 and Osh7 have also been reported to bind Vps4, an
AAA ATPase that is essential for efficient transport in the multivesicular body (MVB) sorting
pathway that functions to disassemble the ESCRT complexes, with no unique roles being
ascribed to either [100-103]. ORP5 and ORP8 share approximately 80% similarity in sequence
homology and constitute a unique group in human ORPs, as they are the only two ORPs to
possess a C-terminal transmembrane domain (TMD) and both lack the FFAT motif [94]. ORP5
and ORP8 were found to localize at ER-mitochondria contact sites and affect mitochondria
morphology and function [104]. Thus, experimental evidence and homology analysis have
supported the model of overlapping functions between Osh6 and Osh7 as well as their human
counterparts ORP5 and ORP8. In this study, we explored the conserved nature of Osh6 and
Osh7, as well as evidence for differential roles and regulation of Osh6 and Osh7 through in vivo
and in vitro studies.
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2.5 Results
2.5.1 Evolutionary relationships of OSBP families supports a close relationship between
Osh6 and Osh7
Phylogenetic analysis of amino acid sequence utilizing Maximum Likelihood methods
[MegaX] showed that OSBP family proteins are grouped into four lineages among S. cerevisiae,
H. sapiens, C. elegans and D. melanogaster (Figure 2-1). Osh6 and Osh7 are the most closely
related yeast homologs, and their closely related human counterparts are ORP5 and ORP8.
Sequence similarities between Osh6 and Osh7 (69.7% identity and 81.5% similarity) supports
evolution by gene duplication, which often results in similar but disparate, selectable functions,
yet only overlapping roles have been reported thus far.
2.5.2 AMPK/ Snf1 phosphorylates ORP8/ Osh7 directly but not Osh6
In our previous study of PAS kinase in yeast, Osh7 was identified as a substrate of a
copurified kinase [82]. This contaminating kinase may be Snf1, an upstream regulator of PAS
kinase. In support of this conclusion, purified yeast Snf1 or human constitutively active
mammalian AMPK α1(1-312) is able to phosphorylate Osh7 or its human homolog ORP8
directly in vitro (Figure 2-2A -D). Kinase dead (KD) Snf1 was used in the assay to test for
contaminating kinases copurifying with Snf1. These results confirm direct phosphorylation of
Osh7 by Snf1.
As mentioned above, sequence homology suggests that Osh6 and Osh7 are close
homologs of each other that arose during a yeast genome duplication event and are often treated
as such. However, in vitro kinase assays suggest that Snf1 and AMPK α1(1-312) were able to
differentiate between Osh6 and Osh7 as neither Snf1 nor AMPK phosphorylate Osh6 in vitro,
suggesting differential regulation of Osh6 and Osh7 in yeast (Figure 2-2E & F).
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Figure 2-1 Evolutionary history and relationships of OSBP families in S. cerevisiae, H. sapiens, C. elegans, and D.
melanogaster The phylogenetic tree was constructed using the Maximum Likelihood method and JTT matrix based
model [105].The bootstrap consensus tree inferred from 2000 replicates is taken to represent the evolutionary history
of the taxa analyzed [106]. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates are
collapsed. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test
(2000 replicates) are shown next to the branches [106]. Initial tree(s) for the heuristic search were obtained
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a
JTT model, and then selecting the topology with superior log likelihood value. This analysis involved 27 amino acid
sequences. There were a total of 1669 positions in the final dataset. Evolutionary analyses were conducted in MEGA
X [107].
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Figure 2-2 Evidence supporting the direct phosphorylation of Osh7 by Snf1 and direct phosphorylation of ORP8 by
AMPK (A) Full length Osh7 (expressed in E. coli from pJG1054) was phosphorylated in vitro when incubated with
wild type Snf1 (expressed in yeast from pJG1193) but not the kinase dead Snf1 (Snf1-KD, expressed in yeast from
pJG1338). In vitro kinase assays were conducted using purified Snf1 incubated with radiolabeled ATP (32P) with or
without purified Osh7. Reactions were visualized with 10% SDS-PAGE gel stained with coomassie brilliant blue
(CB, bottom) followed by exposure on X-ray film (32P, top). Lane 1&2: WT Snf1+FL Osh7; Lane 3: WT Snf1
only; Lane 4&5 KD-Snf1+FL Osh7; Lane 6: FL Osh7 only. CB: Snf1 appear at the top of the double band in each
lane. The bottom of the double band is a protein that co-purified with Osh7. (B) Full length Osh7 was shown to be
phosphorylated by human AMPK α1(1-312) (AMPK α1312). Lane 1&2: FL Osh7 + AMPK α1312; Lane 3: FL
Osh7 Only; Lane 4: AMPK α1312 only. (C) ORP8 (ORP8107-701: PH-OSBP domain, pJG1658; ORP8366-701:
OSBP domain, pJG1659) were shown to be phosphorylated by AMPK α1312. ORP8 was purified from yeast
(JGY91, ∆snf1) due to poor expression in E. coli BL21 and to prevent background phosphorylation from WT Snf1
(data not shown). Lane 1: ORP8107-701 + AMPK α1312; Lane 2: ORP8366-701 + AMPK α1312; Lane 3: AMPK
α1312 only; Lane 4: ORP8107-701 only; Lane 5: ORP8366-701 only. (D) Diagram of ORP8 constructs utilized in
this study. (E) Snf1 does not phosphorylate Osh6 in vitro. Purified Snf1 was incubated with radiolabeled ATP (32P)
with or without purified Osh6/ Osh7. Lane 1: Snf1 + FL Osh7; Lane 2&3: Snf1+FL Osh6; Lane 4: Snf1 only; Lane
5: FL Osh6 only. (F) Purified AMPK α1312 was incubated with radiolabeled ATP (32P) with or without Osh6/
Osh7. Lane 1: AMPK α1312 + Osh7; Lane 2&3: AMPK α1312 + Osh6; Lane 4: AMPK α1312 only; Lane 5: Osh6
only.
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2.5.3 Evidence for the direct interaction and stabilization of Osh7 by SNF1
The heterotrimeric S. cerevisiae SNF1 complex consists of a catalytic subunit Snf1, three
inter-changeable beta subunits Gal83, Sip1 and Sip2, and a gamma subunit Sip4. Beta subunits
of SNF1 bind Snf1 and Snf4 to form a functioning complex, and act as substrate binding domain
[55, 108]. Direct interactions between Osh7 and Snf1, Gal83, Sip1 or Sip2 were investigated
through the Yeast-2-Hybrid (Y2H) system. Full-length and/ or truncations of each SNF1
subunits mentioned above were cloned into bait and prey plasmids and tested against full-length
Osh7, and the Osh7 OSBP domain (a.a. 53- a.a 392) or coiled-coil domain (CC domain, a.a. 366a.a. 437) in the Y2H bait or prey plasmid (Figure 2-3A&B). The Y2H Gold yeast strain
(Clontech) with 4 reporter genes (HIS3, ADE2, AUR1-C, MEL1) was transformed with bait and
prey plasmids and spotted on synthetic minimum plates lacking leucine (LEU), tryptophan
(TRP), histidine (HIS) and adenine (ADE) for selection of plasmid maintenance (LEU or TRP)
or protein-protein interactions (HIS and ADE). All constructs were tested for autoactivation by
transforming the bait or prey plasmid with target protein against an empty bait or prey plasmid to
eliminate the possibility of false positive interactions. Direct interactions between the OSBP
domain of Osh7 were observed with all beta subunits of SNF1 (Figure 2-3C), but not with the
catalytic subunit Snf1 (data not shown). The Snf1/Snf4 binding domain of Gal83 (a.a 141- a.a.
417) [63, 109] is necessary for binding of the OSBP and CC domain of Osh7, but does not find
full length Osh7; Full length Sip1 and Sip2 binds the OSBP domain of Osh7 directly, but not the
CC domain or full length Osh7.
In addition to direct interaction via the yeast two hybrid, copurification supports an
interaction between Snf1 and Osh7, but not Snf1 and Osh6 (Figure 2-3D). Lysates from yeast
expressing Snf1-myc were incubated with equal amounts of purified Osh6 or Osh7, then
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subjected to myc purification. Prominent bands are seen with Osh7, but only faint bands with
Osh6.
Phosphorylation of Osh7 appears to stabilize the Osh7 protein in that the presence of
wildtype Snf1 is necessary for maintaining intracellular Osh7. A wildtype (JGY1) or ∆snf1
(JGY91) strain harboring a plasmid containing Osh7-His under the GAL 1-10 promoter
(pJG1357) were grown for 12 hours in SD-Trp and switched to SGal-Trp for 36 hours to induce
Osh7 expression. Cells were then broken open and subjected directly to western blotting. Results
indicate no detectable amount of Osh7 after 36 hours of induction in the ∆snf1 yeast (Figure 23E). In order to show that this deficit in Osh7 was due to Snf1 and not an adaptation of the ∆snf1
yeast, WT and ∆snf1 yeast were co-transformed with plasmids containing Snf1-Myc, Snf1 KDMyc, or the EV-Myc control along with the Osh7-HIS, grown for 12 hours in SD-Ura-Trp
followed by 36 hours growth in SGal-Ura-Trp to induce protein expression. Cells were then
broken open and Osh7 was purified using His-tagged protein purification. Results indicate that
Osh7-His can only be stably expressed when wildtype Snf1 is supplied, but not when Snf1 KD is
present (Figure 2-3F).
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Figure 2-3 Evidence that direct interaction with SNF1 maintains the intracellular stability of Osh7 (A-C) Evidence
that Osh7 directly interacts with the three beta subunits of the SNF1 complex (Gal83, Sip1 and Sip2). Constructs of
Osh7 used in yeast-2-hybrid assays are diagrammed in (A) whereas interacting regions of Osh7 with Gal83 are
shown in (B). The Snf1 binding domain of Gal83 and Snf4 interacting domain of Gal83 are necessary for
recognizing OSBP domain of Osh7 (C, top). A weaker interaction of this truncation of Gal83 is also seen with
coiled-coil domain of Osh7. Full-length Sip1 interacts with OSBP domain but not coiled-coil domain of Osh7 (C,
middle). Full-length Sip2 interacts with OSBP domain but not coiled-coil domain of Osh7 (C, bottom). Y2HGold
cells (Clontech) were co-transformed with OSBP domain/ coiled-coil domain of Osh7 (AD) and Gal83 Δ141-417
truncation/FL Sip1/ FL Sip2 (BD) and spotted on SD-Leu-Trp-His-Ade for selection of protein-protein interactions
and SD-Leu-Trp as growth control. (D) Myc pull-down assay provides evidence that Osh7(His-tag) co-purifies
strongly with Snf1(Myc-tag) from mixed cell lyastes, and Osh6 (His-tag) co-purifies with Snf1 to a lesser extent.
Crude extract is shown to control for protein expression in the cell. (E) Overexpressed Osh7 is detected in wildtype
yeast overexpressing Osh7-His (JGY1) but not ∆snf1 (JGY91) yeast. Anti-UGP1 antibody was used to probe UGP1
as loading control. (F) Overexpressed Osh7 is purified from WT but not ∆snf1 yeast. WT or ∆snf1 yeast strain
transformed with Osh7-His or EV-His and Snf1-Myc, Snf1-KD-Myc or EV-Myc were subject to His-tagged
purification followed by western blot. Lane 1: WT yeast with Osh7-His and EV-Myc plasmids; Lane 2: ∆snf1 strain
with Osh7-His and EV-Myc plasmids. Lane 3: ∆snf1 Strain with Osh7-His and Snf1-Myc plasmids; Lane 4: ∆snf1
strain with Osh7-His and Snf1 KD-Myc. Lane 5: ∆snf1 strain with EV-His and Snf1-Myc plasmids.
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2.5.4 Osh7, but not Osh6, co-localizes with mdm34; Snf1 does not affect Osh7
localization
In addition to the differential regulation of Osh6 and Osh7 by Snf1, the function of Osh6
and Osh7 was explored to investigate similarities and differences. The human homologs of Osh6
and Osh7, ORP5 and ORP8 were recently reported to localize at ER-mitochondrial contact sites
and to affect mitochondria function [104], thus we looked at ER-mitochondrial contact site
localization of these two proteins. In addition, the effects of Snf1 on this localization were
investigated by varying the growth media to increase or decrease Snf1 activity, since Osh7 is
degraded in ∆snf1 mutant and is not visible by microscopy. Snf1 becomes activated under low
glucose conditions due to the increased AMP:ATP ratio, therefore glucose gradients were
utilized [55]. Osh7 co-localized with Mdm34 at the ER-and mitochondria contact sites in WT
yeast 45% of the time (Figure 2-4), while some remained cytosolic. This localization did not
change with altered glucose levels. A small fraction of ∆snf1 mutant yeast also displayed some
Osh7, and it was localized to the ER-and-mitochondria contact sites. Osh6 on the other hand
remained cytosolic in both the WT and ∆snf1 strain, and its expression was not altered in
response to Snf1. Thus, Snf1 does not appear to play a role in localization of Osh6 nor Osh7, but
only a very low level of Osh7 was detected ∆snf1 mutant in the and usually seen as foci, which is
consistent with the observation of Snf1 being necessary in maintaining Osh7 intracellular
stability (see Fig. 2-3).
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Figure 2-4 Osh7, but not Osh6, localizes to ER-mitochondrial contact sites in a Snf1 independent manner, and its
stable expression is affected by Snf1 (A) WT and ∆snf1 cells with genome tagged Mdm34::mCherry harboring
Osh6-YFP/ Osh7-YFP plasmid under ADH promoter were grown to log phase in SD-URA and then subject to low
glucose/ nutrient stress in SD-URA for 2 hours. Cells were imaged before and after stress with Fluoview confocal
microscope. B. Cell count and statistical analysis of Osh7-YFP co-localization with Mdm34-mcherry. (B) Statistical
analysis of cells with or without at least 1 co-localizing foci of Osh6/Osh7-YFP with Mdm34 in WT/Δsnf1 strain,
before and after 2 hours 0,05% glucose stress. Cells were visualized using Fluoview confocal microscope.
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2.5.5 Both Osh6 and Osh7 plays a role in mitochondrial function; with Osh6 playing a
more prominent role
To better understand the cellular functions of Osh6 and Osh7, including the Osh7
localization to ER-mitochondria contact sites, we examined the mitochondria morphology and
functions in WT, ∆osh6, ∆osh7, ∆osh6∆osh7 yeast. Our data showed that ∆osh6 plays a more
important role in mitochondria dysfunction compared to Osh7, as Δosh6 mutant cannot grow on
media with non-fermenting carbon source (Figure 2-5A, 2% Glycerol-Ethanol in this
experiment). The double mutant (∆osh6∆osh7) appeared to restore the mitochondria dysfunction
observed in ∆osh6 strain, consistent with differential rather than redundant functions for Osh6
and Osh7. On the other hand, the ∆osh7 strain did not show obvious signs of mitochondrial
dysfunction when grown on 2% Glycerol-Ethanol. We then subjected each strain of cells to
Seahorse XFp OCR (oxygen consumption rate) analysis. Measurements were taken in basal,
inhibited, and uncoupled respiratory environments and are represented as pmol O2
consumed/min/cell. Consistent with the plate assay (Figure 2-5B), Δosh6 yeast consumed
significantly less oxygen than WT at all timepoints (p<0.00001) when normalized to cell number
as shown in Figure 2-5E. However, as opposed to the plate assay it appears that some oxygen is
consumed, which in conjunction with weak reactions to the inhibitory and uncoupling respiratory
drugs TET and FCCP indicates low levels of respiratory carbon source utilization as opposed to
non-mitochondrial oxygen consumption. The most surprising result is the respiratory defect
observed in the Δosh7 knockout strain. The Δosh7 yeast consumed significantly less oxygen than
WT, a divergence from the plate phenotype, at all timepoints (p<0.001). This may suggest a
difference in carbon source utilization between solid and liquid media or truly represent a
defective respiratory phenotype that does not affect growth. In accordance with the plate assay,
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the Δosh6osh7 double mutant showed a recovery of respiratory function, although the OCR was
lower than WT at all timepoints (p<0.01) indicating a potential genetic interaction between the
two genes.
Further analysis of the respiratory data revealed differences in the strains response to the
uncoupling drug FCCP, which transport H+ across the inner mitochondria membrane.
Respiratory rates between Δosh6 and Δosh7 were not significantly different during basal and
inhibitory readings however upon the addition of FCCP the Δosh6 saw an increase of 40% while
Δosh7 respiration increased by 100% resulting in significantly differences in uncoupled
respiratory rates. For reference WT OCR increased by 99% and Δosh6osh7 increased by 61%.
Florescent microscopy with plasmid containing mito-TFP was then used to examine
mitochondria morphology in all four strains (Figure 2-5C). No obvious altered mitochondria
morphology was observed suggesting the respiratory dysfunction of ∆osh6 yeast is due to a
mitochondrial dysfunction rather than deficit.
Mitophagy, the process of selectively degrading damaged mitochondria, was monitored
using the OM45-GFP processing assay shown in previous study [110] and florescent microscopy
with mitochondria-targeting TFP (Figure 2-6). Interestingly, the ∆osh6 strain displayed no
detectible mitophagy after 36 hours growth in YPL, much like ∆atg32 control. Atg32 is a
mitophagy specific receptor in yeast and mitophagy is completely inhibited in cells lacking
ATG32 [111], therefore it serves as a negative control. Our data showed that Osh6 plays a
significant role in mitophagy while Osh7, on the other hand, displayed only a decrease in
mitophagy (Figure 2-6A&B). Once again the double mutant (∆osh6∆osh7) appeared to rescue
the ∆osh6 defect and phenocopied the less severe decrease in mitophagy of the ∆osh7 strain.
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Figure 2-5 Both Osh6 and Osh7 plays a role in mitochondria function with Osh6 playing a more prominent role (A)
An ∆osh6 knockout display a respiratory-defect on synthetic media with glycerol/ethanol (SGE-complete) when
compared with glucose (SD- complete) and ∆osh6∆osh7 double knockout strains suppresses the mitochondria
defect. Yeast were spotted in WT, ∆osh6, ∆osh7, ∆osh6osh7 strain on SD-complete and SGE-complete plates. (B)
Δosh6, Δosh7, and Δosh6Δosh7 knockouts were tested in Seahorse respiration assays in SGE-complete media after
growth in SD-complete. OCR of both Δosh6 and Δosh7 are significantly lower than WT at all timepoints with
p<0.001 and Δosh6Δosh7 at all timepoints with p<0.01. There were no significant differences in OCR between
Δosh6 and Δosh7 up until FCCP was added and asterisk (*) represent where significant difference of OCR between
Δosh6 and Δosh7 occur. Dotted lines represent injections of mitochondrial inhibitory and uncoupler drugs TET and
FCCP. Error bars represent SEM. (C) Neither Osh6 nor Osh7 appears to affect mitochondria morphology.
Mitochondria morphology were analyzed using florescent microscope. Cells were grown to logarithm phase in 0.5%
glucose and switched to SD-N for 6h. Mitochondria morphology was visualized at growth phase and after 6h of
nitrogen starvation.
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Figure 2-6 Osh6-deficient cells display mitophagy defects (A) Representative image of western blot analysis
showed that ∆osh6 strain has significant defects in mitophagy. Osh7 on the other hand, affects mitophagy to a lesser
extent. Cells were grown to mid-log phase and switched to YPL for 36 hours. OD600 = 1 of cells were analyzed
using western blotting. (B) Statistical analysis of free GFP relative signal intensity between WT, ∆osh6, ∆osh7,
∆osh6∆osh7 and ∆atg32 in A. (C) Cells expressing Mito-TFP and Vph1-mcherry were analyzed with florescent
microscopy before and after 24 h nitrogen starvation. Mito-TFP construct contained mitochondrial leader sequence
fused with TFP for mitochondria targeting, where Vph1-mcherry allows visualization of vacuole. Overlap of MitoTFP and Vph1-mcherry following nitrogen starvation indicates mitophagy. Results for ∆osh6 strain not shown due
to cell death resulted under these conditions. (D) Statistical analysis of % mitophagy in C. was graphed with the
indicated genotype (mean ± SEM, n ≥ 2). “****” indicates p-value < 0.0001 by one-way ANOVA followed by
post-hoc Tukey analysis.
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2.6 Conclusions
Gene duplication followed by divergence is a likely pathway for the evolution of novel
protein functions. The first models for gene duplication were fairly simplistic, suggesting that
gene duplication allowed for a wild type copy of the gene to be present while a second copy
could evolve a side activity or novel function. A more accurate model for the evolution of
paralogous genes may be the innovation, amplification, and divergence (IAD) model proposed
by Bergthorsson, Andersson and Roth, which allows for selection at every step of the process
[112]. In this model, a gene containing a side activity is amplified, sometimes in large duplicated
arrays held by selection for the side activity. A copy of the gene may then acquire a mutation
allowing for the side activity to predominate, and the amplified copies may collapse. In the case
of the Osh6 and Osh7 paralogs, which may have evolved from a whole genome duplication of
yeast, such homologous genes are often thought to have redundant function, where side activities
are revealed following further investigation. Herein we present a further investigation into the
Osh6 and Osh7 proteins, providing evidence for their divergent regulation and function as well
as pathways for evolutionary selection.
Osh7 but not Osh6, appears to be directly phosphorylated by Snf1 and binds the SNF1
complex in vivo (Figure 2-2&3). To our knowledge, this is the first report of an OSBP as a
substrate for SNF1, which regulation may be conserved from yeast to mammalian cells since the
Snf1 homolog AMPK α1 (1-312) also phosphorylates the mammalian Osh7 homolog ORP8 in
vitro (Figure 2-2). The Snf1-dependent phosphorylation appears to stabilize the Osh7 protein in
vivo because yeast deficient in Snf1 or harboring a Snf1-KD mutant have no detectible Osh7
protein (Figure 2-3). Thus, Osh6 and Osh7 appear to be differentially regulated by Snf1.
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In addition to the differential regulation of these two proteins, Osh6 and Osh7 also appear
to have evolved disparate functions. Osh7 localized to ER-mitochondrial contact sites in this
study but Osh6 remained cytosolic (Figure 2-3), only yeast lacking Osh6 displayed defects on
respiratory media (Figure 2-4). Osh6 have a more significant role in mitochondria function
according to Seahorse assay compared to Osh7 along with a severe defect in mitophagy (Figure
2-5&6). Remarkably, no difference was seen in yeast morphology of mitochondria from either
yeast lacking Osh6 or Osh7, suggesting a defect in function rather than structure of the
mitochondria from ∆osh6 yeast. These results describe the first connection of Osh7 to yeast ERmitochondrial contact sites as well as the first role for Osh6 in respiration and mitophagy.
Thus far the human homologs of Osh6 and Osh7, ORP5 and ORP8, have been shown to
have overlapping function, being recruited to the ER-plasma membrane contact sites by
phosphatidylinositol4-5 bisphosphate (PtdIns(4,5)P2) and regulating PtdIns(4,5)P2 at the plasmid
membrane [88] . In addition, they have also been shown to affect respiratory function [104]. The
results in the study of differential function for the yeast paralogs of Osh6 and Osh7 may provide
a basis for the study of differential functions of the mammalian OSBP’s, particularly with respect
to mitophagy and the regulation by the Snf1 homolog AMPK. Mammalian ORPs have been
linked to a wide variety of diseases from dyslipidemia to ALS and cancer, making the
understanding of paralogous evolution particularly crucial.
2.7 Experimental procedures
2.7.1 Yeast Strains, plasmids and primers
Yeast strains, plasmids and primers used in this study is shown in Table 1. Yeast strains
generated in this study were constructed using standard polymerase chain reaction (PCR) based
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gene disruption followed by sporulation method as previously described [113, 114], unless
otherwise stated.
Table 2-1 List of yeast strain used
Background

genotype

abbreviation

a/
α

Reference/ Source

JGY 1

W303

his3, Leu2, lys2, met15, trp1,
ura3

WT

a

David Stillman,
University of Utah

JGY 91

W303

snf1::hphMX4, his3, Leu2, lys2,
met15, trp1, ura3

Δsnf1

a

Demille D, 2015

LYS2::GAL1UASGAL1TATA-His3 GAL2UASGal2TATA-Ade2
URA3::MEL1UASMEL1TATA, AUR1-CMEL1,
ura3-52, his3-200, ade2-101,
trp1-901, leu2-3, 112, gal4del,
gal80del, met-

Y2H Gold

a

Clontech

osh6::KanMX4, MATa his3∆1,
leu2∆0, met15∆0, ura3∆0

Δosh6
Diploid

a/α

GE Health Care
(CloneID:25074)

Strain

JGY 1031

JGY 1366

BY4742/BY474
1

MATα his3∆1, leu2∆0, lys2∆0,
ura3∆0
JGY 1400

SGAY7039

osh7::hphMX4 can1∆::STE2prLeu2, lyp1∆, ura3∆0, leu2∆0,
his3∆1, met15∆0

Δosh7

α

Joanna ZukowskaKasprzyk. Gavini
Research Group,
EMBL

JGY 1410

BY4741

mdm34::mCherry::KanMX4,
his3∆1, leu2∆0, met15∆0,
ura3∆0

Mdm34mCherry

a

Maya Schuldiner's
Lab, Weizmann
Institute of Science

JGY1416

BY4741

his3∆1, leu2∆0, lys2∆0, ura3∆0

WT

α

This study

JGY1418

BY4741

osh6::KanMX4, his3∆1, leu2∆0,
lys2∆0, ura3∆0

Δosh6

α

This study

JGY1419

BY4741

osh7::hphMX4, his3∆1, leu2∆0,
lys2∆0, ura3∆0

Δosh7

α

This study

JGY1425

BY4741

osh6::KanMX4, osh7::hphMX4,
his3∆1, leu2∆0, lys2∆0, ura3∆0

Δosh6Δosh7

α

This study

JGY1547

BY4741

atg32::KanMX4

Δatg32

Tim Formosa,
University of Utah

JGY1586

W303

OM45::GFP::HIS, ade2, ade6,
can1-100, his3-11,15, leu2-3,112,
trp1-1, ura3-1

OM45-GFP

Katrina Cooper,
Rowan University
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JGY1589

W303

osh7:hphMX4, his3, leu2, lys2,
met15, trp1, ura3

Δosh7

a

This study

JGY1628

BY4741

snf1::hphMX4,
mdm34::mCherry::KanMX4,
his3∆1, leu2∆0, met15∆0, ura3∆0

Δsnf1

a

This study

Table 2-2 List of plasmids used
Plasmid

Gene

Backbone

Organism

Origi
n

selection

Reference/ Source

pJG124

Empty
vector

pRS424

S. cerevisiae

2u

TRP

Jared Rutter,
University of Utah

pJG485

Y2H BD
Empty
vector

pGBKT7

S. cerevisiae

2u

TRP

Clontech

pJG549

Y2H AD
Empty
vector

pGADT7

S. cerevisiae

2u

LEU

Clontech

pJG725

Empty
vector

pRS416

S. cerevisiae

2u

URA

[82]

pJG1009

Empty
vector

pET15b with James
Y2H MCS

E. coli

Amp

[82]

pJG1054

Osh7

pET15b

E. coli

Amp

[82]

pJG1115

Osh7

pRS426

S. cerevisiae

2u

URA

This study

pJG1193

Snf1

pRS313

S. cerevisiae

CEN

URA

[75]

pJG1238

Sip2

YEp-GBD

S. cerevisiae

2u

TRP

[75]

pJG1260

Gal83
aa141-417

YEp-GBD

S. cerevisiae

2u

TRP

[75]

pJG1333

FL Osh7

pGADT7

S. cerevisiae

2u

LEU

This study

pJG1338

Snf1-KD

pRS313

S. cerevisiae

CEN

URA

This study

pJG1353

Osh7 c.c.
domain

pGADT7

S. cerevisiae

2u

LEU

This study

pJG1355

Osh7 OSBP
domain

pGADT7

S. cerevisiae

2u

LEU

This study

pJG1357

Osh7

pRS424

S. cerevisiae

2u

TRP1

This study

pJG1375

Sip1

YEp-GBD

S. cerevisiae

2u

TRP

This study

pJG1611

Osh7

pRS416

S. cerevisiae

CEN

URA

This study

pJG1656

Osh6

pET15b

E. coli

Amp

This study
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pJG1657

ampk α1
a.a.312

pET30a+

E. coli

Amp

Dave Thomson,
Brigham Young
university

pJG1658

ORP8 (PHOSBP)

pRS426

S. cerevisiae

2u

Amp

This study

pJG1659

ORP8
(OSBP)

pRS426

S. cerevisiae

2u

Amp

This study

pJG1660

ORP8

pCDNA4/TO

mammalian

Amp

Vesa Olkkonen,
University of
Helsinki

pJG1684

mito-TFP

pRS316

S. cerevisiae

URA

Katrina Cooper,
Rowan University

pJG1685

Vph1mCherry

pRS313

S. cerevisiae

HIS

Katrina Cooper,
Rowan University

pJG1688

mito-TFP

pRS313

S. cerevisiae

HIS

Katrina Cooper,
Rowan University

pJG1697

Osh7-YFP

pRS416

S. cerevisiae

URA

Katrina Cooper,
Rowan University

pJG1698

Osh6-YFP

pRS416

S. cerevisiae

URA

Katrina Cooper,
Rowan University

CEN
CEN

Table 2-3 List of primers used
Primers

Sequence

JG1000

CATGCGTCAATCGTATGTGAATGC

JG2184

CTGCAGCGAGGAGCCGTAAT

JG3185

GGCGAATTCATGGCTCTCAATAAACTAAAGAATATACC

JG3186

GCCTCGAGATTCTTTTGGATTCCATGCTTTTTATAAG

JG3207

GGC CATATGGCTCTCAATAAACTAAAGAATATACC

JG3209

GCCTCGAGTTAATTCTTTTGGATTCCATGCTTTTTATAAG

JG3398

CTTGAGTTTCCTAAAAATTTCGCTTTTGGCACAACAACTC

JG3996

GGCCCCGGGCTCTCCCTTAGTGCTTGTGAAATAAAC

JG3997

GGCGGATCCTATTCTTTTGGATTCCATGCTTTTTATAAGCC

JG3401

GTTCTTCTTATCTACTTTTTAACTTGTGTG

JG3402

GATGCGGAAACAACGGGTTGAACC

JG3592

GCCAAAAAGTTGCTCTAAGAATCATTAATAAGAAGG

JG3603

CAACTTTCTCTTCTTGGATCTCTCC
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JG3604

GGGAAATTTCAAAGATTTTTTTAATAGAGGC

JG3763

ATTCATATGAATATTATTTCCCAGCTGAAGCCAGG

JG3764

TCCTCGAGCTACTTGTAAATATAATAATCTAAATCCTCAC

JG3765

GAACATATGGCCGAAGACGGCGTTGAATTTCATTC

JG3988

GGCGGATCCATGGGCTCCAAAAAACTGACCGTAGGATCTG

JG3989

CGGCTCGAGCTATTGTTTTGCTGGGTTCTGCTTTTCG

JG4442

GGCGTCGACTTATTTGTACAATTCATCCATACCATGGGTAATACC

JG4445

GGCCCCGGGATGTCTAAAGGTGAAGAATTATTCACTGGTGTT

JG4446

GGCCAATTGACACTATTGAAACAAGTCCGTCCTGGC

JG4447

GCCGTCGACGTAATGCCATTCTCCTGTGAGTGGATCAAG

JG4448

GGCCAATTGATTGTTATGGCTGATTGGTTAAAGATTCGTGG

JG4522

TTTGACTCTCCTGCCTGCATGGTG

JG4523

AATAGCCCTGCGTTCACAAACTCG

JG4524

CGTTATCTAAGGCGAAGGAGGACTTG

JG4525

CGCCGGCAAAGTTACCCATAG

JG4551

GTTCCCGGGTTTGTACAATTCATCCATACCATGGG

JG4552

GGCACTAGTATGTCTAAAGGTGAAGAATTATTCA

JG4605

GGCCCCGGGATGGGCTCCAAAAAACTGACCGTAG

2.7.2 Growth media
Yeast strains were grown aerobically at 30°C unless otherwise stated. Medium used:
YPAD (1% yeast extract, 2% peptone, 2% glucose with adenine), synthetic minimal medium
with glucose or galactose (SD-/ SGal-; 0.67% yeast nitrogen base without amino acids, 0.2%
auxotropic amino acids with vitamins, 2% glucose or 2% galactose), YPD (1% yeast extract, 2%
peptone, 2% glucose), YPL (1% yeast extract, 2% peptone, 2% lactic acid, pH 5.5), synthetic
minimal medium lacking nitrogen (SD-N; 0.17% yeast nitrogen base without amino acids, 2%
glucose), depleted synthetic medium with glucose (SDD-; 0.17% yeast nitrogen base without
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amino acids, 0.6% of auxotrophic amino acids, 0.5% ammonium sulfate, 2% glucose or 0.05%
glucose).
2.7.3 In vitro kinase assays
Yeast plasmids expressing human ORP8 were constructed by PCR amplifying from
plasmid containing ORP8 cDNA (pJG1660)-- a kind gift from Dr. Vesa M. Olkkonen
(University of Helsinki). Plasmid with ORP8 PH-OSBP domain (pJG1658) were amplified
using JG4447/JG4448, plasmid with ORP8 OSBP domain (pJG1659) were amplified using
JG4446/JG4447 and cloned into EcoRI/XhoI site of pJG859. Bacteria expressing full length
Osh7 (pJG1054), constitutively active human AMPK α1 (PRKAA1) [115], full length Osh6
(pJG1656) was constructed by PCR amplifying Osh6 from JGY1 using JG3988/JG3989 and
cloned into the BamHI and Sall site of pJG1009, were also used.
Yeast (JGY1 or JGY91) harboring wildtype Snf1-myc, Snf1 kinase dead Snf1 KD-myc
(pJG1193) or ORP8-HIS (pJG1658, pJG1659) plasmids were grown in selective 2% glucose
synthetic minimal medium (SD-Ura) overnight, diluted 1:100 into 500mL of SD-Ura and grown
for 12 hours, pelleted and resuspended in 500mL of selective 2% galactose synthetic minimal
media (SGAL-Ura) and grown for 36 hours.
BL21 (DE3) Escherichia coli harboring Osh7-HIS (pJG1054), Osh6-HIS (pJG1656) or
PRKAA1-HIS (pJG1657) were grown overnight at 37°C in Luria Bertani broth supplemented
with ampilicin (LB Amp), diluted 1:100 into 500mL of LB Amp and grown for 3 hours,
followed by 5 hours induction in LB Amp supplemented with 0.5 mM of IPTG.
Cells were pelleted and resuspended in appropriate lysis buffer: Myc-tagged purification
lysis buffer (20 mM HEPES, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, 10%
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glycerol, 1 mM β-mercaptoethanol, Pierce Protease Inhibitor Tablet, pH 7.4, with or without
phosphatase inhibitor-- 50 mM NaF, 35mM glycerophosphate); and HIS-tagged purification
lysis buffer (50 mM HEPES, 300 mM NaCl, 20 mM imidazole, 10 mM KCl, 1 mM βmercaptoethanol, Pierce Protease Inhibitor Tablet, pH 7.8). Cell suspension were then lysed with
Microfluidics M-110P homogenizer (Microfluidics, Westwood, MA). Cell debris were then
pelleted by centrifugation at 12,000 rpm, 4°C for 30min twice, transferring supernatant to a new
tube after the first and second centrifugation. For HIS-tagged purification, 300 μL of nickelnitrilotriacetic acid (Ni-NTA) agarose beads (Qiagen, Valencia, CA) was added to each 500mL
culture of cell lysate and incubated at 4°C for 3 hours with agitation; for Myc-tagged
purification, 20-25 μl of Myc-conjugated magnetic beads (Cell Signaling, Danvers, MA) were
added to each 500 mL culture of cell lysate and incubated at 4°C for 2 hours with agitation. After
incubation, Ni-NTA beads for HIS-tagged purification were washed twice with 10-15 mL ice
cold lysis buffer without protease inhibitor (centrifugation at 1000 rpm, 4°C), transferred to
polypropylene column and washed with additional 50 ml of lysis buffer without protease
inhibitor. Myc-conjugated magnetic beads were washed with 4 ml of ice-cold lysis buffer
without protease inhibitor per 5 μl of beads, using magnetic field to separate liquid from the
beads. HIS-tagged protein were then eluted 3 times with 300 μl of elution buffer containing 250
mM imidazole and 100 mM NaCl without protease inhibitors. HIS-tagged protein can then be
stored in 15% glycerol at -80°C. Myc-tagged protein were used immediately after purification
without eluting.
WT Snf1-Myc/ Snf1 KD-Myc/ PRKAA1 were incubated with Osh6/ Osh7/ ORP8 PHOSBP/ ORP8 OSBP in total volume of 30 μl of reaction mixture containing 1X Snf1 kinase
buffer (50 mM Tris-HCl, 10 mM MgCl2), 1 mM dithiothreitol (DTT), pH 7.5, 10 μM ATP, and
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7.5 μCi of γ32P-ATP (MP Biomedicals) for 35 min at 30°C. Kinase assays were stopped by the
addition of 6X SDS-PAGE sample buffer, analyzed by SDS-PAGE, stained with coomassie blue
(30 min), destained for 2 h, soaked in water for 1 h, dried and exposed to film in -80°C.
2.7.4 Yeast-2-hybrid assays
Plasmid containing Osh7 OSBP domain (pJG1355) and coiled coil (CC) domain
(pJG1353) were PCR amplified using JG3763/JG3764, JG3765/JG3209 from pJG1115 and
cloned into pJG549. Bait plasmid with Gal83/Sip1/Sip2/EV control were co-transformed with
prey plasmid with full length Osh7/ OSBP/ CC/ EV control into Y2H Gold strain (JGY1031) and
selected on SD-Leu-Trp plates and grown for 2 days at 30°C. Transformants were inoculated
into 5 mL liquid cultures in SD-Leu-Trp and grown overnight, then serial diluted 1:5- 3,125 fold
and 5uL of each dilution were spotted on SD-Leu-Trp plates as growth control and SD-Leu-TrpHis-ade plates to select for protein-protein interaction. Each construct has been tested with
corresponding EV bait/prey plasmid control to eliminate false positive results.
2.7.5 Co-IP of Osh6/ Osh7 with Snf1
His-tagged Osh6/Osh7 were purified from E. coli BL21 (DE3) using standard His-tagged
protein purification as previously described. Yeast (JGY4) harboring plasmid with Snf1 under
ADH promoter (pJG1193) were grown in SD-URA for 12 hours then transfer to SGal-Ura for 36
hours. Cells were then pelleted and resuspended in myc-tagged purification lysis buffer (20 mM
HEPES, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, 10% glycerol, 1 mM βmercaptoethanol, Pierce Protease Inhibitor Tablet, pH 7.4, with phosphatase inhibitor-- 50 mM
NaF, 35mM glycerophosphate) and lysed open using glass beads disruption. Cell lysate were
then centrifuged at 14,000 rpm for 30 min twice to remove cell debris. Purified Osh6-HIS and
Osh7-His were then added into JGY4-Snf1-myc lysate followed by Myc-tagged protein
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purification using Myc-Tag mouse mAB conjugated magnetic beads (Cell Signaling Technology
#5698) to pull down Snf1-myc. Protein bound beads were then washed multiple times and boiled
in sample buffer before separation on 10% SDS-PAGE. Osh6/Osh7 were detected with western
blotting using anti-His antibody (Proteintech #HRP-66005) at 1:10,000, 2.5% milk TBST, and
Snf1 using anti-myc antibody at 1:1000, 5% BSA, TBST.
2.7.6 Stability assays
WT yeast (JGY1) and Snf1 knockout yeast (JGY91) harboring plasmids with WT Osh7/
WT Snf1/ Kinase dead (KD) Snf1/ EV-HIS and/ or EV-Myc control were grown overnight at
30°C, diluted 1:100 into 100mL of SD-Ura-Trp and grown for 12 hours. Cells were then pelleted
and resuspended in SGal-Ura-Trp and induce protein expression for 36 hours. Cells were subject
to standard His-tagged purification followed by western blotting or crude lysate analysis. Crude
lysate analysis: OD600 =1 number of cells were resuspended in 10% Trichloroacetic acid (TCA;
10% final concentration) and incubated for 10 min on ice. Cells were then pelleted by
centrifugation at 14,000 rpm at 4°C for 10 min. After washing the pellet twice with 1 ml of icecold acetone, the pellet is air-dried. Air dried pellet were then resuspended in 100 μl of sample
buffer (150 mM Tris-HCl, pH 8.8, 6% SDS, 25% glycerol, 6 mM EDTA, 0.5% 2mercaptoethanol, and 0.05% bromophenol blue) and lysed by vortex with glass beads for 4 min
followed by boiling at 100°C for 3 min. Proteins in crude lysate were then resolved in 10% SDSPAGE and subject to western blots analysis. Presence of Osh6/Osh7-His were detected with antiHis and anti-UGP1 (a kind gift from Jared Rutter’s Lab) were used as a loading control.
2.7.7 Microscopy for Osh6-YFP and Osh7-YFP localization
Yeast harboring YFP-Osh7 (pJG1697) and YFP-Osh6 were grown overnight in 2%
glucose SD-URA, diluted 1:100 in 10mL 2% glucose SD-Ura and grown to log phase (4 hours at
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30°C). Cells were then pelleted and resuspended in 0.05% glucose SDD-URA for 2 hours. Cells
were imaged before and after starvation using Fluoview confocal microscope. Osh7-YFP colocalization with Mdm34-mCherry were counted (n=100cells) and analyzed using Prism.
2.7.8 Florescent microscopy mitochondria morphology
Cells harboring Mito-TFP plasmid were grown to log phase in SDD-His and then starve
in SD-N for 6 hours. Mitochondria morphology were analyzed using a Nikon microscope (model
E800) before and after starvation.
2.7.9 Plate testing for respiration
WT, Δosh6, Δosh7 and Δosh6Δosh7 were grown for 2 overnights in 3mL SD-complete at
30°C. Saturated culture were then serial diluted to 1:5- 3,125 fold in water and 5uL of each
dilution were spotted on SD-complete plate (growth control) and SGE-complete plate to test for
mitochondria dysfunction. Plates were incubated at 30°C for 2-3 days.
2.7.10 Whole yeast seahorse respiration assay
Cell Culturing and Culture Plate Preparation. A detailed explanation for the entire
Seahorse protocol is contained within the supplementary protocol but will be briefly explained
here. Single and double knockout strains were streaked onto YPAD and then liquid cultures were
started in SD-Complete. During this time a Seahorse Cell Culture Plate was also prepared for cell
seeding on the day of the assay. Overnight cultures were diluted into SGE-Complete after which
cells were plated and allowed to incubate until the beginning of the respiration assay.
Sensor cartridge and drug preparation. While preparing the cell culture plate the wells
and moats of the sensor cartridge utility plate were filled with XF calibrant and placed in a nonCO2 humidified 37⁰ C incubator overnight. Carbonyl cyanide-p-
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trifluoromethoxyphenylhydrazone (FCCP) and triethyltin chrloride (TET) used to test different
respiratory conditions were prepared the day of the assay. Injection ports A and C of the sensor
cartridge were loaded with 20 μl of S-Complete, port B TET, and port D FCCP. The sensor
cartridge and utility plate were loaded into the XFp Analyzer for initial calibration.
OCR Normalization and XFp Analyzer Settings. Measurement cycles were performed as
a 3 min mix, no wait, and 3 min measurement. Basal respiration was measured three times, port
A injection twice, port B four times, port C twice, and port D four times. OCR was normalized to
viable cells by plating serial dilutions of cell cultures on YPAD and calculating CFU/μl.
2.7.11 Mitophagy assays
Mitophagy of WT, Δosh6, Δosh7 and Δosh6Δosh7 yeast were monitored using OM45GFP processing assay as previously described [110] and microscopy using mitochondria
targeting TFP and vacuole targeting Vph1-RFP assays. Mitophagy was induced using post-log
phase method in OM45-GFP processing assays followed by detection of mitophagy using
western-blotting with anti-GFP (Proteintech #66002-1).
Mitophagy studies using chimeric fusion proteins were performed in live cells and
imaged using florescent microscopy. For all experiments, cells were grown to mid-log (5x106
cells/mL), spun down and washed with H2O and resuspended in SD-N media for 24 hours. Cells
were then analyzed by fluorescence microscopy and images were obtained using a Nikon
microscope (model E800) with a 60x objective (Plan Fluor Oil, NA 1.3) and a CCD camera
(RETIGA Exi). Data were collected using Autoquant and processed using Image Pro software.
All images were obtained using the same exposures for the course of the experiment. Plasmids
used: RSB2598 ADH1-mitoTFP-CYC1, RSB2600 ADH1-Vph1-mCherry-CYC1.
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2.8 Supplementary methods
2.8.1 Cell culturing and culture plate preparation
The knockout yeast strains were streaked on YPAD solid media and grown for 54 hours
at RT. Different growth times and temperatures were tested with varying degrees of success.
Room temperature was chosen because we wanted to avoid gaining suppressors in the knockouts
and hiding interesting phenotypes. Using a growth time of 54 hours allowed the colonies to
become large enough to pick but minimized suppressor acquisition. Less time also yielded poor
growing liquid cultures in the next step, which failed to respire. We inoculated 5 ml of SDComplete liquid media in triplicate (to make sure at least one would reach saturation) with single
colonies and grew them at 30⁰ for 42 hours while rotating. At this stage 30⁰ was chosen because
room temperature cultures yielded erratic oxygen rates and sometimes would not respire despite
the cells being alive when tested later. Approximately 18 hours before the assay the wells of the
cell culture plate were coated with 50 μl of 0.25 mg/ml concanavin A, add 400 μl of water per
moat, and store at 4⁰. After the 42 hours we then diluted 100 μl of saturated cell culture into 5 ml
of SGE-Complete, made day of experiment, and let them grow at 30⁰C for 6 hours while
rotating. If the cultures don’t look saturated then there is a good chance it won’t respire. While it
is possible for a strain to be so slow growing it doesn’t get saturated but can still respire we often
saw that lack of saturation correlated with no respiration or it was erratic. The cells were then
centrifuged at 3000 rpm for three minutes and the pellets resuspended in fresh SGE-Complete to
an OD600 between 0.2 and 0.3. Seeding the proper number of cells for a Seahorse respiration
assay is important as the machine has an optimal OCR range where the readings can be
normalized correctly. Using saturated cultures as described above for these strains will put them
close to the 0.2 to 0.3 OD600 range. Most strains are optimal for seeding near 0.25. However, it
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should be noted that strains used in other experiments while this protocol was designed were
optimal near 0.2 and 0.35. We seeded 50 μl of cell suspension into wells B-G and 50 μl of SGEComplete into wells A and H of the cell culture plate. The plate should be washed with water
prior to seeding to remove unbound concanavin A. After seeding the plate was centrifuged at 300
rpm for 1 min with no brakes and cell adherence was verified under a microscope. The volume
of the wells was brought up to 180 μl with SGE-Complete, the moats filled with 200 μl of water,
and the plate was placed in a 30⁰ incubator for 40 min until loading into the Seahorse XFp
Analyzer.
2.8.2 Sensor cartridge and drug preparation
While preparing the cell culture plate the day before the assay. We filled the wells and
moats of the sensor cartridge utility plate with 200 and 400 μl of XF calibrant, respectively and
placed it in a non-CO2 humidified 37⁰ incubator overnight. Three hours prior to beginning the
assay we prepared a 260 μM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) and
10% ethanol solution in S-Complete. At this stage ethanol is the primary carbon source for the
yeast and minimizing the amount added is ideal. To make the FCCP got into solution it was
incubated in a 45⁰ water bath. It should have a transparent very light-yellow color when ready.
After the cell culture plate has started its 40 min incubation we prepared an 806.3 uM solution of
triethyltin chloride (TET) in S-Complete in a chemical fume hood. Warnings on the bottle
included fatal when inhaled, fatal when ingested, and fatal when in contact with skin. Keep
reagent bottle wrapped in absorbent material and in a sealed secondary container. TET has a
damp earth and musty or moldy smell to it. If the smell is strong or present for a long time
something is wrong with containment. The smell is occasionally detectable when the resealed
container is taken from the fumehood but it isn’t detectable when diluted and is safe to handle.

40

We then loaded injection ports A and C of the sensor cartridge with 20 μl of S-Complete, port B
TET, and port D FCCP. The sensor cartridge and utility plate were inserted into the XFp
Analyzer for calibration. Once the calibration was over the cell culture plate was inserted.
2.8.3 OCR normalization and XFp analyzer settings
Measurement cycles were performed as a 3 min mix, no wait, and 3 min measurement.
Basal respiration was measured three times, port A injection twice, port B four times, port C
twice, and port D four times. OCR was first normalized to viable cells by plating serial dilutions
of cell cultures on YPAD and calculating CFU/μl. Using the strains in the OD600 range
described above in serial dilutions and plating has yielded easy counting when 50 μl of a 10-3
and 100 μl of a 10-4 dilution is plated. Cells started appearing after two days but an official count
was taken after four days because some strains will have many colonies appear later.
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Phosphorylation
Kai Li Ong1, Katrina Cooper2, Julianne Grose1
3.1 Author information
1

Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT,

84602, USA
2

Department of Molecular Biology, Graduate School of Biological Sciences, Rowan University,

Stratford, NJ, 08084, USA
*Correspondence: grosejulianne@gmail.com; Tel.: +01-801-422-4940
Kai Li Ong - jkm525@go.byuh.edu
Katrina Cooper - cooperka@rowan.edu
Julianne Grose - julianne_grose@byu.edu

*The work described in this chapter has been submitted to a scientific journal and is under
review. It has been formatted for this thesis, but it is otherwise unchanged.
42

3.2 Abbreviations
SSN2- Suppresor of SNF1
MED13- Mediator complex subunit 13
Cdk8- Cyclin dependent kinase 8
PASK- Per-Arnt-Sim (PAS) kinase
Psk1- Pas domain-containing Serine/threonine protein Kinase 1
Psk2- Pas domain-containing Serine/threonine protein Kinase 2
CWI- Cell wall intergrity
MAPK- Mitogen-activated protein kinases
CKM- Cdk8 Kinase module
Slt2- Suppressor of the LyTic phenotype 2
IDR- Intrinsic disordered region
Rho1- Ras Homolog 1
USF1- Upstream stimulatory factor 1
Pkc1- Protein kinase C 1

43

3.3 Abstract
Per-Arnt-Sim (PAS) kinase is an important nutrient sensing kinase that is evolutionarily
conserved from yeast to man. It is known to increase lipid production in response to nutrients
while decreasing respiratory metabolism. Herein we describe a novel function of PAS kinase in
the regulation of cell death. SSN2 (MED13) was previously retrieved from a yeast two-hybrid
screen for direct PAS kinase binding partners. Together with cylin C, Med13 is part of the CDK8
Kinase Module (CKM) in the multi-subunit mediator complex that acts as an interface between
DNA bound transcription factors and RNA polymerase II. In yeast, Med13 is degraded in
response to unfavorable cellular stress and triggers nuclear release of cyclin C into the cytoplasm
where it promotes mitochondrial fragmentation and programed cell death. Herein we provide
evidence for the direct phosphorylation and stabilization of Med13 by PAS kinase, the
corresponding inhibition of nuclear cyclin C release, and the regulation of mitochondria
fragmentation upon carbon or oxidative stress.
3.4 Introduction
Cells have developed complex mechanisms for sensing their cellular environment and
control key metabolic processes appropriately. At the heart of these mechanisms are sensory
protein kinases, capable of regulating many interrelated pathways through the phosphorylation of
tens of substrates. Per-Arnt-Sim (PAS) kinase is a conserved sensory protein kinase that
regulates glucose homeostasis in yeast, mice and humans.
PAS kinase controls a pivotal point in glucose allocation, the partitioning of glucose to
lipid biosynthesis versus respiratory metabolism. In mice, PAS kinase-deficiency has been
shown to protect against weight gain, hepatic triglyceride accumulation, and insulin insensitivity
when mice are placed on a high-fat diet [77]. These mice are also hypermetabolic in that they
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display increased whole-animal CO2 output and O2 uptake when compared to their wild-type
littermates. This protection from hepatic triglyceride accumulation was also seen in PAS kinasedeficient mice placed on a high-fat high-sugar diet, which more closely resembles the western
diet [116]. In addition, liver and muscle tissue from these mice displayed increased respiratory
rates when compared to the wild type littermates. These effects on triglyceride and respiratory
metabolism appear to be evolutionarily conserved in that yeast PAS kinase also controls lipid
biosynthesis and respiration, in part through the phosphorylation of its substrate Cbf1 [82].
In addition to the regulation of triglyceride biosynthesis and respiratory metabolism, PAS
kinase is regulated by nutrient status. PAS kinase activity increases upon fasting and refeeding,
as well as by the addition of glucose [78]. In addition, PAS kinase has also been shown to
control pancreatic B-cell insulin and glucagon production in response to glucose in both humans
and mice studies [117-120].
Herein we describe a novel function for PAS kinase in regulating mitochondrial
fragmentation and cell death through the phosphorylation and subsequent stabilization of Med13
(also known as SSN2 in yeast). Med13, together with cyclin C, is part of CDK8 Kinase Module
(CKM) in the multi-subunit mediator complex that acts as an interface between DNA bound
transcription factors and RNA polymerase II. In yeast, Med13 is degraded in response to
unfavorable cellular stress such as peroxide stress [121, 122]. This degradation triggers nuclear
release of cyclin C into the cytoplasm, where cyclin C associates with the mitochondria to
promote mitochondrial fragmentation and programed cell death. The glucose responsive kinase
Snf1 has recently been shown to regulate Med13 degradation in response to reactive oxygen
species [122]. Herein we describe a novel, direct role for a second sensory kinase in this
pathway, placing PAS kinase as a regulator of cell death in response to glucose.
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3.5 Results
3.5.1 PAS kinase 1 (Psk1) interacts with Med13 in vivo
A previous large-scale yeast-2-hybrid (Y2H) screen for PAS kinase binding partners
identified Med13 as putative direct binding partner of Psk1 [82]. The interaction between
Med13 and PAS kinase was further studied through truncation analysis, with amino acids 571650 being required (Figure 3-1). This region is part of the intrinsic disordered region (IDR) of
Med13 and has been previously identified as the Med13 degron, the region required for Med13
degradation. IDR’s are defined by a continuous stretch of flexible, disorder-promoting residues
that are key to cellular control in that they facilitate the relay of macromolecular decisions as
they transition to more ordered states.
3.5.2 Psk1 phosphorylates Med13 in vitro
The relationship between Med13 and Psk1 has not been previously explored and there are
many possible outcomes from their protein-protein interaction. For example, Med13 could be a
binding partner that regulates Psk1 activity, such as by localizing it to the CKM, or it could serve
as a substrate of Psk1. We therefore purified Psk1 as well as Med13 and assayed for direct, Psk1dependent phosphorylation through in vitro kinase assays (Figure 3-2). Psk1 phosphorylated
Med13571-650 in vitro, while the kinase dead (KD) mutant of Psk1 showed only weak
phosphorylation, suggesting that Med13 is directly phosphorylated by Psk1. Note that Psk1 has
been previously show selectively for only certain phosphorylate substrates under the in vitro
kinase conditions utilized herein [82].
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A.

B.

Figure 3-1 PAS kinase directly binds to Med13 as found in a yeast two-hyrid assay (A) A diagram of the full length
Med13 protein, indicating the region of the SCFGRR1 degron and the mediator complex subunit 13 (Med13)
domain. The two yeast two-hybrid constructs that bind to PAS kinase 1 (Psk1) are indicated below the full-length
protein. Both contain the degron. (B) A dilution series showing the strength of the interaction between Psk1 and
Med13504-703.
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Figure 3-2 Psk1 phosphorylates Med13 in vitro Purified Med13571-650 was incubated with radiolabeled 32-P ATP in
the presence or absence of purified Psk1/ Psk1-KD for 12 min at 30°C. Samples were then resolved in 12% SDS–
PAGE, followed by staining with Coomassie blue. Gels were then dried and imaged on x-ray film. Lane 1:
Psk1+USF1; Lane 2&3: Psk1+ Med13571-650; Lane 4&5: Psk1-KD+ Med13571-650; Lane 6: Psk1 only; Lane 7: Psk1KD only; Lane 8: Med13571-650 only. Psk1 is not visible in the Coomassie Blue stained gel due to low protein
concentration.

3.5.3 Psk1 is required for Med13 degradation in response to carbon stress
In order to determine the effects of Psk1-dependent Med13 phosphorylation in vivo, the
stability of cyclin C was assessed in response to carbon source, a known regulator of Psk1
activity [123]. As shown in Figure 3-3B, Med13 is degraded upon switching from high glucose
to low glucose (0.5%). This degradation is dependent upon PAS kinase as it is not seen in the
Δpsk1Δpsk2 yeast.
Cyclin C nuclear release before and after glucose stress was also examined with
Fluoview confocal microscope. PAS kinase appears to play a role in the nuclear release of cyclin
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C as well upon 2 hours of 0.05% glucose stress in that cyclin C remains nuclear in many of the
PAS kinase-deficient (Δpsk1Δpsk2) yeast (Figure 3-3B).

A.

B.

Figure 3-3 PAS kinase is required for Med13 degradation in response to carbon stress (A) Wild type and
Δpsk1Δpsk2 yeast overexpressing Med13-Myc were transferred from 2% glucose to 0.5% glucose for 0, 1, 2 and 4
hours, and yeast extracts were analyzed by western blot using anti-myc antibody for MED13-Myc detection (cell
signaling). (B) Cyclin C localization in WT and Δpsk1Δpsk2 knockout strain were observed with Fluoview confocal
microscope before and after 2 hours 0.05% glucose stress. Yeast harboring plasmids with cyclin C-YFP, mitomCherry were used in this study and NucBlueTM Live ReadyProbesTM was used to visualize the nucleus.
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3.5.4 Psk1 affects localization of cyclin C and its nuclear release upon oxidative stress
The degradation of Med13 has been shown to promote the export of cyclin C from the
nucleus into the cytoplasm, where it binds mitochondria to initiate fragmentation and subsequent
cell death. The localization of cyclin C was therefore used as a readout for Med13 activity in
wild type versus PAS kinase-deficient yeast (Δpsk1Δpsk2). As previously shown, cyclin C is
exported to the cytoplasm in response to 1mM H2O2 stress (Figure 3-3). This localization was
inhibited to an extend by PAS kinase deficiency. In Δpsk1Δpsk2 yeast, a single peri-nuclear foci
of cylin C-YFP is seen under normal growth condition and upon 2h oxidative stress, with lesser
nuclear release of cyclin C after 2h oxidative stress compared to wild type.
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Figure 3-4 PAS kinase plays an important role in cyclin C nuclear release upon oxidative stress Localization of
cyclin C-YFP in wild-type or Δpsk1Δpsk2 cells before and following 2 h treatment with H2O2 (1 mM) was
visualized through Fluoview confocal microscope. Perinuclear foci of cylin C-YFP is seen in Δpsk1Δpsk2 cells and
psk1/ psk2 affected nuclear release of cyclin C upon oxidative stress.

3.6 Conclusions
Cell death pathways are intimately tied to external cues, containing many check points in
order to avoid unnecessary destruction. One such cell death pathway is the cyclin C pathway in
which is translocation from the nucleus to the cytoplasm results in mitochondrial fragmentation
and, ultimately, cell death. We have previously shown cyclin C translocation to be dependent on
two critical pathways (Figure 3-5). First is the Cell Wall Integrity (CWI) MAPK pathway. In
this pathway, cell wall sensors including Wsc1, Mtl1 and Mid2 are activated by stresses such as
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hydrogen peroxide, leading to the activation of Rho1 which phosphorylates protein kinase C
(Pkc1), initiating the CWI MAPK cascade. Slt2 is activated by this cascade, and phosphorylates
cyclin C, which in turn phosphorylates Med13 in a priming event. Med13 is then
phosphorylated by Slt2, targeting it for destruction by the ubiquitin-mediated SCFGRR1 pathway.
Recently, the SNF1 complex was shown to be required for this pathway, but the molecular
mechanisms of this pathway have not been described. Herein we provide evidence that PAS
kinase, a known downstream target of SNF1, directly phosphorylates Med13 and is required for
its degradation in response to carbon or hydrogen peroxide stress. A model for the regulation of
cyclin C localization through a cascade including PAS kinase (Psk1) is shown in Figure 3-5.
First, yeast Psk1 directly interacts with Med13 in vivo, specifically at the previously
identified degron (amino acids 571-650, Figure 3-1), and phosphorylates Med13 in vitro (Figure
3-2). PAS kinase is also required for the degradation of Med13 by the SCFGRR1 pathway in
response to carbon stress. And finally, PAS kinase-deficiency leads to cyclin C retention in the
nucleus.
The complexity of two signaling cascades involving several protein kinases allows for
careful control of the cell death pathway in response to several external stimuli. The CWI
pathway has been shown to be activated by many cell membrane perturbing agents, including
chlorpromazine. Interestingly, PAS kinase is also activated by cell integrity stress [123],
including the cell membrane perturbing agent chlorpromazine. In addition to cell integrity stress,
PAS kinase is well-known to respond to nutrient status, particularly glucose, in both yeast and
mammalian cells [75, 78, 123]. Herein we provided the first evidence for Med13 degradation
and cyclin C export in response to glucose depravation (Figure 3-3).
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Figure 3-5 A model for the regulation of cyclin C localization through a cascade including PAS kinase (Psk1) Cell
wall stress (such as peroxide) stimulates cell wall sensors (Wsc1, Mtl1 and Mid2) to activate Rho1 which in turn
activates protein kinase C (Pkc1) which triggers the SWI MAPK cascade, leading to the activation of Slt2. Slt2
directly phosphorylates cyclin C, which then primes the degron through cyclin C/Cdk8 phosphorylation of Med13.
A second phosphorylation event is required. Snf1 kinase, in response to peroxide or carbon stress, activates PAS
kinase and phosphorylates Med13, targeting the degron for ubiquitin-mediated SCFGrr1 degradation.

In addition to Med13, three other yeast PAS kinase substrates have been characterized.
First, UDP-glucose pyrophosphorylase (UGP1), a key enzyme in glucose utilization for glycan
biosynthesis, a component of the yeast cell wall. Phosphorylation of Ugp1 results in increased
increased cell wall biosynthesis, necessary for growth, and decreased glycogen storage. This
pathway is consistent with the role of PAS kinase described herein in-conjunction with the cell
wall integrity pathway. Second, PAS kinase phosphorylates yeast Cbf1, shifting cellular
metabolism from respiration and toward lipid biosynthesis, which lipids are also required for the
cell membrane. And finally, PAS kinase phosphorylates yeast Pbp1 to activate stress granule
formation and TORC1 inhibition at stress granules [124]. In addition to these two substrates,
yeast Psk2 has been shown to activate Rho1 by an unknown mechanism, suppressing the growth
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defect of a tor2 temperature-sensitive mutant [125]. Each of these roles appears to be a cell
survival role, promoting cell growth and proliferation. At first glance, they are strikingly
juxtaposed to the cell death pathway described herein. However, it is likely that these sensory
pathways play a two-fold role in the cell. First, they alert the cell to the need for increased
glucans and lipids necessary for cell growth or to repair cell damage. And second, they initiate
cell death when this damage is too severe. This is supported by the ability of Psk2 to activate
Rho1, an upstream kinase in the Med13 pathway, suggesting PAS kinase regulates the
Med13/cyclin C/Cdk8 pathway by two mechanisms. The Med13/cyclin C/Cdk8 pathway
described herein requires several inputs and priming events, ensuring that cell death is not
initiated without several inputs.
3.7 Experimental procedure
3.7.1 In vitro kinase assay
Yeast (JGY142 or JGY4) harboring wildtype Psk1-HIS (pJG1089), kinase dead Psk1
KD-HIS (pJG1170) or were grown in selective 2% glucose synthetic minimal medium (SDTrp/Ura) overnight, diluted 1:100 into 500mL of SD-Trp/ Ura and grown for 12 hours, pelleted
and resuspended in 500mL of selective 2% galactose synthetic minimal media (SGAL-Trp/Ura)
and grown for 36 hours.
BL21 (DE3) Escherichia coli harboring Med13-HIS were grown overnight at 37°C in
Luria Bertani broth supplemented with ampilicin (LB Amp), diluted 1:100 into 500mL of LB
Amp and grown for 3 hours, followed by 5 hours induction in LB Amp supplemented with 0.5
mM of IPTG. Cells were pelleted and resuspended in HIS-tagged purification lysis buffer (50
mM HEPES, 300 mM NaCl, 20 mM imidazole, 10 mM KCl, 1 mM β-mercaptoethanol, Pierce
Protease Inhibitor Tablet, pH 7.8) with or without phosphatase inhibitor (50 mM NaF, 35mM
54

glycerophosphate). Cell suspension were then lysed with Microfluidics M-110P homogenizer
(Microfluidics, Westwood, MA). Cell debris were then pelleted by centrifugation at 12,000 rpm,
4°C for 30min twice, transferring supernatant to a new tube after the first and second
centrifugation. For HIS-tagged purification, 300 μL of nickel-nitrilotriacetic acid (Ni-NTA)
agarose beads (Qiagen, Valencia, CA) was added to each 500mL culture of cell lysate and
incubated at 4°C for 3 hours with agitation. After incubation, Ni-NTA beads for HIS-tagged
purification were washed twice with 10-15 mL ice cold lysis buffer without protease inhibitor
(centrifugation at 1000 rpm, 4°C), transferred to polypropylene column and washed with
additional 50 ml of lysis buffer without protease inhibitor. HIS-tagged protein were then eluted 3
times with 300 μl of elution buffer containing 250 mM imidazole and 100 mM NaCl without
protease inhibitors. HIS-tagged protein were then be stored in 15% glycerol at -80°C.
WT Psk1-His/ Psk1 KD-HIS were incubated with Med13-HIS in total volume of 30 μl of
reaction mixture containing 1X kinase buffer (pH 7.5), 0.2mM ATP, and 0.2 μCi of γ32P-ATP
(MP Biomedicals) for 12 min at 30°C. Kinase assays were stopped by the addition of 6X SDSPAGE sample buffer, separated by SDS-PAGE, stained with coomassie blue (30 min), destained
for 2 h, soaked in water for 1 h, dried and exposed to film in -80°C.
3.7.2 Cyclin C-YFP nuclear release microscopy
WT (JGY1) and Δpsk1Δpsk2 (JGY4) yeast strain were transformed with cyclin C-YFP
(pJG1703) and mitochondria targeting mCherry plasmid- Mito-mCherry (pJG1691). 50 µL of
overnights from each transformant were transferred to 25mL of SD-URA-TRP (2% glucose) and
cultures were grown to late log phase (OD600 = 0.8~1.3), followed by 2 h of 1mM H2O2/
switching to 0.05% glucose SD-URA-TRP treatment. Cells were then fixed immediately in 70%
ethanol and store in 4°C for >12 h. Before imaging with Fluoview confocal microscope, cells
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were pelleted, washed twice in 1mL ddH2O and stained with NucBlueTM Live ReadyProbesTM at
the concentration of 1 drop/ml for 20 minutes under room temperature.
3.7.3 Yeast-2-Hybrid Assay
Prey plasmid containing Med13570-650 (pJG1465) were co-transformed with bait plasmid
containing psk1(pJG598)/ EV control (pJG421) into Y2H Gold strain (JGY1031) and selected on
SD-Leu-Trp plates and grown for 2 days at 30°C. Transformants were inoculated into 5 mL
liquid cultures in SD-Leu-Trp and grown overnight, then serial diluted 1:5- 3,125 fold and 5uL
of each dilution were spotted on SD-Leu-Trp plates as growth control and SD-Leu-Trp-His-ade
plates to select for protein-protein interaction. Each construct has been tested with corresponding
EV bait/prey plasmid control to eliminate false positive results.
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CHAPTER 4: Concluding Remarks
Metabolic diseases are a global epidemic and deregulation of cellular metabolism can
lead to a wide variety of disease including metabolic syndrome, obesity, neurodegenerative
disorder and various types of cancer. They occur when cells allocate too many of their primary
resources towards one pathway at the expense of another pathway, or simply due to improper
response to cellular stress leading to deregulation of cellular processes, organellar dysfunction, or
even cell death. My research focused on the understanding of interplay between key metabolic
regulators: AMPK/SNF1, PASK/PSK1, identifying novel downstream targets of these kinases:
MED13/SSN2, OSBP/(OSH6/OSH7) and characterizing their role in mitochondrial function as
well as regulation of mitochondria signaling. With the central role of mitochondria in cellular
energy homeostasis as well as the regulation of key cellular processes such as proliferation,
growth and cell death, understanding how cells control mitochondrial respiration and maintain
mitochondrial health through cross-talk between metabolic regulators is key to developing
effective treatments for many common diseases resulting from metabolic dysfunction,
particularly mitochondrial dysfunction.
Sensory protein kinases are a major way in which the cell regulates central metabolism.
They can phosphorylate tens of substrates to control entire metabolic pathways, shifting the
metabolism of the cell depending on nutrient availability, cellular energy level or different
stressors. AMP-activated kinase (AMPK) and Per-Arnt-Sim kinase (PASK) are two of the main
metabolic regulators in the cells. Both kinases regulate critical metabolic nodes of central
metabolism: lipid versus respiratory metabolism, anabolic versus catabolic metabolism and
control mitochondria function and health. In Chapter 2, we explored the regulation of the
oxysterol binding protein Osh7 by SNF1— the yeast AMPK ortholog and provided evidence for
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conservation of this regulation in mammalian cells. As part of this study, we investigated the
localization and function of Osh7 and its close homolog, Osh6. Deficiency of either Osh6 or
Osh7 both causes a mitochondrial phenotype, with Osh6-deficeincy being more severe. We
provide evidence that this mitochondrial defect may be due to defects in mitophagy, a pathway
for clearing damaged mitochondrial which is commonly disrupted in many diseases including
heart disease, diabetes, cancer, and neurodegeneration. Although previously thought to have
redundant cellular roles, evidence is displayed herein for the preferred localization of Osh7 at
ER-mitochondria contact sites, whereas Osh6 remains primarily cytoplasmic. In addition, the
regulation by Snf1 is specific for Osh7. Thus, we have uncovered a major pathway for the
regulation of mitochondrial health, under the control of the master and commander SNF1/AMPK
through oxysterol binding protein.
In Chapter 3 and appendix chapters 1 and 2, we investigated the role of both SNF1 and
PAS kinase in mitochondrial and cell death regulation through the phosphorylation of Med13, a
key regulator of cyclin C. Med13 controls cyclin C export from the nucleus, when Med13 is
inactivated cyclin C is exported to the cytoplasm. In the cytoplasm cyclin C associates with the
mitochondria to induce fragmentation and ultimately, cell death. In collaboration with the cyclin
C experts at Rowan University (Katrina Cooper’s Laboratory), we have shown that Snf1 is
required for Med13 activity in response peroxide stress, whereas PAS kinase directly
phosphorylates Med13 and controls its activity in response to both peroxide and carbon stress.
In a Snf1 mutant or a PAS kinase mutant, cyclin C is trapped in the nucleus. Nuclear release of
cyclin C is known to promote mitochondria fission and timely apoptosis when necessary.
Combined these results support a model in which Snf1 and PAS kinase control cell death in
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response to both AMP and glucose levels. Each of these proteins are conserved from yeast to
man, suggesting that these pathways may be key in metabolic diseases in human as well.
The complexity of these metabolic pathways is only matched by the complexity of their
regulation, requiring exquisite control by sensory proteins that can regulate entire processes.
Herein we have further characterized two key metabolic controllers, AMPK and PAS kinase, and
their control of mitochondrial health and cell death. Further characterization of these signaling
pathways involving mitochondrial signaling, mitochondria health and functions may provide
novel therapeutic targets in treating metabolic diseases, neurodegenerative disorders and cancer.
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A1.2 Abbreviations
PCD - Programmed cell death
ROS - Reactive oxygen species
SCF - Skp1, Cullin, F box E3 ligase
IDR - intrinsic disordered region
Cdk - cyclin dependent kinase
PKA - Protein Kinase A
MAPK - MAP Kinase
AMPK - 5' adenosine monophosphate-activated protein kinase
AMPKK - 5' adenosine monophosphate-activated protein kinase kinase
ORF - Open reading frame
ßME - ß-mercaptoethanol
CKM – cyclin C/Cdk8 kinase module
ROS - Reactive Oxygen Species
Y2H –Yeast Two Hybrid

A1.3 Keywords
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61

A1.4 Abstract
Eukaryotic cells, when faced with unfavorable environmental conditions mount either
pro-survival or pro-death programs. The conserved cyclin C-Cdk8 kinase plays a key role in this
decision. Both are members of the Cdk8 kinase module that, along with Med12 and Med13,
associate with the core Mediator complex of RNA polymerase II. In S. cerevisiae, oxidative
stress triggers Med13 destruction, which releases cyclin C into the cytoplasm to promote
mitochondrial fission and programmed cell death. The SCFGrr1 ubiquitin ligase mediates Med13
degradation dependent on the cell wall integrity pathway MAPK Slt2. Here we show that the
AMP kinase Snf1 activates a second SCFGrr1 responsive degron in Med13. Deletion of Snf1
resulted in nuclear retention of cyclin C and failure to induce mitochondrial fragmentation. This
degron was able to confer oxidative-stress-induced destruction when fused to a heterologous
protein in a Snf1 dependent manner. Although snf1∆ mutants failed to destroy Med13, deleting
the degron did not prevent destruction. These results indicate that the control of Med13
degradation following H2O2 stress is complex being controlled simultaneously CWI and MAPK
pathways.
A1.5 Introduction
All eukaryotic cells are continually exposed to changing environmental conditions.
Consequently, they have evolved elaborate mechanisms to both sense damage and transmit this
signal to the nucleus. The resulting response varies dependent upon the stress encountered but in
gross terms cells have to decide whether to activate pro-survival or pro-death programs. Despite
this being a critical decision point, what remains understudied are the molecular details of how
cells decide their fate upon encountering unfavorable environments. Previous studies revealed
that the conserved cyclin C protein plays a key role in this decision in response to increased
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environmental reactive oxygen species (ROS) [126-134]. Cyclin C, together with its kinase
partner Cdk8, Med12 and Med13, form the Cdk8 Kinase Module (CKM) of the multi-subunit
Mediator complex. This complex acts as an interface between DNA bound transcription factors
and RNA polymerase II (RNAP-II [135-137])When the CKM module is bound, it predominantly
negatively regulates expression of a subset of stress response genes[126, 138-141]. Following an
increase in environmental ROS (induced by H2O2 treatment), this repression is relieved by the
nuclear release of cyclin C to the cytoplasm[127, 129, 134, 142]. Intriguingly, here cyclin C
plays a second role directing stress-induced mitochondrial fission as well as promoting
programmed cell death (PCD) [127, 132, 143, 144]. Consistent with this function, cells lacking
cyclin C cells are less able to execute stress-induced mitochondria fission and are more resistant
to oxidative stress [127, 143]. Taken together, these results argue that cyclin C nuclear release
must be carefully controlled as it signals a commitment to PCD.
Our previous studies have revealed that a complex molecular mechanism that controls
cyclin C nuclear release. In response to environmental ROS, cyclin C is directly phosphorylated
by Slt2, the MAP kinase of the Cell Wall Integrity (CWI) signal transduction pathway ([131] and
Figure A1-1A). This canonical pathway is characterized by a family of cell-surface sensors
(Wsc1, Mid2 and Mtl1[144]) that transmit the stress to a small G protein Rho1, which thereafter
activates protein kinase C (Pkc1)[145, 146]. Once activated, Pkc1 transmits the intracellular
signal to the MAPK Slt2/Mpk1 [147] as well as to the pseudo-kinase Kdx1/Mlp1 via
the MAPK module. In addition to cyclin C[131], Slt2 directly phosphorylates two other
transcription factors (Rlm1, Swi4/Swi6) that stimulate the expression of other stress response
genes[148-151]. More recently, Slt2 has also been shown to regulate gene expression by
phosphorylating tyrosine-1 of the RNAP II carboxy-terminal domain[146, 152]. This event is
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associated with pause/termination processes in mammals[153]. Intriguingly, it is required for the
loss of cyclin C and Cdk8 from target genes following stress in yeast [152].

Figure A1-1 Cdk8 module regulation by the CWI MAPK pathway (A) H2O2 stimulates cell wall sensors Wsc1,
Mtl1 and Mid2, leading to activation of Rho1 that in turn triggers the cell wall integrity (CWI) MAPK pathway by
activating Protein Kinase C (Pkc1). Activation of this cascade triggers the MAPK, Slt2, to directly phosphorylate
cyclin C, an event required for the 1st step towards its release from the nucleus. The second step requires Slt2 to
directly phosphorylate Med13-degron742-844, which targets it for ubiquitin mediated degradation by SCFGrr1.
Cyclin C-Cdk8 activity is needed to prime the degron before it is recognized by SCFGrr1 9. (B) Outline of the
AMPK pathway in yeast. It remains unknown how this pathway is activated in response to H2O2 stress. The gray
box represents the Snf1 kinase complex (see text for details).

In S. cerevisiae, Med13 destruction is required for cyclin C nuclear release[154].
Consistent with this, cyclin C is cytoplasmic in unstressed med13∆ and the mitochondria are
predominantly fragmented[154]. More recently we identified SCFGrr1 as the E3 ligase that
mediates Med13 destruction[133]. Like other SCF targets[155], recognition of this phosphodegron requires it first to be primed by one kinase (cyclin C-Cdk8) and then activated by another
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(Slt2). These studies also revealed that phosphorylation of cyclin C by Slt2 is required for the
SCFGrr1 to recognize Med13 ([133] and Figure A1-1A). Like the Slt2-degron, this domain lies
within the large intrinsic disordered region (IDR) of Med13 (Figure A1-2A). IDR’s are defined
by a continuous stretch of disordered promoting residues which easily transition into more
ordered states. These structural transitions afford IDR’s great flexibility and as such these
regions are known to play key roles in macro-molecular decisions including signaling
pathways[156, 157].
In addition to Slt2, the highly conserved 5’ adenosine monophosphate-activated protein
kinase (AMPK), which plays a major role in the utilization of alternative carbon sources after
glucose depletion[158], is also activated in response to various environmental stresses including
oxidative stress[159]. In S. cerevisiae, the catalytic subunit of the heterotrimeric AMPK complex
is encoded by SNF1. Other members of the complex (outlined in Figure A1-1B) include two
regulatory subunits, the γ subunit Snf4 and one of the three alternative β subunits, Sip1, Sip2, or
Gal83[158]. The three β isoforms determine the respective cellular addresses after activation of
Snf1, with the Snf1-Gal83 isoform being enriched in the nucleus[160-162]. The catalytic activity
of Snf1 is regulated by phosphorylation at Thr-210 that is located in the activation loop of its
kinase domain[163]. This is executed by one of three upstream kinases, Sak1, Tos3, and
Elm1[159, 164, 165]. These in turn are activated by an unknown mechanism in response to a
variety of stresses which lends specificity to the system[159].
In this report we show that Snf1, Sak1 and at least one β isoform are required for the
H2O2 induced degradation of Med13. Using yeast two-hybrid analysis the Snf1-interacting
domain on Med13 was identified. This domain lies in the large IDR region of Med13 and is
recognized by SCFGrr1 after Snf1 directed phosphorylation. Consistent with this, Snf1 is required
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for efficient cyclin C nuclear release following H2O2 stress. Taken together, this reveals that
Med13 degradation is regulated by two SCFGrr1 degrons that are regulated by three different
classes of kinases, a Cdk, a MAPK and an AMPK. As all three kinases are required for Med13
degradation, this complex molecular mechanism ensures that cyclin C nuclear release is tightly
controlled and prevents its untimely release into the cytoplasm.

Figure A1-2 Med13 contains two H2O2 stress responsive degrons (A) Cartoon of the results from ProteinPredict®
89 analysis of yeast Med13. The amino and carboxyl terminal domains are structured and separated by a large
intrinsic disordered region. The positions of the two degrons are indicated. (B) Yeast two hybrid analysis of
degron571-650 and Grr1 derivatives. Yeast PJ69-4a cells harboring Med13-activating domain plasmid (pDS15) and
either pAS2, pAS-Grr1 or pAS2-Grr1∆F∆L binding domain plasmids were grown on -LEU, -TRP drop out medium
to select for both plasmids (left panel) and -TRP, -LEU, -HIS -ADE (right panel) to test for Med13-Grr1 interaction.
(C) Wild-type (RSY10) or grr1∆ cells (RSY1770) harboring degron571-650 (pDS15) were treated with 0.4 mM
H2O2 for the timepoints indicated and Med13571-650-HA levels analyzed by Western blot. Tub1 levels were used
as loading controls. (D) Degradation kinetics of the degron571-650 constructs shown in C. Values represent
averages ± SD from a total of at least two Western blots from two independent experiments.

A1.6 Results
A1.6.1 Med13 contains two SCFGrr1 phospho-degrons
We have previously shown that SCFGrr1 is the E3 ligase responsible for mediating Med13
degradation following H2O2 stress [121, 133]. This degron (amino acids 742-844, Figure A12A,) is primed by cyclin C-Cdk8 and activated by Slt2. In these studies we also observed that
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another Med13 domain (amino acids 571-650) can also bind to Grr1 using the Gal4 yeast two
hybrid (Y2H) assay[166]. These results were repeated using two baits, wild-type Grr1 and a
grr1∆F∆L mutant, which can neither bind to the SCF or recognize substrates[167, 168]. As
anticipated, the Gal4 activating domain Med13571-650 fusion protein (hereon out referred to as
degron571-650) can associate with wild-type Grr1 as an interaction is detected selecting for the
dual HIS3 and ADE2 reporter genes (Figure A1-2B). The vector control and mutant bait were
unable to grow on this media suggesting that the interaction is specific.
To confirm that degron571-650 is responsive to SCFGrr1 we examined its degradation, via
Western blot analysis, following 0.4 mM H2O2 treatment in wild-type and grr1∆ cells. This
concentration of H2O2 induces mitochondrial outer membrane permeabilization (MOMP)
dependent regulated cell death response in yeast [169-171] and triggers cyclin C nuclear
release[127, 129, 131, 154]. The results show that although less degron571-650 is present in
unstressed grr1∆ cells, the protein is more stable following H2O2 stress (Figure A1-2C and
quantified in A1-2D). Taken together with the Y2H data, these results argue that degron571-650 is a
SCFGrr1 responsive degron. They are also consistent with our previous published work
demonstrating that Grr1 is required for H2O2 induced degradation of Med13 [133].
A1.6.2 Snf1 is required for stress-induced degradation of Med13
We next addressed if the H2O2 mediated destruction of degron571-650 required Cdk8 kinase
activity. To execute this, the degradation of degron571-650 was monitored as described above in
cells deleted for cyclin C harboring either functional myc-tagged cyclin C or a vector control.
The results revealed that the degron571-650 is degraded with the same kinetics in the presence or
absence of cyclin C (Figure A1-S1A and quantified in Figure A1-S1B). These results suggest
that another kinase phosphorylates degron571-650. One candidate is the PAS kinase. This kinase is
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required for glucose homeostasis and is encoded by two orthologs Psk1 and Psk2[172].
Intriguingly, previous Y2H studies have revealed that a domain of Med13 (amino acids 505703), that encompasses the degron571-650, interacts with Psk1 [173]]. The Y2H assay was repeated
using Psk1 as bait and the smaller degron571-650 as prey and again an interaction was observed
(Figure A1-S2A). We next tested if the PAS kinase plays a role in the degradation of full length
Med13. Wild-type and psk1∆ psk2∆ cells harboring a functional HA-tagged Med13 plasmid
[133] were treated with H2O2 and Med13 degradation monitored by Western blot analysis. The
results show that Med13 is degraded with similar kinetics in the mutant and wild-type cells
(Figure A1-S2B and quantified in Figure A1-S2C). These results indicate that although the PAS
kinase can interact with degron571-650, it is not required for Med13 degradation following H2O2
stress.
PAS kinase activation by carbon sources is dependent on the Snf1 complex [124, 174].
Since Snf1 has many targets [175], we next tested if Snf1 mediates Med13 degradation following
H2O2 stress as just described. The results show that Med13 is significantly more stable in snf1∆
cells (Figure A1-3A and quantified in Figure A1-3C). Similar results were obtained when the
Snf1 kinase dead mutant (K84R, [176]) was the only source of Snf1 (Figure A1-3B and
quantified in Figure A1-3D). Taken together, these results indicate that Snf1 activity is required
for Med13 degradation following H2O2 stress.
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Figure A1-3 Snf1, Sak1 and at least one β subunit are required for degradation of Med13 following H2O2 stress (A)
Wild-type (RSY10), snf1∆ (RSY2080), sak1∆ (YPDahl17) and gal83∆ sip1∆ sip2∆ (MSY557) cells harboring full
length Med13-HA (pKC801) were treated with 0.4 mM H2O2 for the timepoints indicated and Med13-HA levels
analyzed by Western blot. Tub1 levels were used as a loading control. (B) snf1∆ cells harboring Med13-HA
(pKC803) and either wild- type Snf1 (JG1193), a vector control (pRS316) or snf1K84R (JG1338) were treated and
analyzed as described in A. (C and D) Degradation kinetics of the Med13-HA shown in A and B. Values represent
averages ± SD from a total of at least two Western blots from independent experiments.

Sak1 has been identified as the AMPK kinase that is activated in response to oxidative
stress [177]. Therefore, we next addressed if Sak1 is required for H2O2 induced Med13
degradation. The degradation assays described above were repeated in sak1∆ cells and results
revealed that Med13 was again significantly more stable in sak1∆ than wild type (Figure A1-3A
and quantified in Figure A1-3C). This result supports the previously proposed model that Sak1
is the AMPKK that activates Snf1 in response to oxidative stress [159]. We next addressed if the
nuclear enriched isoform, Snf1-Gal83 [143, 160-162], is required for Med13 degradation under
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similar circumstances. Unexpectedly, the results show that Med13 is still degraded in gal83∆
cells (Figure A1-S3A). Likewise, similar results were obtained when Med13 degradation was
monitored in a sip1∆ sip2∆ strain (Figure A1-S3A). However, deletion of all three β subunits
significantly inhibited the degradation of Med13 to a similar extend as observed in snf1∆ (Figure
A1-3A and quantified in Figure A1-3C). Taken together, this suggests at least one of the β
subunits of the Snf1 complex is required for Med13 degradation following H2O2 stress.
A1.6.3 Snf1 activation alone is not sufficient to mediate Med13 degradation
We next addressed if Snf1 activation was sufficient to mediate Med13 degradation in the
absence of H2O2 stress. To execute this Med13 levels were examined in wild-type cells after they
had been switched from 2% to 0.05% glucose which, is sufficient to activate Snf1 (Figure A1-4A
and [159]). No differences in Med13 levels were observed following glucose deprivation (Figure
A1-4B). Taken with the results presented in Figure A1-3, this suggests that Snf1 activation is
necessary but not sufficient to mediate the degradation of Med13 following H2O2 treatment.
A1.6.4 The CWI pathway sensors proteins are not required for Snf1 activation
It is known that both the CWI and AMPK pathways are activated in response to oxidative
stress but how these two pathways communicate is not well understood [178]. Importantly,
although it is known how the signal is transmitted to the CWI pathway, it is unclear how the
AMPK pathway is activated (Figure A1-1B). One possibility is that the pathways cross talk,
through the cell wall sensor proteins. To test this, we examined Snf1 phosphorylation status in a
strain lacking the three cell wall sensors (Wsc1, Mid2 and Mtl1[144]). Consistent with
previously published work [159], Snf1 is phosphorylated following H2O2 treatment in a Sak1
dependent manner (Figure A1-4C). Likewise the cell wall sensor triple mutant is also able to
activate Snf1 following H2O2 treatment (Figure A1-4C). These results suggest that the activation
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of the CWI pathway is not required to transmit the stress signal to the AMPK pathway. Others
have demonstrated that Snf1 is not required for activation of Slt2 [179]. Consistent with this, we
observed that the Med13 degron571-650 is still degraded following H2O2 stress when a mutant of
cyclin C, that cannot be phosphorylated by Slt2 (S266A [131]), is used as the sole source of
cyclin C (Figure A1-S1C&D). Taken together, these results argue that the AMPK and MAPK
signaling pathways act independently of each other. The extension of this conclusion is that both
pathways contribute independently to regulating Med13 destruction following H2O2 stress.

Figure A1-4 Snf1 activation does not mediate Med13 degradation (A) Mid-log -type cells (RSY10) growing in 2%
glucose (T=0) were switched to media containing 0.05% glucose. Snf1 phosphorylation and Snf1 itself were
detected as described in materials and methods for the timepoint indicate. (B) Wild-type cells harboring Med13-HA
(pKC801) were switched to media containing 0.05% glucose. Med13-HA levels were detected by Western blot
analysis for the timepoints indicated. Tub1 was used as a loading control. (C) As in (A) except that Snf1
phosphorylation was monitored after 0.4 mM H2O2 treatment in the strains indicated.

A1.6.5 The Snf1 degron lies within the IDR of Med13
Snf1 has previously been shown to phosphorylate an SCFGrr1 phospho-degron in Pfk27, a
key regulator of glycolysis [180]. Taking this into account, we asked if the Gal4 activating domain
Med13571-650 fusion protein (degron571-650) is an Snf1 responsive degron by monitoring its H2O2
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mediated degradation snf1∆ cells. The results show that degron571-650 is more stable in snf1∆ cells
compared to wild type following H2O2 stress (Figure A1-5A and quantified in Figure A1-5B). This
suggests that degron571-650 is a Snf1 responsive degron. To further support this conclusion, we
examined the degradation kinetics of a degron mutated for either of the potential Snf1
phosphorylation sites previously identified in proteomic screens (S587 [181] and S636 [182],
Figure A1-6A) although none of these sites perfectly fit the Snf1 consensus sequence [183, 184].
The studies revealed that both mutants were degraded following H2O2 treatment with kinetics
similar to wild type (Figure A1-S3B). We also noted that serine 634 could potentially be
phosphorylated by Snf1 (see Figure A1-6A). As it lies very close to serine 636, we made a double
mutant (S634A, S636A) and repeated the assay. Again this mutant degron was degraded following
H2O2 treatment (Figure A1-S3B). However, the triple mutant (S587A, S634A, S636A) exhibited
enhanced stability following H2O2 stress (Figure 5C and quantitated in Figure 5B). Taken together,
these results suggest that Snf1 phosphorylates Med13 following H2O2 stress targeting S587, S634
and S636. Consistent with this model, we (Figure 5D and S3C) and others [185] have shown that
Snf1 can co-immunoprecipitates with Cdk8 both before and after H2O2 stress. As cyclin C directly
binds to the adjacent degron742-844 (Figure 2A and [133]) this places Snf1 in close proximity to
degron571-650. In addition, these data also support the notion suggested by others that a
subpopulation of Snf1 is nuclear in unstressed cells [143, 162, 185].
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Figure A1-5 Snf1 phosphorylates degron571-650 (A) Mid-log wild-type (RSY10) or snf1∆ cultures (RSY202)
harboring degron571-650 (pDS15) were subjected to an H2O2timecourse experiment and protein extracts analyzed by
Western blot. Tub1 levels were used as loading controls. (B) Degradation kinetics of degron571-650 shown in (A) and
(C). Values represent averages ± SD from a total of at three Western blots from independent experiments. (C) As in
(A) except that degron571-650,S587A, S634A, S636A (pDS56) was analyzed in wild-type cells. (D) Co-immunoprecipitation
analysis of Snf1-myc and Cdk8-HA. Mid log wild-type cells harboring Snf1-myc and Cdk8-HA on single copy
plasmids were treated with 0.4 mM H2O2 for the timepoints shown. Protein extracts were immunoprecipitated with
anti-HA, separated by SDS-PAGE Western analysis and the membrane probed with the antibodies shown. []
represents no IP antibody and the asterisk represents the heavy chain. See Figure A1-S3C for vector control.
(E) Potential phospho-sites in Med13571-650. (F) Upper panels: Kinase assays using Snf1 and Snf1K84R-myc (kinase
dead) immunoprecipitated from yeast protein extracts prepared from either wild type (left panel) or cdk8∆ cells
(right panel) and Med13-degron571-650 (GST-Med13571-906,S608A purified from E. coli) as the substrate. The reactions
were separated by SDS PAGE and subject to autoradiography. Lower panels: Coomassie stained gels showing the
input used in the kinase assays.
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To address if Snf1 directly phosphorylates Med13 kinase assays were performed with
wild-type and kinase dead Snf1 (K84R). The activated kinase was immunoprecipitated from
yeast extracts and incubated with GST-Med13561-650, S608A purified from E. coli. Serine 608 was
mutated to alanine as it is a potentially contaminating PAS kinase site (Figure A1-5E and [124]).
In addition, although this site has also been identified as target of PKA mediated phosphorylation
[186], we have previously shown that this site does not play a role in Med13 degradation in
response to oxidative stress [133]. Lastly, it is documented that Snf1 does not phosphorylate
GST so this control was not included here [187]. The results (Figure A1-5F) show that Snf1 is
able to directly phosphorylate degron571-650. However, despite taking the precautions listed
above, kinase activity was also observed using the kinase dead version. This suggests that
another kinase that immunoprecipitates with Snf1 is able to phosphorylate this degron. One
strong possibility is Cdk8, which is a proline directed kinase that can phosphorylate the minimal
consensus sequence S/T-P [188]. Med13571-650 contains one such site (Figure A1-5E). Therefore
the kinase assays were repeated using Snf1 extracts isolated from a cdk8∆ strain. The result show
that degron571-650 was phosphorylated by Snf1 and this activity was reduced in the kinase dead
control (Figure A1-5F). Taken together, these results are suggestive that Snf1 directly
phosphorylates Med13571-650. However, as some phosphorylation of degron571-650 was observed
when Snf1K84R was used, we cannot rule out the possibility that an intermediary kinase may be
playing a role.
A1.6.6 Other potential Snf1 sites on Med13 are not needed for its degradation following
H2O2 stress
The Snf1 proteomic screen mentioned above also identified 5 additional potential Snf1
sites in Med13 [182]. Intriguingly, these sites all lie within the large IDR of Med13 (Figure A1-
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6A). As IDR regions provide ideal environments for post-translational modifications which
effect signaling events [189], we asked if these additional sites also play a role in Med13
degradation. To address this question, Med13-HA fragments were fused to the SV40 nuclear
localization sequence (NLS) and assayed for H2O2 mediated destruction. The results revealed
that the construct that contains both degrons as well as all the potential Snf1 sites (amino acids
306-906) is degraded. However, the Med13306-570 construct, that contains the remaining potential
Snf1 sites but not the two SCFGrr1 responsive degrons, was significantly more stable. This
suggests that these other potential Snf1 sites do not play a role in the H2O2-stress mediated
degradation of Med13. To address if the head and tail regions of Med13 contain unidentified
Snf1 sites, Med13 constructs spanning these regions (amino acids 1-306 and 907-1420) were
also tested as described above for stability following H2O2 stress. The results (Figure A1-6C)
demonstrate that these constructs are not destroyed under these conditions. This supports our
conclusion that the Snf1 degron lies within amino acids 571-650. Degron742-844 also contains a
potential Snf1 target site (Figure A1-6A). However, this degron fused to the Gal4 activating
domain is destroyed following H2O2 stress in wild-type and snf1∆ cells alike (Figure A1-6D).
Taken together, these results support the above conclusions that the Snf1 phosphorylation sites
lie within degron571-650.
A1.6.7 Snf1 is necessary for cyclin C nuclear release and stress-induced mitochondrial
fission
As Med13 degradation is required for cyclin C nuclear release [133, 154] we next tested
if Snf1 was also required for this event. To address this, the location of a functional cyclin CYFP reporter protein [130] before and after stress in wild-type and snf1∆ cells was examined
(Figure A1-7A and quantified in FigureA1-7B). The results show that a majority of cyclin C-
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YFP is cytoplasmic in wild-type cells whereas it remains significantly more nuclear in snf1∆
cells. These data indicate that Snf1 is required for the oxidative stress induced nuclear release of
cyclin C. We next examined the mitochondrial morphology in snf1∆ cells as cyclin C nuclear
release initiates stress-induced mitochondrial fission [127, 129, 134]. As previously reported,
unstressed wild-type cells exhibited mainly reticular mitochondrial morphology (Figure A1-7C)
that switched to a predominantly fragmented phenotype after 3 hours of 0.4 mM H2O2 treatment.
In snf1∆ cells, significantly less fragmented mitochondria are seen after H2O2 treatment. Taken
together, these results indicate that activation of Snf1 is required for stress-induced
mitochondrial fragmentation through C nuclear release.

Figure A1-6 Other potential Snf1 sites in Med13 are not required for its degradation following H2O2 stress (A) Map
of Med13 outlying the positions of the two Med13 degrons, the consensus Snf1 target site 57 and potential Snf1
sites, identified by published proteomic screens. (B) and (C) Wild-type (RSY10) cultures harboring the NLSMed13-HA constructs shown were grown to mid-log phase (0 h) then treated with 0.4 mM H2O2 for the indicated
times. Med13-HA levels were determined by Western blot analysis. Tub1 levels were used as a loading control.
(D) Mid-log wild type or snf1∆ cultures (RSY202) harboring HA tagged Med13 degron742-844 (pDS32) were
subjected to an H2O2 timecourse experiment and protein extracts analyzed by Western blot. Tub1 levels were used
as loading controls.
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Figure A1-7 Cyclin C remains predominantly nuclear following H2O2 stress in snf1∆ (A) Fluorescence microscopy
of mid-log phase wild-type and snf1∆ cells harboring a cyclin C-YFP expression plasmid (pBK38). Cells were
stained with Dapi to visualize the nucleus. (B) Quantification of the results obtained in (A). At least 200 cells were
counted per timepoint from 3 individual isolates. The percent of cells (mean ± SEM) within the population
displaying cytoplasmic cyclin C is given. * p < 0.05 difference from wild type. (C) Right panel: representative
images of the two mitochondrial morphologies scored. Left panel: as in (B) except that percent of cells displaying
fragmented mitochondria was scored. Representative images of the mitochondrial morphologies scored are shown in
the left hand panel. The percent of cells (mean ± s.e.m.) within the population displaying fragmented mitochondria
is given. * p < 0.05 difference from wild type. ** p < 0.01 difference from wild type. Bar = 13 µM.
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A1.6.8 Med13-degron571-650 is not required for the degradation of Med13 following H2O2
stress
We next addressed if Snf1 mediated phosphorylation of Med13 is required for Med13
degradation. Degron571-650 was deleted from full length Med13 and the degradation kinetics of
this construct (Med13deg∆571-650) was examined in med13∆ cells. The results show that
Med13deg∆571-650 was degraded with kinetics similar to wild type (Figure A1-8A upper two
panels, quantified in Figure A1-8B). We also observed that this construct retained cyclin C in the
nucleus in unstressed cells and released it into the cytoplasm following H2O2 stress (Figure A1S5). These results were unexpected as deletion or inactivation of Snf1 results in Med13
stabilization following H2O2 stress (Figure A1-3). Similarly, deletion of the Slt2 responsive
degron (amino acids 742-844) only partially rescued the deletion (Figure A1-8A, bottom two
panels) whereas Med13 is significantly stabilized in slt2∆ cells following H2O2 stress [133].
These results suggest a complex model in which the function of either Snf1 or Slt2 is only
required when their respective degron is present. If correct such a model would predict that the
degron impeaches degradation when not phosphorylated. Moreover these studies predict
independent roles for these two signaling pathways that ultimately direct in the same outcome of
Med13 degradation.
A1.7 Discussion
Our previous work has shown that nuclear release of the yeast and mammalian cyclin C
predisposes cells to initiate PCD following stress [127, 134]. In S. cerevisiae, this nuclear release
requires the destruction of Med13 [154] mediated by the E3 ligase complex SCFGrr1, which
requires Slt2 and Cdk8 activity [133]. In this current work, we provide evidence that Sak1
activated Snf1 is also required for H2O2 induced Med13 degradation and cyclin C nuclear

78

release. In the absence of this kinase, Med13 degradation following H2O2 stress is inhibited and
cyclin C remains predominantly nuclear. Consistent with this model, we showed that Snf1 is
required for the degradation of the Med13 degron571-650. Paradoxically, deletion of this degron
did not prevent H2O2 induced destruction of Med13. Instead this mutant exhibited H2O2 induced
Med13 degradation and cyclin C nuclear release. Intriguingly, deletion of the Slt2-resonsive
degron (Med13742-844) also did not protect Med13 from H2O2 induced degradation although the
protein was slightly more stable than wild type. Taken together, this study indicates that Slt2 and
Snf1 pathways cooperate to trigger Med13 destruction. The use of two required pathways may
help insure the proper signals are in place to target Med13.

Figure A1-8 Either Med13 degron is sufficient for Med13 degradation (A) med13∆ (RSY1701) cells harboring
either Med13571-650deg∆-HA (pKC805, upper panels) or Med13742-844deg∆-HA plasmids (pKC814, lower panels) were
treated with 0.4 mM H2O2 for the timepoints indicated and Med13deg∆-HA levels analyzed by Western blot. Tub1
levels were used as a loading control. (B) Degradation kinetics of the results shown in (A). Values represent
averages ± SD from a total of at least two Western blots from independent experiments. For clarity, the degradation
kinetics of wild-type Med13-HA from previous experiments was included. (C) Model depicting how two
SCFGrr1 phospho-degrons mediate the destruction of Med13 following H2O2 stress. In unstressed cells cyclin C-Cdk8
phosphorylates degron742-844 9 but both degrons are protected by an unknown mechanism from Snf1 and Slt2 kinase
activity (depicted by the red circle). Following H2O2 stress Snf1 and Slt2 are activated and permitted access to the
now exposed degrons. This results in SCFGrr1 mediated degradation of Med13 and cyclin C nuclear release (not
shown).
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To accommodate these two results the following model that best fits the data is proposed
(outlined in Figure A1-8C). In unstressed cells the IDR region of Med13, which encompasses
both degrons, is protected from SCFGrr1 activity (depicted by red circle in Figure A1-8C) by an
unknown mechanism. Following H2O2 stress, two events happen, the hierarchy of which is
unknown. The protection is lost (depicted by green circle in Figure A1-8C) and the activated
kinases Snf1 and Slt2 phosphorylate their respective degrons, triggering SCFGrr1 mediated
degradation of Med13. Although we currently favor the hypothesis that Snf1 directly
phosphorylates Med13, we could not definitively exclude the possibility that Snf1 may promote
Med13 phosphorylation indirectly via an intermediary kinase another kinase. That being said, the
model presented in Figure A1-8C could accommodate this possibility. More importantly
however, the model supports the observation that both the AMPK and MAPK pathways act
independently of each other (Figure A1-4), and are required for Med13 degradation. However,
in the absence of either the Snf1 or Slt2 degron, this protection is lost, allowing SCFGrr1 to
recognize either activated degron. This model also accounts for the observation that when either
degron is expressed in isolation then it would require its kinase to render it recognizable by
SCFGrr1.
If this model is correct, then how could this region be protected from AMPK and MAPK
activity in unstressed cells? One strong possibility could be connected to the fact that both
degrons lie within the very large IDR domain of Med13 (Fig 2A). IDR’s are known to endow
proteins with highly malleable structures that undergo disorder-to-order transitions [190]. It has
been proposed that the IDR domains can have different binding partners that transiently associate
[142]. In some cases, this can lead to proteins binding the same region that possess unrelated, or
even opposite functions [191]. Thus proteins that contain IDR regions are frequently involved in
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signaling as they can easily change their conformational state in response to changing
environmental conditions. Taken together, it is feasible to propose that in unstressed cells, the
IDR region of Med13 is in one conformational state that, by associating with an unknown
protein, protects this region. Upon stress, the confirmation changes and the degron becomes
exposed. This model is also consistent with the observation that IDR regions are notorious for
being regulated by multiple kinases [189, 192]. This has led to the idea that IDRs and multiple
phosphorylation events together provide structural variability [193] resulting in ultra-sensitive
molecular switches that are triggered at a threshold level of phosphorylation. Thus our results
suggest a model in which Med13 degradation is regulated by three types of different kinases, a
cyclin dependent kinase, a MAPK and AMPK.
Lastly, here we show that Snf1 phosphorylates Med13, either directly or by an
intermediary kinase, as well as being able to associate with the CKM before stress (Figure A15D). These results are consistent with a growing number of papers that have shown that a subpopulation of the Snf1-Gal3 isoform is present in the nucleus under normal conditions [143, 185,
194], as well as enriched in the nucleus upon glucose starvation [65, 160, 162]. In addition, Sak1
is needed for Snf1 nuclear localization [195]. In support of this model, Snf1, Gal83 and Sak1
localize to the SUC2 promotor under non-starvation conditions [143]. This promotor is also
negatively regulated by the CKM [196]. Repression is relieved by Snf1 mediated
phosphorylation of two proteins known to repress SUC2 expression, the DNA binding protein
Mig1 [197] and the glucose kinase Hxk2 [143, 198], causing them to be released into the
cytoplasm [199, 200]. Likewise, carbon starvation results in the degradation of cyclin C [128], an
event that occurs in the cytoplasm [129]. Surprisingly we found that although Sak1 is needed for
Med13 destruction following H2O2 stress, deletion of Gal83 has no effect (Figure A1-3A and
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A1-S2A). However, deletion of all three β-subunits does inhibit Med13 degradation. This would
suggest that in the absence of Gal83 either Sip1 or Sip2 are able to activate nuclear Snf1.
However, the Snf1-Sip1 and Snf1-Sip2 isoforms have not been reported to be nuclear, either
dispersing to the vacuolar membrane (Sip1) or remaining cytoplasmic following carbon
deprivation (Sip2) [65, 160, 162]. Further studies need to be executed to address if Sip1 or Sip2
can translocate into the nucleus in the absence of Gal83. Intriguingly, just recently the
Mitochondrial Voltage-Dependent Anion Channel Protein Por1 (yVDAC1) has been shown to
enhance Snf1 nuclear enrichment by promoting the nuclear enrichment of Gal83 [194]. This
unexpected finding serves to emphasize that there is much still to learn about the role Snf1
kinase plays in response to changing environmental conditions.
A1.8 Materials and methods
A1.8.1 Yeast strains and plasmids
Most experiments were performed in the S. cerevisiae W303 strain [201] and are listed in
Table S1. Exceptions to this are the sak1∆ (YPDahl17, a gift from S. Hohmann [202]), the sip1∆
sip2∆ (MML1445, a gift from E. Herrero) and psk1∆ psk2∆ strains which are W303-1A strains.
The sip1∆ sip2∆ gal83∆ strain (MSY557, a gift from M. Schmidt [203]) is an S288c strain.
Finally, the Y2H assays were performed in PJ69-4a [166] that was obtained from the Yeast
Resource center, a gift from S. Fields. In accordance with the Mediator nomenclature unification
effort [204], we use CNC1 and CDK8 gene designations for cyclin C (SSN8/UME3/SRB11) and
Cdk8 (SSN3/UME5/SRB10) respectively. The snf1∆ and gal83∆ strains (RSY1949 and RSY2080
respectively) were constructed using gene replacement methodology as described [205]. The
sak1∆ (RSY1976) was a gift from S. Hohmann [202]. All cells were grown at 30°C.
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All plasmids used in this study are listed in Table S2. The wild-type epitope tagged
plasmids pKC801, pKC803 (MED13-HA), pBK38 (ADH1Pro-CNC1-YFP), Snf1-Myc and
ADH1Pro-CNC1-MYC (pKC337) are functional and have been previously described [126, 129,
130, 133, 206, 207]. All other plasmids were constructed using PCR cloning techniques and
details are available upon request. In short, all constructs were amplified from plasmid DNA
using Phusion Taq (Thermo) digested using Thermo fast digest restriction enzymes and ligated
using Thermo fast ligase into their respective vectors. Site directed mutagenesis (New England
Bio-Labs Q5) was used to create plasmids harboring amino acid mutations and the change
confirmed by sequencing (Eurofins Genomics). The MED13 Y2H plasmids were constructed by
PCR cloning regions of Med13 in frame with the Gal4 activating domain of pACT2. The NLSMed13 fusion constructs were made by first creating a backbone vector (pNLS-HA) that
contains the SV40 nuclear localization sequence (NLS) in frame with a single HA epitope tag
under the control of the ADH1 promotor. PCR-cloning was then used to place fragments of
Med13 in frame with NLS. All in frame fusion proteins were verified by sequence analysis.
Other plasmids that were used in this study that have been previously described are listed in
Table S2.
A1.8.2 Cell growth
Yeast cells were grown in either rich, non-selective medium (YPDA) or synthetic
minimal medium (SC) allowing plasmid selection as previously described [126]. For all
experiments, the cells were grown to mid-log phase (~ 6 x 106 cells/ ml) before treatment with
low concentrations of 0.4 mM H2O2 as previously described [130]. 25 mls of cells were
collected per timepoint, washed in water, then the pellet flash frozen in liquid nitrogen. Yeast
two hybrid experiments were executed as described [168]. E. coli cells were grown in LB
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medium with selective antibiotics. For the kinase assays cells were grown initially grown in SDUra (1.7 g Yeast Nitrogen Base, 5 g Ammonium Sulfate, 20 g Dextrose per liter), overnight,
diluted 1:100-fold into 500 ml of SD-Ura, and grown for 10–12 h. Thereafter the cells were
pelleted, and resuspended in 500mL SGal-Ura (1.7 g Yeast Nitrogen Base, 5 g Ammonium
Sulfate, 20 g Galactose per liter)
A1.8.3 Western blot analysis and co-immunoprecipitation
Tagged full length Med13-HA constructs were detected by using NaOH lysis of cell
pellets exactly as described in [121]. To detect Med13-HA, 1 in 5000 dilutions of anti-HA
antibodies (Abcam) were used. The co-immunoprecipitation analysis was performed essentially
as described [128]. Anti-alpha tubulin antibodies (12G10) were obtained from the
Developmental Studies Hybridoma Bank, University of Iowa. Western blot signals were detected
using either goat anti-mouse or goat anti-rabbit secondary antibodies conjugated to alkaline
phosphatase (Sigma) and the CDP-Star chemiluminescence kit (Thermo). Signals were
quantitated by CCD camera imaging (Kodak) and standardized to the loading control. All
degradation assays were performed two or three times. SEM’s were generated for each point
(error bars are indicated on the graphs) and the data analyzed using linear regression analysis
using GraphPad Prism 7 program.
A1.8.4 Snf1 activation and kinase assays
The Snf1 activation assays were executed as follows. Cells were grown to mid log and
treated with 0.4 mM H2O2 for the times indicated. They were then immediately boiled for 3
minutes and pellets frozen using liquid nitrogen. Protein extracts were made using the NaOH
method described in [121] and analyzed by SDS-PAGE and Western blotting. Anti-phosphoThr172–AMPK (Cell Signaling Technology; Cat. No. 2531) was used to detected
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phosphorylated Snf1 and polyhistidine antibody H1029 (Sigma-Aldrich) to detect Snf1. This is
possible as Snf1 ORF contains 13 contiguous histidine residues at its N terminus. The in vitro
kinase assays were executed as follows. Wild-type yeast or cdk8∆ harboring myc-tagged Snf1,
Snf1 kinase dead (K84R) plasmids under the control of the GAL1-10 promotor, were first grown
in SD-Ura followed by SGal-Ura as described above and then resuspended in lysis buffer (20
mM HEPES, 10 mM KCl, 1 mM EDTA, 1 mM ethylene glycol tetra-acetic acid (EGTA), 50
mM NaCl, 10% glycerol, 1 mM β-mercaptoethanol, Pierce™ Protease Inhibitor Tablets, pH 7.4
with phosphatase inhibitors). Resuspended cultures were lysed using a Microfluidics M-110P
homogenizer (Microfluidics) and cell debris removed by centrifugation at 12,000 x g for 30 min.
Supernatants were transferred to new tubes and incubated with 5–10µl of Myc-conjugated
magnetic beads (Cell Signaling) for 2–3 h at 4°C. Beads were separated using magnetic force
and washed four times with 1 ml of lysis buffer lacking the protease inhibitor. Beads containing
Myc-tagged proteins were used directly for in vitro kinase assays without eluting. GSTMed13571-650 S608A was purified from E. coli BL21 DE3 strain as previously described [121] and
assayed for Snf1–dependent phosphorylation. In short, GST-Med13571-650 S608A was incubated
with the Snf1 immunoprecipitates in 30 μl of reaction buffer containing 1X Snf1 kinase buffer
(50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol (DTT), pH 7.5, 10 μM ATP, and 7.5 μCi
of γ32P-ATP, and reactions were incubated for 35 min. Kinase assays were stopped by the
addition of SDS–PAGE sample buffer and analyzed by SDS-PAGE, stained with coommassie
(30 mins), destained for 2 h, dried and exposed to film.
A1.8.5 Fluorescence microscopy
Cyclin C-YFP subcellular localization and mitochondrial morphology were monitored as
described previously [127, 129]. For all experiments, the cells were grown to mid-log (6 x 106
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cells/ ml), treated with 0.4 mM H2O2 for the timepoints indicated, then analyzed by fluorescence
microscopy. Cyclin C-YFP release analysis was performed on cells stained with DAPI in
mounting medium (10 mg/ml p-phenylenediamine, 50 ng/ml 4',6-diamidino-2-phenylindole,
Molecular Probes) to visualize nuclei and prevent photo bleaching. Images were obtained using a
Nikon microscope (model E800) with a 100X objective with 1.2X camera magnification (Plan
Fluor Oil, NA 1.3) and a CCD camera (Hamamatsu model C4742). Data were collected using
NIS software and processed using Image Pro software. All images of individual cells were
optically sectioned (0.2 µM slices at 0.3 µM spacing) deconvolved and the slices were collapsed
to visualize the entire fluorescent signal within the cell. Cyclin C-YFP foci were scored as being
cytoplasmic when 3 or more foci were observed outside of the nucleus. Mitochondrial fission
assays were performed on live cells as described [127]. In brief, mitochondrial fission was scored
positive if no reticular mitochondria were observed that transversed half the cell diameter.
Fusion was scored when cells exhibited one or more reticular mitochondria the diameter of the
cell. Fission and fusion was scored for 200 cells from three independent isolates. Statistical
analysis was performed using the Student’s T-test.
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Supplemental Table A1-1 Yeast strains used in this study
Strain

Genotype*

Source

RSY10

[201]

RSY1696

cnc1::KANMX6

[208]

RSY1701

med13::HIS3

[154]

RSY1707

mid2::HIS3 mtl1::TRP1 wsc1::KANMX4

[130]

RSY1770

grr1∆::his5+

[121]

RSY1726

cdk8∆::KANMX4

[154]

RSY1949

gal83::KANMX4

This study

RSY2080

snf1::KANMX4

This study

YPDahl17

sak1::KANMX4

[202]

MML1445

sip1::natMX4 sip2:: KANMX4

[209]

MSY557

sip1::HIS3 sip2:: HIS3 gal83::HIS3

[203]

JGY1

[82]

JGY4

psk1::HIS3 psk2∆:: KANMX4

[75]

PJ69-4

LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ

[166]

gal4∆ gal80∆
*Genotype of all strains is MATa ade2 ade6 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 except YPDahl17,
MML1445, JGY1 and JGY4 which are MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 and PJ69-4
which is MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4∆ gal80∆.
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Supplemental Table A1-2 Plasmid used in this study
Plasmid
Name

Gene

Epitope Tag

Marker

Promoter

2µ/
CEN

Reference

pBK38

CNC1

YFP

URA3

ADH1

CEN

[129]

pKC337

CNC1

CNC1

TRP1

ADH1

CEN

[126]

pKC801

MED13

3HA

URA3

TRP1

CEN

[121]

pLR166

CNC1S266A

CNC1

TRP1

TRP1

CEN

[210]

pKC803

MED13

3HA

LEU2

ADH1

CEN

[121]

pKC805

MED13571-650deg∆

3HA

URA3

ADH1

CEN

This study

pKC814

MED13742-844deg∆

3HA

URA3

ADH1

CEN

This study

pDS8

GAL4AD-MED13571-

1HA

LEU2

ADH1

2µ

[121]

pDS15

GAL4AD-MED13571-

1HA

LEU2

ADH1

2µ

[121]

pDS16

GAL4AD-MED13651-

1HA

LEU2

ADH1

2µ

[121]

pDS32

GAL4AD-MED13742-

1HA

LEU2

ADH1

2µ

[121]

pDS44

GAL4AD-MED13571-

1HA

LEU2

ADH1

2µ

This study

pDS51

GAL4AD-MED13571-

1HA

LEU2

ADH1

2µ

This study

pDS55

GAL4AD-MED13571-

1HA

LEU2

ADH1

2µ

This study

1HA

LEU2

ADH1

2µ

This study

906

650

906

844

650 S636

650 S636, S634A

650

S587A

pDS56

GAL4AD-MED13571650

S58A7, S636A, S634A

pDS45

NLS-Med131-306

1HA

LEU2

ADH1

2µ

This study

pDS46

NLS-Med13306-570

1HA

LEU2

ADH1

2µ

This study

pDS47

NLS-Med13907-1420

1HA

LEU2

ADH1

2µ

This study

pDS52

NLS-Med13307-570

1HA

LEU2

ADH1

2µ

This study

pDS54

GST-Med13571-650,S608A

GST

AMP

-

-

This study

pJG1215

HIS6-PSK1-KD

HIS6

AMP

-

-

[75]

pUM504

CDK8

1HA

TRP

GPD

CEN

[128]

pACT2

GAL4AD

1HA

LEU2

ADH1

2µ

[211]
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pAS2

GAL4BD

1HA

TRP

ADH1

2µ

[211]

pAS2-Grr1

GAL4BD-GRR1

1HA

TRP

ADH1

2µ

[168]

pAS2Grr1∆L∆F

GAL4BDGRR1Grr1∆L∆F

1HA

TRP

ADH1

2µ

[168]

pJG1465

GAL4AD-MED13504-

1HA

TRP

ADH1

2µ

[82]

pAS2-

GAL4BD-PSK1

1HA

TRP

ADH1

2µ

[82]

JG1193

Snf1

8Myc

URA3

Snf1

CEN

[206]

JG1338

Snf1K84R

8Myc

URA3

Snf1

CEN

[207]

Snf1

8Myc

URA3

GAL1-10

2µ

[207]

Snf1K84R

8Myc

URA3

GAL1-10

2µ

[207]

pNLS-HA

SV40 NLS

1HA

LEU2

ADH1

2µ

This study

Mt-Cherry

Mito-targeting

mCherry

TRP1

ADH1

CEN

This study

pRS314

-

-

TRP1

-

CEN

[212]

pRS316

-

-

URA

-

CEN

[212]

703

Psk1
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A2.2 Abbreviations
RCD – Regulated Cell Death
ROS - Reactive Oxygen Species
SCF - Skip1, Cullin, F box E3 ligase
IDR - Intrinsic Disordered Region
MoRF - Molecular Recognition Feature
Cdk - cyclin dependent kinase
PKA - Protein Kinase A
MAPKKK - MAP Kinase Kinase Kinase
MAPK - MAP Kinase
ORF - Open Reading Frame
ßME - ß-mercaptoethanol
3-AT - 3-amino-1,2,4-triazole
CKM – cyclin C/Cdk8 kinase module
Y2H – Yeast Two Hybrid
Keywords:
Med13, cyclin C, Cdk8, Slt2, Programmed Cell Death
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A2.3 Abstract
In response to oxidative stress, cells decide whether to mount a survival or cell death
response. The conserved cyclin C and its kinase partner Cdk8 play a key role in this decision.
Both are members of the Cdk8 kinase module that, with Med12 and Med13, associate with the
core mediator complex of RNA polymerase II. In S. cerevisiae, oxidative stress triggers Med13
destruction, which thereafter releases cyclin C into the cytoplasm. Cytoplasmic cyclin C
associates with mitochondria where it induces hyper-fragmentation and regulated cell death. In
this report, we show that residues 742-844 of Med13’s 600 amino acid intrinsic disordered
region (IDR) both directs cyclin C-Cdk8 association and serves as the degron that mediates
ubiquitin ligase SCFGrr1-dependent destruction of Med13 following oxidative stress. Here, cyclin
C-Cdk8 phosphorylation of Med13 most likely primes the phospho-degron for destruction. Next,
pro-oxidant stimulation of the cell wall integrity pathway MAP Kinase Slt2 initially
phosphorylates cyclin C to trigger its release from Med13. Thereafter, Med13 itself is modified
by Slt2 to stimulate SCFGrr1-mediated destruction. Taken together, these results support a model
that this IDR of Med13 plays a key role in controlling a molecular switch that dictates cell fate
following exposure to adverse environments.
A2.4 Introduction
Protein-protein interactions are at the heart of nearly all facets of cell physiology
including transducing exogenous signals necessary for proper cell fate decisions to be adopted.
For example, following exposure to cytotoxic compounds, the cell must assess the level of
damage and decide whether to arrest cell division and repair the damage or execute programmed
cell death. Recently, it has become apparent that intrinsic-disordered regions (IDRs) defined by a
continuous stretch of disordered promoting residues, play key roles in directing protein−protein
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interaction networks especially those involved in macro-molecular decisions including signaling
and control pathways (reviewed in [156, 157]). This hotspot for communication is achieved in
part by the ability of IDR’s to contribute to the formation of large, malleable interfaces that can
interact with multiple partners. These protein interactions can occur via short segments termed
molecular recognition features (MoRFs) that undergo disorder-to-order transition upon binding
to their cognate ligands [213]. Consistent with these domains being communication hubs, the
binding of IDR’s to their targets is often regulated by covalent modifications including
phosphorylation, which can serve as simple biological switches [214].
In budding yeast, cyclin C and its kinase partner Cdk8 are predominantly negative
regulators of a diverse set of stress response genes [126, 138-141]. Together with Med13 and
Med12, they form the Cdk8 kinase module (CKM) of the multi-subunit Mediator complex which
acts as an interface between DNA bound transcription factors and RNA polymerase [135-137].
In addition to its transcriptional role, cyclin C possesses another function following oxidative
stress that is found in both yeast and mammalian cells [127, 129, 134, 215]. Specifically, nuclear
release of cyclin C, but not Cdk8, allows its re-localization to the mitochondrial outer membrane.
At this new subcellular address, cyclin C is necessary and sufficient for stress-induced
mitochondrial fission and is required for MOMP dependent normal regulated cell death (RCD)
execution [127, 129, 134]. This type of cell death is the reclassification of programmed cell
death (PCD) passed by the international Nomenclature Committee on Cell Death in 2015 [216].
In the budding yeast, cyclin C release is dependent upon its direct phosphorylation by Slt2
MAPK [131] and the ubiquitin mediated degradation of Med13 ([154] and see Figure A2-1) In
the CKM, Med13 contains a large centrally located IDR, the extent and placement of which is
conserved across metazoans, plants and fungi [217]. As Med13 also bridges the CKM to the
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Mediator complex [218] this centrally placed IDR may provide structural plasticity, allowing the
CKM to interface with different mediator components according to the environment. Consistent
with Med13 IDR being a potential communication hub, computer predictions suggest the
presence of several MoRPs biased toward an alpha helical confirmation [219].

Figure A2-1 Cdk8 module (Cd8, cyclin C, Med12 and Med13) regulation by the CWI MAPK pathway H2O2
stimulates cell wall sensors leading to activation of the cell wall integrity (CWI) MAP kinase module. Slt2
phosphorylation triggers cyclin C translocation to the mitochondria and Med13 degradation [154]. The pseudokinase
Kdx1 is also required for cyclin C nuclear release via an unknown mechanism [131]. Med12 is not required for
cyclin C nuclear release [154].

In this report, we provide mechanistic details on how Med13 is targeted for destruction
following oxidative stress in the budding yeast S. cerevisiae. We show that the Cell WalI
Integrity (CWI) pathway MAPK Slt2 directly phosphorylates Med13, which is required for
recognition by the SCFGrr1 E3 ligase complex. Consistent with other SCF targets in yeast and
higher eukaryotes (reviewed in [155]), degradation of Med13 by SCFGrr1 also requires the
phosphorylation by cyclin C-Cdk8 which most likely primes this phospho-degron. Furthermore,
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this phospho-degron partly overlaps with the predicted Med13 IDR [219]. Consistent with this
region serving as an interaction hub [220], this IDR directs both Cdk8 and Grr1 binding and is
sufficient to retain cyclin C in the nucleus. Taken together, these results define a multi-step
switch required for the cellular decision to release cyclin C from the nucleus and identifies a
Med13 IDR as the communication hub that co-ordinates this pro-death decision.
A2.5 Results
A2.5.1 SCFGrr1 is required for Med13 H2O2-mediated degradation
We have previously shown that Med13 degradation is dependent upon a functional 26S
proteasome indicating that a ubiquitin ligase is required [154]. In unstressed human cells, Med13
is turned over by the conserved SCF ubiquitin ligase utilizing the Fbw7 F-box recognition
protein [221]. Grr1, a yeast homologue of Fbw7, is a non-essential F-box protein that utilizes a
Leucine Rich Region (LRR, Fig. 2A) for substrate recognition [221, 222]. SCFGrr1 is required
for degradation of the mediator component Med3 [222] as well as proteins regulating the
glycolytic-gluconeogenic switch [180]. More recently it has also been shown to regulate Whi7, a
repressor of Start transcriptional gene expression [223]. To determine whether SCFGrr1 plays a
role in H2O2-induced Med13 degradation, we examined Med13 degradation following 0.4 mM
H2O2 treatment in wild type and grr1∆ cells harboring functional Med13-HA on a single copy
plasmid. This concentration of H2O2 has long been established to induce a MOMP dependent
RCD response in yeast [169, 171, 224] as well as trigger cyclin C nuclear export [127, 129, 131].
The results (Figure A2-2B) show that Med13-HA is significantly more stable in grr1∆ cells. We
next repeated these experiments using endogenous MED13 tagged with the myc epitope in wild
type (RSY1798) and grr1∆ mutant strains (RSY1771) harboring a plasmid expressing either
wild-type GRR1, a vector control or a GRR1 derivative deleted for the LRR domain (grr1∆L)
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[221]. Following H2O2 treatment, Med13-myc was again significantly more stable in grr1∆ cells
harboring either the vector control or grr1∆L than in wild-type cells (Figure A2-2C and A2S1A). These results suggest that SCFGrr1 is the E3 ligase responsible for mediating Med13
degradation following H2O2 stress.

Figure A2-2 SCFGrr1 mediates Med13 degradation following H2O2 stress (A) Model of the SCFGrr1. (B) Wild type
(RSY10) and grr1∆ cells (RSY1770) harboring Med13-HA (pKC801) were treated with 0.4 mM H2O2 for the
timepoints indicated and Med13 levels analyzed by Western blot. (C) Top panel: RSY1798 (MED13-myc::KAN)
was treated with 0.4 mM H2O2 for the timepoints indicated and Med13 levels analyzed by Western blot. Tub1 levels
were used as loading controls. Bottom panel: RSY1771 (grr1∆::HIS3 MED13-myc::KAN) harboring ADH1PROgrr1∆L was analyzed as for RSY1798. Tub1 levels were used as loading controls. (D) Yeast two hybrid analysis of
Med13 and Grr1 derivatives. Y69a cells harboring Med13-activating domain plasmid (pKC800) and either pAS2,
pAS-Grr1 or pAS2-Grr1∆L binding domain plasmids were grown on -LEU, -TRP drop out medium to select for
both plasmids (left panel), -TRP, -LEU, -HIS –ADE (middle panel) and -TRP,-LEU, -HIS, -ADE +3AT (right panel)
to test for Med13-Grr1 interaction.
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If SCFGrr1 is the ubiquitin ligase directing Med13 proteolysis, then Grr1 should interact
with Med13. To test this possibility, Grr1 and Med13 association was assayed using a twohybrid strategy. This approach has been previously used to both identify and confirm Grr1
substrates [167, 168]. We expressed either the wild type or grr1∆L mutant GRR1 allele fused to
the Gal4 DNA binding domain bait with the full length Med13 fused to the activator domain
(AD) prey. These studies revealed that Grr1 interacts with Med13 and this interaction survives
addition of the histidine analog 3-amino-1,2,4-triazole (3-AT) suggesting that the HIS3 reporter
gene induction is robust (Figure A2-2D). With the grr1∆L mutant bait, an interaction is detected
selecting for the dual HIS3 and ADE2 reporter genes but colony formation is uneven (middle
panel) or absent in the presence of 3-AT (right panel). Taken together with the increased stability
of Med13 observed in grr1∆ cells, these results argue that Med13 is an SCFGrr1 substrate.
A2.5.2 The intrinsic disordered region of Med13 interacts with Grr1
Many SCF targets require phosphorylated substrates for F-box recognition [225].
Consistent with this model, the LRR of Grr1 specifically recognizes phosphorylated
serine/threonine-proline motifs within its substrate degron [221]. In human cells,
phosphorylation of T326 is required for Med13 destruction by SCFFbw7 [226]. To address
whether a similar mechanism directs H2O2-induced Med13 degradation in yeast, the requirement
of the analogous threonine in yeast (T210, Fig S1B) was tested. For these studies we expressed
Med13-HA from a single-copy plasmid in med13∆ cells. These studies revealed that both the
wild type and the Med13T210A derivative were still degraded following 0.4 mM H2O2 stress
(Figure A2-S1C, D and quantitated in E) indicating that T210 phosphorylation is not necessary
for oxidative stress-induced destruction of Med13. Furthermore, consistent with our previously
published results with endogenously tagged Med13-myc [154], Med13-HA degradation is not
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dependent upon new protein synthesis as it is still observed following cycloheximide treatment
(Figure A2-S1C).

Figure A2-3 The unstructured domain of Med13 binds Grr1 (A) ProteinPredict® [227] analysis of yeast Med13.
Med13 contains amino and carboxyl terminal structured domains separated by an intrinsic disordered domain (IDR).
Grr1 and Med13 interaction regions are indicated below the schematic. ± = qualitatively reduced binding (B).
Med13-Grr1 Y2H analysis. Y69a cells harboring pAS-Grr1 and the indicated Gal4AD-Med13 subclone were
streaked on media selecting for plasmid maintenance (left) or induction of the ADE2 and HIS3 reporter genes (right)
by Y2H interaction. (C) Wild type (RSY10) and grr1∆ (RSY1770) cells harboring the minimal Med13 interaction
domain expression plasmid (Gal4AD-Med13571-906) were treated with 0.4 mM H2O2 for the timepoints indicated
and Med13571-906 levels analyzed by Western blot. Pgk1 levels were used as a loading controls.

We next employed Y2H assays to identify the Med13 region able to interact with Grr1.
Med13 has structured head and tail domains flanking a large intrinsic disordered region (IDR)
[219] (Figure A2-3A). A series of Gal4AD-Med13 constructs that span the length of Med13
were built and tested for their ability to interact with Gal4BD-Grr1. The results revealed that the
Grr1 interaction domain lies within the unstructured domain, between amino acids 571 and 906
(Figure A2-3B, summarized in Figure A2-3A). To confirm that the Med13 degron lies within
this region, we performed a classical degron assay. The levels of the prey Gal4AD-Med13571-906
fusion protein were monitored following 0.4 mM H2O2 stress in wild type and grr1∆ cells. The
results indicated that Med13571-906 was destroyed following oxidative stress in a Grr1-dependent
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manner (Figure A2-3C). Taken together, these results indicate that the SCFGrr1 degron lies within
the IDR.
A2.5.3 The Med13 IDR binds cyclin C
As cyclin C nuclear release represents an important step toward entering the cell death
pathway, we next sought to identify the Med13 region that binds cyclin C using two hybrid
strategies. However, the yeast cyclin C self activates when tethered to a Y2H bait protein [126].
Therefore, we used the human cyclin C as it does not self-activate two-hybrid reporter genes
[228]. Using this approach, we found that the same region associating with Grr1 (amino acid
residues 571-906) also bound cyclin C (Figure A2-4A, summarized in Figure A2-3A). To
confirm these results, as well as to address if this interaction is direct, we used a pull down
approach. We expressed a central region of the Med13 interaction domain (amino acid residues
742-844) as a Gst fusion protein. Gst-Med13742-844 was passed over a cobalt column on which E.
coli prepared human His6-cyclin C was bound. Following extensive washing, bound proteins
were eluted with imidazole and the presence of Gst-Med13742-844 was determined by Western
blot analysis using antibodies to 6His or human cyclin C. These results show that human cyclin
C interacts with Med13742-844 (Figure A2-4B). The experiments were repeated using yeast cyclin
C (Figure A2-4C). Although the residual cleaved GST that was present in the GST-Med13
construct showed some interaction with yeast cyclin C, the full length construct showed a
significantly stronger interaction. Confidence was garnered in this interaction being specific as
no interaction was observed when GST alone was used in either Figure A2-4B or 4C.
Interestingly, although amino acid residues 571-650 of Med13’s IDR can associate with Grr1
(Figure A2-3B) this region does not associate with cyclin C (Figure A2-4D). Thus taken together
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these results indicate that cyclin C binds the same region of Med13’s large IDR that is
recognized by SCFGrr1.

Figure A2-4 The Med13 IDR binds cyclin C (A) Y2H analysis of human cyclin C DNA binding domain plasmid
(pSW108) and the indicated Gal4AD-Med13 subclone derivatives. The numbers indicate the amino acids remaining
in the activation domain plasmids. Transformants were patched onto either -LEU, -TRP (-L –T) or -HIS -ADE -LEU
-TRP (-H-A-L-T) to select for plasmid maintenance or Y2H interaction, respectively. (B) Western blot analysis of
pull down assays with His6-human cyclin C and GST-Med13742-844 (DS30). The load control contains 1/10 of the
input. Single and double asterisks represent cleaved GST and cross-reaction between anti-GST antibody and human
cyclin C, respectively. Molecular weight markers (kDa) are indicated. (C) As in (B) except that yeast cyclin C was
used. (D) Western blot analysis of pull down assays with GST yeast cyclin C and 6His-Med13571-650 (DS22). The
load control contains 1/50th of the input. Molecular weight markers (kDa) are indicated.
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A2.5.4 The Med13 IDR is sufficient to retain cyclin C in the nucleus
To determine whether the yeast cyclin C also associates with the same region of Med13’s
IDR in vivo, we asked if this region (Med13571-906) is sufficient to retain cyclin C in the nucleus
in the absence of stress. To address this question, mitochondrial morphology and subcellular
localization of a functional cyclin C-YFP [129] was monitored in unstressed med13∆ cells
harboring either a vector control or one of four Gal4AD-Med13 fusion proteins. As expected,
cyclin C was predominantly cytoplasmic and co-localized with fragmented mitochondria in the
vector control (A, top row, quantitated in Figure A2-5B and see Figure A2-S2 for DAPI stained
images). Similarly, expression of Gal4AD-Med13571-650 was unable to retain cyclin C in the
nucleus or prevent mitochondrial fragmentation (second row). However, cells expressing either
Gal4AD-Med13571-906 Gal4AD-Med13651-906 or Gal4AD-Med13742-844 exhibited both nuclear
retention of cyclin C and fused mitochondria. Taken together with the pull down assays, these
results suggest that Med13742-844 is sufficient s sufficient to retain yeast cyclin C in the nucleus.
A2.5.5 Cdk8 phosphorylation primes Med13 for destruction
SCF substrates are typically recognized following phosphorylation of the degron.
However, many substrates require two phosphorylation marks; one to “prime” the substrate and
the other that represents the trigger for ubiquitylation (reviewed in [155]. Previous work revealed
that Protein Kinase A (PKA) phosphorylates Med13 on Serine 608 and 1236 [229]. However, a
derivative mutated for both phosphor acceptor sites (Med13S608A,S1236A-HA) was still destroyed
with similar kinetics to wild type (Figure A2-S3A) indicating that PKA phosphorylation is not
required for Med13 degradation following H2O2 treatment. Consistent with this result, the
Med13S608A,S1236A-HA complements the aberrant mitochondrial morphology exhibit by med13∆
cells (Figure A2-S3B).
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Figure A2-5 The unstructured domain of Med13 retains cyclin C in the nucleus (A) Fluorescence microscopy of
mid-log phase med13∆ cells (RSY1701) harboring the Gal4AD-Med13 construct indicated or a vector control
(pACT2) and both cyclin C-YFP and DsRed mitochondrial targeting (mt-DsRed) plasmids. Blue boxes indicated
enlarged regions of the image. Bar = 10 µM. (B) The percent of the population of cells in (A) displaying at least 3
cyclin C-YFP foci in the cytoplasm (top panel) or fragmented mitochondria (bottom panel) is quantified (mean ±
s.e.m.). At least 200 cells were counted per timepoint from 3 individual isolates. * p<0.05 difference from vector
control.

In addition to PKA, cyclin C-Cdk8 phosphorylates Med13 in humans [218, 230]
suggesting the possibility that Cdk8 represents the priming kinase. To test this model, Med13
destruction kinetics were monitored in a cnc1∆ null strain transformed with either the wild type
CNC1 gene or the vector control. These experiments indicated that cyclin C-Cdk8 kinase is
required for Med13 destruction (Figure A2-6A and quantified in Figure A2-S4A). Our previous
studies showed that Slt2 phosphorylates cyclin C on Ser266 following H2O2 and this
modification is required for its release from Med13 and translocation to the cytoplasm [131].
Therefore, one possibility is that cyclin C release is a prerequisite for Med13 destruction.

102

Consistent with this possibility, Med13 was protected from destruction in a cnc1∆ mutant
harboring a plasmid expressing cyclin CS266A (Figure A2-6A, right panel). These results indicate
cyclin C phosphorylation by Slt2 is also required for Med13-HA destruction (see below).

Figure A2-6 Cyclin C-Cdk8 directly stimulate Med13 proteolysis (A) Mid-log cnc1∆ cultures (RSY391) harboring
either wild-type CNC1 (pKC337), vector (pRS314) or cnc1S266A (pLR166) expression plasmids and pKC803 (CEN,
Med13-HA) were subjected to an H2O2 timecourse experiment. Pgk1 levels were used as loading controls. (B) Phostag gel analysis of pDS8 (Gal4AD-Med13571-906) in unstressed wild type (RSY10) or cdk8∆ (RSY1796) cultures.
Arrow indicates phosphorylated Med13571-906 species. Molecular weight markers (kDa) are indicated. (C) RSY2066
harboring the Ubi-Ile3-Cdk8-HA expression plasmid (pCM1888) were grown to mid-log phase and doxycycline
added for the indicated times. Cdk8-HA levels were monitored by Western blot analysis. Tub1 levels were
monitored for loading control. (D) RSY2066 harboring pCM1888 and Med13-HA (pKC803) were grown to mid-log
phase, the culture split, and doxycycline added to one for 1 hour. Both cultures were then treated with 0.8mM H2O2
and Med13-HA degradation monitored as previously described. Tub1p was monitored for loading control.
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The results just presented indicated that the cyclin C-Cdk8 kinase is required for Med13
destruction in response to oxidative stress. Consistent with this Med13 is protected from
degradation in cells harboring kinase dead cdk8 as the only source of this enzyme [127]. As
cyclin C-Cdk8 is active in unstressed cells these results suggest this kinase could prime the
degron for recognition by SCFGrr1. To test this model attempted to perform in vitro kinase assays
with cyclin C-Cdk8 and Med13571-906 as the substrate. Unfortunately, we were unable to get these
assays to work. Thus we decided to ask examine the phosphorylation state of the Med13 degron
derivative (GalADMed13571-906) using the Phos-Tag™ SDS-PAGE system that severely retards
the movement of a phosphorylated peptide [231]. Protein extracts prepared from unstressed wild
type or cdk8∆ cultures harboring GalADMed13571-906 were subjected to Phos-Tag western blot
analysis. The results revealed the presence of a slower migrating band in the wild type extract
that was missing in the cdk8∆ sample (Figure A2-6B). This indicates that Cdk8 is required for
Med13 phosphorylation in unstressed cells.
To test whether cyclin C-Cdk8 activity was required before or after oxidative stress, a
Cdk8-N-end rule degron was constructed. This system takes advantage of the rapid turnover of
proteins that contain arginine as the amino terminal residue [232-234]. The Cdk8-N-end rule
construct is under the control of a doxycycline-repressible promoter such that the administration
of doxycycline coupled with the rapid turnover of the Cdk8-N-end rule fusion protein results in
rapid depletion of Cdk8 from yeast cells (Figure A2-6C). To test the execution point for Cdk8
phosphorylation, a mid-log culture expressing an epitope-tagged allele of full length MED13
(MED13-HA) and Cdk8-N-end degron was untreated or treated with doxycycline for one hour
prior to H2O2 addition to ensure Cdk8 depletion. A timecourse was conducted and samples
collected, extracts prepared and Med13-HA levels monitored by Western blot analysis. These
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studies revealed that Med13-HA levels were reduced similarly in both cultures (Figure A2-6D)
indicating that Cdk8 function was required before oxidative stress. Thus taken together, these
results are consistent with a model that Cdk8 phosphorylation primes Med13 for degradation.
A2.5.6 The CWI pathway is required for ROS-mediated destruction of Med13
The CWI signal transduction pathway is the major MAPK pathway in yeast that transmits
the reactive oxygen species (ROS) stress signal to transcription factors [235]. To facilitate cyclin
C nuclear release, the CWI employs two MAPKs, Slt2 and its pseudokinase paralog Kdx1. Slt2
phosphorylates cyclin C on Serine 266 to induce cytoplasmic re-localization [129-131] while
Kdx1 functions through an unknown mechanism [236]. To address if Kdx1 and/or Slt2 are
required for Med13 degradation, we examined Med13-HA degradation kinetics in wild type and
slt2∆ or kdx1∆ single mutant cultures following 0.4 mM H2O2 stress. As slt2∆ mutants are
temperature sensitive, these experiments were conducted at 23°. The results show that Med13HA was degraded in wild type or kdx1∆ cells but stable in the slt2∆ mutant (Figure A2-7A,
quantified in Figure A2-S4B). These results indicate that unlike cyclin C, only Slt2 but not Kdx1,
is required for Med13 destruction. Repeating this experiment with cells expressing a kinase dead
version of SLT2 (slt2K54R) produced similar results (Figure 7B) indicating the Slt2 kinase activity
is required for Med13 proteolysis. To investigate whether the role of Slt2 in Med13 degradation
was direct, in vitro kinase assays were performed using activated Slt2-HA or the kinase dead
derivative (Slt2K54R-HA) [149] immunoprecipitated from yeast extracts. The immunoprecipitate
was incubated with the E. coli prepared Med13 degron (amino acids 571-906) described above.
These experiments revealed enhanced phosphorylation of Med13571-906 above background that
was dependent upon a functional kinase (Figure A2-7C) indicating that Slt2 directly regulates
Med13 stability. Finally, we asked whether Slt2 activation was sufficient to induce Med13
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destruction or whether another stress signal was required. To address this question, Med13-HA
levels were monitored in an unstressed culture expressing a constitutively active allele of the
upstream MAPKKK BCK1 (BCK1-20). Mid-log cultures expressing BCK1-20 exhibited
dramatically reduced Med13-HA levels compared to vector control (Figure A2-7D). These
results indicate that the CWI pathway is both necessary and sufficient to induce Med13
destruction. Finally, to test the epistatic relationship between BCK1-20 and cdk8∆ alleles, the
experiment just described was repeated in a cdk8∆ background. Western blot analysis revealed
that Cdk8 was required for BCK1-20 induced Med13 destruction in unstressed cells (Figure A26D). Taken together, these results indicate that Slt2 activation is necessary for H2O2-mediated
Med13-HA degradation and that this signal requires Cdk8 activity. These results are consistent
with a three-step model for initiating the Med13 destruction pathway (see Discussion).

Figure A2-7 Slt2 directly stimulates Med13 destruction (A) Wild type (RSY10), kdx1∆ (RSY1736) and slt2∆
(RSY1006) cultures expressing pKC801 (CEN, Med13-HA) were grown to mid-log phase (0 hr) then treated with
0.4 mM H2O2 for the indicated times. Med13-HA levels were determined by Western blot analysis. (B) As in A
except that the slt2∆ cells expressed a kinase dead SLT2 mutant (slt2K54R) plasmid. (C) Upper panel: Slt2-HA or
Slt2K54R-HA (kinase dead) was immunoprecipitated from extracts prepared from cells treated for 60 min with 5mM
sodium orthovanadate was mixed with Med13571-906 and radioactive ATP as indicated. All reactions were conducted
in duplicate then separated by SDS PAGE and subject to autoradiography. Med13571-906 is indicated by the
arrowhead. Lower panel: Coomassie stained gel showing the Med13571-906 input used in the kinase assays. (D) Wildtype (RSY10) or cdk8∆ (RSY1796) mutant cells expressing either an empty vector control or the hyperactive allele
of BCK1 (BCK1-20) and MED13-HA (pKC803) were grown to mid-log and Med13-HA levels determined by
western blot analysis. Tub1 served as a loading control.
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A2.5.7 Slt2 and Cdk8 phosphorylation of the IDR region is required for Med13
destruction
IDR regions confer conformational flexibility to proteins that are often targets of posttranslational modifications [190]. Notably IDR's are enriched for phosphorylation sites raising
the possibility that they are substrates for multiple kinases [192]. As our data indicate that Cdk8
and Slt2 are required for Med13 degradation, we next asked if the sites they phosphorylate lie
within the same IDR region of Med13 that associates with Grr1 and cyclin C (amino acids 651906). Slt2 and Cdk8 are both proline directed kinases that preferentially phosphorylate the
consensus sequences PX(S/T)P or S/T-P-X-K/R (where X is any amino acid), respectively.
They also can phosphorylate the minimal consensus sequence S/T-P [188]. Med13651-906 contains
a conserved Slt2 consensus sequence at position 748 that has been identified as potential
phosphorylation site in two genomic screens [181, 237] well as four additional TP sites (Figure
A2-8A). Thus, to address if these kinases phosphorylate the five S/T-P sites in Gal4ADMed13651-906 fusion protein, its degradation was monitored following H2O2 stress in wild type,
slt2∆ and cdk8∆ cells. The results show that Gal4AD-Med13651-906 fusion protein is stable in
either slt2∆ or cdk8∆ cells (Figure A2-8B). These results are consistent with a model that the
Med13 phospho-degron is targeted by both Cdk8 and Slt2. Consistent with the Y2H data
presented in Figure A2-3B, the phopho-degron is stable in grr1∆ cells (Figure A2-8C). If the
Med13 phospho-degron is regulated by two kinases, then two separate S/T-P sites within the
degron should stabilize the protein. To test this, wild-type cells harboring either a wild type
Gal4AD-Med13742-844 fusion protein or mutant derivatives were subjected to 0.4 mM H2O2 stress
and analyzed as described above. As anticipated, the smaller Gal4AD-Med13742-844 fusion protein
that contains all 5 S/T-P sites was still degraded in wild-type cells (Figure A2-8C). Interestingly,
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the S748A, T781A and T803A mutants were also degraded with the same kinetics as wild type
(Figure A2-S4C). In addition, the double mutants (T781A T803A and S748A T781A) were also
degraded with wild-type kinetics (Figure A2-8D and E). However, the T835A, T837A double
mutant was significantly more stable than wild type (Figure A2-8C and E) suggesting that these
sites are required for Med13 degradation. Taken together, these results suggest that both kinases
have to be active in order for SCFGrr1 to recognize this 100 amino acid phospho-degron, at
position T835 and T837.

Figure A2-8 The Med13 IDR contains the phospho-degron (A) Map of Med13 showing the location of potential
Cdk and MAPK sites within the IDR. (B) Wild type (RSY10), slt2∆ (RSY1737) and cdk8∆ (RSY1796) cultures
expressing pDS16 (Gal4AD-Med13651-906) were grown to mid-log phase (0 hr) then treated with 0.4 mM H2O2 for the
indicated times. Med13651-906-HA levels were determined by Western blot analysis. Pgk1 levels were used as a
loading control. (C) (D) Wild type (RSY10) cultures harboring wild type Gal4AD-Med13742-844 (pDS32) or various
point mutations as indicated were grown to mid-log phase (0 hr) then treated with 0.4 mM H2O2 for the indicated
times. Med13-HA levels were determined by Western blot analysis. Pgk1 levels were used as a loading control. The
Gal4AD-Med13742-844 levels were also monitored in the grr1∆ strain. (E) Degradation kinetics of the Gal4ADMed13742-844 constructs shown in C and D.
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A2.6 Discussion
Communication between organelles is critical to coordinate the cellular response to a
variety of external or internal signals including oxidative stress. The data presented here and in
previous publications [126, 127, 129-131, 134, 154, 228, 236] has revealed that the Cdk8 module
(cyclin C, Cdk8, Med12 and Med13) of the mediator complex plays a key role in both yeast and
mammalian cells. Previously, we reported that the cyclin C, but not Cdk8, translocates from the
nucleus to the mitochondria following oxidative stress in both yeast and mammalian cells. At the
mitochondria, cyclin C associates with the fission machinery to induce fragmentation and directs
programmed cell death [127, 129, 134]. Therefore, releasing cyclin C from the nucleus
represents an important step determining whether the cell initiates the RCD pathway or not.
Importantly, we found that the nuclear anchor for cyclin C, Med13, is destroyed in response to
oxidative stress providing a mechanism for how cyclin C nuclear release was orchestrated [154].
Interestingly, Med12, is neither required for this response [154] nor destroyed following H202
stress (Figure A2-S4D). In this report, we provide the molecular details of how Med13
destruction is triggered to operate this important molecular switch in yeast. First, Med13
proteolysis is mediated by the ubiquitin ligase SCF and the specificity factor Grr1. Several
studies in yeast and higher eukaryotes found that SCF substrates require a complex interplay
between multiple kinases to generate the requisite phospho-degron on the substrate (reviewed in
[155]). For example, Cdk1 acts as a priming kinase for Cdc5 [238, 239] whereas Cdc5 acts as a
priming kinase for Wee1 [240]. In all cases, the priming kinase first phosphorylates the substrate,
while the second kinase completes the formation of the phospho-degron by modifying residues
that are recognized by the SCF. This has led to the current model that priming phosphorylations
create docking sites for downstream kinases. Moreover, local structural disorder most likely
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facilitates how multiple kinases regulate a protein within a small region. We identified a small
region (amino acids 742-844) within the intrinsic-disordered region (IDR) of Med13 that acts as
a communication hub. This region is sufficient to retain cyclin C in the nucleus, associates with
Grr1, and contains the Med13 phospho-degron that is primed by Cdk8 and activated by Slt2
following oxidative stress exposure. This dual kinase requirement provides the cell with a
mechanism to integrate multiple input signals into a single read out.
A2.6.1 The Med13 phospho-degron activation requires a three-step process
Our results indicate that cyclin C-Cdk8 provides the priming signal for Med13 destruction
(Figure A2-9, Step 1). Although technical reasons prevented us from addressing whether this
activity is direct or indirect, four independent experiments support a model that this is a direct
phosphorylation event. 1. The observation that Med13651-906 was not destroyed following H2O2
stress in cdk8∆ cells (Figure A2-8B). 2. Observation of a slower migrating band seen in PhosTag™ SDS-PAGE analysis of unstressed in wild type extracts that was missing in the cdk8∆
sample (Figure A2-6B). 3. The end-N rule experiments conducted in Figure A2-6C and D also
revealed that Med13-HA levels were reduced regardless of the presence of Cdk8 after stress. 4.
Lastly, in vitro evidence revealed that cyclin C directly interacts with this region of Med13
(Figure A2-4B and 4C) which would position the kinase with direct access to the Med13 degron.
Thus taken together, these results suggest that Cdk8 phosphorylation primes Med13 for
degradation, most likely by a direct event. Consistent with this, human Cdk8 directly
phosphorylates human Med13 on S749, which lies in the intrinsic disorder domain in what
appears to be a non-conserved residue compared to yeast [230]. This requirement may be
necessary to inform the cell that Med13 is in the Cdk8 module and its destruction will lead to
cyclin C release and Cdk8 inactivation. Slt2 activation by oxidative stress provides the trigger
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mechanism that commits the cell to destroying Med13 and releasing cyclin C from the nucleus
(Step 3). This event accomplishes two goals. First, removing cyclin C and destroying Med13
inhibits the repressor activity of Cdk8 for several stress responsive genes including chaperones
(e.g., SSA1), anti-oxidants such as catalase (CTT1) and the multi-stress responsive gene DDR2
[126, 129, 139]. In addition, Slt2 activation stimulates several transcription factors, such as Rlm1
that is required for the transcriptional arm of the stress response [148, 151, 241]. Therefore, Slt2
activation both stimulates transcriptional activators and inhibits repressors. By releasing cyclin
C, the cell is able to transmit the stress signal to the rest of the cell including the mitochondria.
We have previously demonstrated that cyclin C-induced fission alone is not sufficient to induce
cell death but does make cells hypersensitive to oxidative stress [154]. Therefore, cyclin C
release poises the cell to initiate RCD but additional regulatory layers exist. Unlike other
priming/trigger two-kinase degron phosphorylation switches, we have identified an additional
step in the system regulating Med13. Specifically, Slt2 also modifies cyclin C on S266, which
promotes its dissociation from Med13 [131]. Our finding that the S266A mutation protects
Med13 from destruction is consistent with a model that S266 modification disrupts cyclin CMed13 interaction (Step 2) allowing Slt2 access to the phospho-degron. Taken together, our
model predicts a three-step system that controls Med13 stabilityand cyclin C nuclear release.
If cyclin C phosphorylation is sufficient to initiate cyclin C nuclear release, then why
would it be important to completely destroy Med13? First, our results indicate that S266
phosphorylation is capable of stimulating only partial release of cyclin C in unstressed cells
[131]. Therefore, Med13 destruction may be necessary for complete cyclin C release. Not
exclusive of this model, another possibility is that Med13 destruction prevents the
reaccumulation of cyclin C in the nucleus after its cytoplasmic translocation. In this model,
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Med13 proteolysis fixes the decision of cyclin C release thus directing a complete transcriptional
and mitochondrial response to oxidative stress.

Figure A2-9 Three-step model of cyclin C release from Med13 following H2O2 stress Step 1. Cdk8-Cyclin C kinase
phosphorylates Med13 in unstressed cells to provide the priming modification for this degron. Step 2 requires stressactivated Slt2 that phosphorylates cyclin C on S266 leading to disassociation of cyclin C from Med13. This event
allows Slt2 access to the phospho-degron to deliver the trigger modification leading to Med13 recognition by
SCFGrr1 and its destruction.

A2.6.2 Med13 Intrinsic disordered Region (IDR) is a communication hub
It has recently been suggested that IDR's play important roles in protein:protein
communication as they provide a flexible interaction surface to multiple partners [189]. Using
protein two different structure prediction algorithms IUPred/ANCHOR and Phyre2 [242-244]
Med13 has a large IDR spanning the middle of the protein (amino acids residues 307-906 and
Figure A2-S5A and B). Although not conserved in amino acid sequence, it is notable that the
position and presence of Med13’s IDR is conserved throughout three kingdoms [217]. Also
conserved is the observation that Med13 is the CKM member that brings this kinase module in
contact with the Mediator complex [218]. This suggests a model in which the IDR of Med13
provides conformational plasticity to the CKM, which is important for bringing the kinase and
other proteins in contact with different mediator members on a “pro re nata” basis. This idea is
consistent with the results presented here in which we show that the IDR of Med13 can bind to
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cyclin C before stress and Grr1 after. Although speculative, taken together this suggests a model
in which Med13 IDR is conserved functionally and may contain signature motifs that are
important for protein binding. Consistent with this idea is the observation that two other
conserved proteins that regulate transcription (CCR4-NOT4 and TFIIS) also bind to the IDR
region of yeast Med13 but in a different location (Fig S5, [245, 246]. Such a signature could be
a MoRF, which is defined as a short binding region located within longer intrinsically disordered
regions that bind to protein partners via disorder-to-order transitions [247]. ANCHOR analysis
[243] predicts that the IDR of Med13 has many such domains, with two lying within the cyclin C
binding region (residues 742-844 - Figure A2-S5A). As additional factors are identified that
bind the Med13 IDR, the rules that govern these interactions may become better understood.
The need to understand the role Med13 IDR plays in protein communication has become
important in the last decade as in humans truncating or loss of function mutations in MED13L, a
paralogue of MED13 [248], results in MED13L happloinsufficiency syndrome. This syndrome is
complex and presents with either complex congenital heart and neurodevelopmental defects or
severe neurocognitive deficiencies and facial dysmorphism [249-252]. Interestingly many of
these mutations lie in the IDR region of MED13L [252]. In yeast, a hallmark of med13∆ cells is
that they are respiratory deficient which is dependent upon cyclin C nuclear export [154]. Thus it
would be anticipated that a strain deleted for Med13 residues 742-844 would have a similar
phenotype. Taken together, these studies emphasize the need for further analysis of both yeast
and human Med13 IDR’s to understand the molecular details of how this region contributes to
Med13 function.
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A2.6.3 Role of SCFFbw7 and Med13 in higher eukaryotes following stress
Our previous studies described the conserved role of cyclin C in stressed and unstressed
cells [127, 134]. However, differences are observed in cyclin C regulation between yeast and
humans. In yeast, all of cyclin C is released into the cytoplasm followed by its destruction by the
Not1 ubiquitin ligase. Conversely, only about 10% of total cyclin C is released from the nucleus
in mammalian cells following oxidative stress and we do not detect any significant changes in its
overall protein levels [134]. Steady state turnover of the human Med13 is directed by the
analogous SCF ubiquitin ligase by a homologue of Grr1, called Fbw1 [226]. As Med13 tethers
the Cdk8 module to the Mediator complex [218], Med13 turnover determines the promoter
residency of the module and therefore impacts transcriptional regulation. However, we found
that the phospho-degron directing the turnover of Med13 in human cells (T326) is not required
for stress-induced destruction of Med13 in yeast. These results suggest that either a different
degron system is employed in these two systems or that stress-induced destruction is regulated
differently than that observed under normal growth conditions. Consistent with this is the
observation that Cdk substrates are often clustered in regions of intrinsic disorder (reviewed in
[253]). However, similar to other intrinsic disordered regions, their exact position in the protein
is often poorly conserved in evolution, indicating that precise positioning of phosphorylation
may not be required to permit a shared function (reviewed in [253]). Thus, it is possible that
following oxidative stress in human cells, a similar two-kinase mechanism could regulate Med13
degradation. In support of this model, phosphorylation by two kinases of has been observed for
other SCFFbw1 substrates [254] including oncogenic transcription factors. This has led to
classifying Fbw1 as a tumor suppressor (reviewed in [255]). Fbw7 degrades numerous oncogenic
transcription factors (e.g., Myc, Notch, and Jun) as well as other proteins that contribute to
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carcinogenesis. As cyclin C has also recently been given this tumor suppressor designation
[256], it is imperative to understand the relationship between these proteins following stress in
higher eukaryotes.
A2.7 Materials and methods
A2.7.1 Yeast strains and plasmids
All experiments, except the yeast two-hybrid assays (Y2H), were performed in S.
cerevisiae W303 strain RSY10 [201] and are listed in Table S1. The Y2H assays were performed
in PJ69-4a [166]. In accordance with the Mediator nomenclature unification effort [204], cyclin
C (SSN8/UME3/SRB11) and Cdk8 (SSN3/UME5/SRB10) will use CNC1 and CDK8 gene
designations, respectively. The cnc1∆, cdk8∆, med13∆, slt2∆, kdx1∆ and kdx1 slt2∆ and strains
have been previously described [126, 127, 131, 228]. The grr1∆ strain RSY1770 and myc tagged
Med12 strain (RSY18787) were constructed using gene replacement methodology as described
[205]. The MED13-13myc allele was generated in this strain to create RSY1771 using the same
methodology. RSY2066 was made by integrating pMK634 [234] into the CDK8 locus of
RSY10. The strain was then transformed with pCM188 [257] which contains the TET activator
on a plasmid. The yeast two hybrid strain PJ69-4a was obtained from the Yeast Resource center,
courtesy of a gift from S. Fields. All cells were grown at 30°C apart from slt2∆ and slt2∆ kdx1∆
which were grown at 23°C.
All plasmids used in this study are listed in Table S2. The wild-type epitope tagged
plasmids pHY1066 (MED13-HA, 2µ), pKC337 (ADH1Pro-cyclin C-myc), pUM511 (GPD1ProCDK8-HA) and pBK38 (ADH1Pro-CNC1-YFP) are functional and have been previously
described [126, 129, 130, 229, 258]. pLR141 was made by cloning the ADH1Pro-CNC1-myc,
CYCTerm from pKC337 into pRS426. The 2µ MED13-HA plasmids (PHY1066 and PHY1089)
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and were a gift from P. Herman [229]. The wild-type MED13 centromere based plasmids
pKC801 and pKC803 were made by PCR cloning the ADH1 promoter, MED13-3HA ORF, and
MED13 terminator from PHY1022 into pRS316 and pRS315 respectively. Site directed
mutagenesis (New England Bio-Rad Q5) was used to create plasmids harboring amino acid
mutations except for DS36 which was made using the Change-ITTM kit by Affymetrix. The
CNC1S266A and the SLT2K54R (a gift from D. Levin) have been previously described [131, 149].
The MED13 Y2H plasmids were constructed by PCR cloning from pHY1022 into the Xho1 site
of the Gal4 activating domain plasmid pACT2. Likewise the human cyclin C Y2H Gal4 binding
domain plasmid pSW108 was made by PCR cloning of cyclin C cDNA amplified from pEGFPcyclin C [259] into Nco1 digested pAS2. The GST-MED13 fusion plasmid was made by PCR
cloning from PHY1022 into pGEX4T-1. Oligonucleotide sequences were used to make plasmids
and strains are available upon request. In short, all constructs were amplified from plasmid DNA
using Phusion Taq (Thermo) digested using NEB fast digest restriction enzymes and ligated
using Thermo fast ligase into their respective vectors. All protein fusion constructs were
sequenced (Eurofins Genomics). Other plasmids that were used in this study that have been
previously described are listed in Table S2.
A2.7.2 Cell growth
Yeast cells were grown in either rich, non-selective medium (YPDA) or synthetic
minimal medium (SC) allowing plasmid selection as previously described [126]. For all
experiments the cells were grown to mid-log phase (~ 6 x 106) before treatment with low
concentrations of 0.4 mM H2O2 as previously described [130]. 25 mls of cells were collected per
timepoint, washed in water, then the pellet flash frozen in liquid nitrogen. Yeast two hybrid
experiments were executed as described [168]. 10 mM 3-amino-1,2,4-triazole (3-AT) was added
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to the selective plates to increase the stringency of the interactions. E. coli cells were grown in
LB medium with selective antibiotics. The degron experiments described in Figure A2-5D and
E were executed as follows. In Figure A2-5D, cells (RSY2066) were grown to mid log and
samples removed at the timepoints shown for analysis of Ubi-isoleucine::3HA-Cdk8 degradation
after the addition of 2 µg/ml doxycycline. In Figure A2-5E, RSY2066 was transformed with
Med13-3HA plasmid (pKC803), grown to mid-log, split and into one flask 2 µg/ml doxycycline
added. After 60 minutes, 0.8 mM H2O2 was added to both sets of cells and samples taken for
NaOH lysis and Western analysis as described below.
A2.7.3 Western blot analysis
Tagged Med13 constructs were detected by using NaOH lysis of cell pellets as basically
described by [260]. In short, the frozen cell pellets were defrosted on ice, resuspended in 2M
LiOAc on ice for 5 minutes, centrifuged and then resuspended in 0.4 M NaOH for a further 5
minutes on ice. Thereafter, the pellets were finally resuspended in 100 µl 2X SDS loading dye
[126], boiled for 5 minutes and 15µl loaded onto a 6% SDS-PAGE gel (Novagen). For the phostag gel (Figure A2-9B), proteins were prepared as just described and analyzed on an 7.5%
polyacrylamide gel containing 7.5 µM phos-tag (Wako Laboratory Chemicals) and 15 µM
MnCl2. The proteins were transferred to a nylon membrane (Millipore) using 10% methanol,
0.02% SDS and 10X running buffer [126]. To detect Med13-myc, Med12-myc and Med13-HA,
1 in 5000 dilutions of either anti-myc (Roche) or anti-HA antibodies (Clontech) were used.
Tub1 and Pgk1 were visualized as previously described [261] except that anti-alpha tubulin
antibodies (12G10) were obtained from the Developmental Studies Hybridoma Bank, University
of Iowa. Western blot signals were detected using either goat anti-mouse or goat anti-rabbit
secondary antibodies conjugated to alkaline phosphatase (Sigma) and the CDP-Star
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chemiluminescence kit (Tropix). Signals were quantitated by CCD camera imaging (Kodak Inc.).
All degradation assays were performed more than once. S.E.M. were generated for each point
and error bars are indicated on the graphs which were generated using GraphPad Prism 7
program.
A2.7.4 Fluorescence microscopy
YFP-cyclin C subcellular localization and mitochondrial morphology was monitored as
described previously [127, 129]. For all experiments, the cells were grown to mid-log (6 x 106
cells/ml), treated with 0.4 mM H2O2 for the timepoints indicated, then analyzed by fluorescence
microscopy. Cyclin C-YFP export analysis was performed on cells fixed with 4%
paraformaldehyde/3.4% sucrose for 1 h at room temperature. The cells were washed three times
in water and prepared for fluorescence microscopy as described previously [262] using mounting
medium (10 mg/ml p-phenylenediamine, 50 ng/ml 4',6-diamidino-2-phenylindole) to visualize
nuclei and prevent photo bleaching. Images were obtained using a Nikon microscope (model
E800) with a 100X objective with 1.2X camera magnification (Plan Fluor Oil, NA 1.3) and a
CCD camera (Hamamatsu model C4742). Data were collected using NIS software and processed
using Image Pro software. All images of individual cells were optically sectioned (0.2 µM slices
at 0.3 µM spacing) deconvolved and the slices were collapsed to visualize the entire fluorescent
signal within the cell. Cyclin C-YFP foci were scored as being cytoplasmic when 3 or more foci
were observed outside of the nucleus. Mitochondrial fission assays were performed on live cells
as described [127]. In brief, mitochondrial fission was scored positive if no reticular
mitochondria were observed that transversed half the cell diameter. Fusion was scored when
cells exhibited one or more reticular mitochondria the diameter of the cell. Fission and fusion
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was scored for 200 cells from three independent isolates. Statistical analysis was performed
using the Student’s T-test with p<0.05 used to indicate significant differences.
A2.7.5 Pull down assays and kinase assays
Purified proteins that were used in the pull down assay (Figure A2-4B) were made as
follows. The GST constructs (DS30, GST hCCNC and GST alone) were transformed into BL21
DE3 E. coli strain and expression induced with 0.5 M IPTG at 37°C for 3 h. Cell pellets were
resuspended in 50 mL GST lysis buffer (150 mM KCl, 50 mM HEPES, pH 7.5, 1mM ßME),
sonicated (25 x 10 sec. bursts) and the supernatant recovered by centrifugation at 40000xg for 30
minutes. The supernatant was then added to 1mL of washed glutathione beads (LifeTech) rotated
at 4°C for 1 hr. The unbound fraction was removed from the beads by gravity flow. The beads
were washed twice with lysis buffer and the bound protein was eluted in five 1mL fractions with
the elution buffer (lysis buffer supplemented with 10 mM reduced Glutathione). The protein
containing fractions were pooled and then desalted using 4 mL Zebra7K desalting columns that
had been pre-equilibrated with the lysis buffer. The protein fraction was supplemented with
glycerol to a final concentration of 10% and stored at -80 °C in small aliquots. 6His tagged
human or yeast cyclin C was purified the same way with the following exceptions. The lysis
buffer (buffer A) was 500 mM KCl, 50mM HEPES pH7.5, 1mM ßME, 20mM imidazole. Talon
beads (Clontech,) were used and washed with buffer B (150mM KCl, 50mM HEPES pH7.5,
1mM BME, 20 mM imidazole) and the bound protein was eluted in elution buffer (150 mM KCl,
50mM HEPES pH7.5, 1 mM BME, 500 mM imidazole). The desalting columns were preequilibrated with the B buffer without Imidazole. The concentrations of all the recombinant
proteins were determined by Bradford assay. The pull down assays in Figure A2-4B and C were
performed using His-tagged human or yeast cyclin C respectively as bait and GST-tagged
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Med13742-844 (DS30) as target. 500nM cyclin C was mixed with 1uM of Med13742-844 in a final
reaction volume of 250 µL with B buffer and incubated for 1hr at room temperature. Bound
protein was precipitated with 100 µL of washed Talon beads and eluted using 500mM imidazole.
The protein mixture was resolved using SDS-PAGE and Western blotting with either anti-GST
(Abcam), anti-His (Bethal) or anti human cyclin C antibodies (Bethal). Controls with only the
target protein and no bait protein were included in all the experiments. The pull down assays in
Figure A2-4D were performed using 500 nM of either GST, GST-tagged yeast cyclin C and
1µM 6His-Med13571-660 (DS22). The proteins were incubated together in GST lysis buffer and
incubated at RT for 1hr. Then 100uL of GSH beads (pre-equilibrated with GST wash/lysis
buffer) was added to the protein mixture and incubated with rotation for 1hr. The beads were
centrifuged for 30sec washed twice with 500uL of GST wash/lysis buffer. The protein mixture
was resolved using SDS-PAGE and Western blotting with either anti-GST or anti-His antibodies
The in vitro kinase assays were executed basically as described [75]. Slt2-HA and
Slt2K54R-HA kinases were immunoprecipitated from cells treated with 5mM sodium
orthovanadate for 60 minutes which activates Slt2 [263]. In short, yeast extracts harboring the
respective plasmids were made by resuspending cells in lysis buffer (20 mM HEPES, 10 mM
KCl, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid [EGTA], 50 mM NaCl, 10% glycerol,
1 mM β-mercaptoethanol, cOmplete Protease Inhibitor Cocktail Tablet, pH 7.4, with
phosphatase inhibitors for Cdk8-HA purification) and protein immunoprecipitation was
conducted as previously described [75]. with anti-HA magnetic beads (PierceTM)/ anti-myc
magnetic beads (Cell Signaling). Med13571-906 was purified from E. coli BL21 DE3 strain
induced with 0.5 mM IPTG for 5 hours at 37ºC using 6X His-tagged purification method
previously described [75]. The Slt2 in vitro kinase assay was conducted as previously described
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[264] by resuspending Slt2 beads in kinase buffer (20 mM HEPES, 10 mM MgCl2, 100 μM
Na3VO4, pH 7.5), with 20uM ATP, 5 uCi of 32P-ATP and purified Med13571-907. Reactions were
incubated at 30ºC for 30 minutes.
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A2.9 Supplementary materials
Supplemental Table A2-1 Yeast strains used in this study
Strain
RSY10

Genotype*
-

Source
[201]

RSY1006

slt2∆::his5+

[228]

RSY1696

cnc1∆::KANMX6

[208]

RSY1701

med13∆::HIS3

[154]

RSY1706

med13∆:: KANMX6

[154]

RSY1726

cdk8∆:: KANMX6

[154]

RSY1736

kdx1∆::KANMX6

RSY1737

kdx1∆::KANMX6 slt2∆::his5

RSY1798

Med13-myc::KANMX4

[154]

RSY1770

grr1∆::his5+

This study

RSY1771

grr1∆::his5+ MED13-13Myc:: KANMX6

This study

RSY1787

Med12-myc::KANMX4

This study

RSY2066

PTetO7-Ubi-Ile::3HA-Cdk8::NatMX4

This study

PJ69-4a

LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ gal4∆

[131]
[131]

+

[166]

gal80∆
*Genotype of all strains is MATa ade2 ade6 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 except PJ69-4alpha
which is MATa trp1-901 leu2- 3,112 ura3-52 his3-200 gal4∆ gal80∆
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Supplemental Table A2-2 Plasmids used in this study.
Plasmid
Name

Gene

Epitope
Tag

Marker

pBK38

CNC1

GFP

URA3

ADH1

CEN

[129]

pKC337

CNC1

1myc

TRP1

ADH1

CEN

[126]

pKC800

GAL4AD-MED13

1HA

LEU2

ADH1

CEN

This study

pKC801

MED13

3HA

URA3

ADH1

CEN

This study

pKC802

MED13T210A

3HA

URA3

ADH1

CEN

This study

pKC803

MED13

3HA

LEU2

ADH1

CEN

This study

pLR106

BCK1-20

None

HIS3

ADH1

CEN

[228]

pLR141

CNC1

1 myc

URA

ADH1

2µ

This study

pLR166

CNC1S266A

1 myc

TRP1

ADH1

CEN

[131]

pDS2

GAL4AD -MED131-305

1HA

LEU2

ADH1

CEN

This study

pDS4

GAL4AD-MED13907-1421

1HA

LEU2

ADH1

CEN

This study

pDS5

GAL4AD-MED13306-906

1HA

LEU2

ADH1

CEN

This study

pDS6

GAL4AD-MED131-906

1HA

LEU2

ADH1

CEN

This study

pDS7

GAL4AD-MED13306-570

1HA

LEU2

ADH1

CEN

This study

pDS8

GAL4AD-MED13571-906

1HA

LEU2

ADH1

CEN

This study

pDS10

6HIS- MED13571-906

-

-

-

pDS15

GAL4AD-MED13571-650

1HA

LEU2

ADH1

CEN

This study

pDS16

GAL4AD-MED13651-906

1HA

LEU2

ADH1

CEN

This study

pDS30

GST-MED13742-844

GST

-

-

-

This study

pDS22

6His-MED13571-650

6His

-

-

-

This study

pDS32

GAL4AD-MED13742-844

1HA

LEU2

ADH1

2µ

This study

pDS33

GAL4AD-MED13742-844 S748A

1HA

LEU2

ADH1

2µ

This study

pDS34

GAL4AD-MED13742-844 T781A

1HA

LEU2

ADH1

2µ

This study

pDS36

GAL4AD-MED13742-844 T835A,

1HA

LEU2

ADH1

2µ

This study

pDS40

GAL4AD-MED13742-844 T801A

1HA

LEU2

ADH1

2µ

This study

pDS41

GAL4AD-MED13742-844 T781A,

1HA

LEU2

ADH1

2µ

This study

pDS42

GAL4AD-MED13742-844 S748A,

1HA

LEU2

ADH1

2µ

This study

T837A

T801A

T781A

Promoter

2µ/ CEN/

Reference

int
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This study

pSW108

hCCNC1-GAL4BD

1HA

TRP1

ADH1

2µ

This study

GSTyCNC1

GST-yCNC1

GST

-

-

-

[259]

6HishCNC1

6His-hCNC1

6His

-

-

-

This study

6His-

6His-yCNC1

6His

-

-

-

This study

pACT2

GAL4AD

1HA

LEU2

ADH1

CEN

[211]

pAS2

GAL4BD

1HA

TRP

ADH1

CEN

[211]

pAS2-Grr1

GAL4BD-GRR1

1HA

TRP

ADH1

CEN

[168]

pAS2Grr1∆L

GAL4BD-GRR1∆L-

1HA

TRP

ADH1

CEN

[168]

pGrr1

Grr1

1HA

TRP

ADH1

[221]

pGrr1∆L

Grr1∆L

1HA

TRP

ADH1

[221]

Mt-dsRed

Mito-targeting

dsRed

URA3

ADH1

CEN

[265]

pHY1022

MED13

3HA

URA3

ADH1

2µ

[229]

pHY1089

MED13S608A,S1236A

3HA

URA3

ADH1

2µ

[229]

Slt2

SLT2

3HA

LEU2

SLT2

2µ

[149]

Slt2K54R

SLT2K54R

3HA

LEU2

SLT2

2µ

[149]

pCM188

TET

-

URA3

ADH1Tet02

CEN

[257]

pMK634

Ubi-lLe-3HA

NATMX4

ADH1

Int.

[234]
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Figure A2-S1 The human Fbw7 degron on Med13 is not required for Med13 degradation (A) RSY1771
(grr1∆::HIS3 MED13-myc::KAN) harboring either ADH1PRO-GRR1 or a vector control were treated with 0.4 mM
H2O2 for the timepoints indicated and Med13 levels analyzed by Western blot. Tub1 levels were used as loading
controls. (B) Conservation of the human Med13 SCFFbw7 degron in yeast. (C) Degradation of Med13-HA after
treatment of the cells with cycloheximide. Wild type cells (RSY10) harboring Med13-HA (pKC801) were treated
with cycloheximide as previously described [131] and Med13-HA degradation analyzed as described. Pgk1 was
used as a loading control. (D) med13∆ cells (RSY1701) harboring Med13T210A as the only copy of Med13 were
treated with 0.4 mM H2O2 for the timepoints indicated and Med13 levels analyzed by Western blot. Tub1 levels
were used as a loading control. (E) Quantification of Med13-HA degradation from C and D.
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Figure A2-S2 Fluorescence microscopy of mid-log phase med13∆ cells (Y1701) harboring the GalAD-Med13 fusion
constructs shown and cyclin C-YFP (pBK38) Cells were stained with Dapi to visualize the nucleus. Bar = 10µM
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Figure A2-S3 PKA mediated phosphorylation of Med13 is not required for its degradation following H2O2 stress
(A) Wild type (RSY10) cultures expressing either PHY1066 (2µ Med13-HA) or PHY2081 (2µ Med13-HA plasmid
with PKA sites, S608 and S1236 mutated to alanine) were grown to mid-log phase (0 hr) then treated with 0.4 mM
for the indicated times. Med13-HA levels were determined by Western blot analysis. Tub1 levels were used as a
loading control. (B) The Med13S808A, S1236A mutant complements med13∆ mitochondrial morphology. med13∆
cells (RSY1701) expressing either PHY1066, PHY2081 or a vector and the DsRed mitochondrial targeting plasmid
(mt-DsRed) were grown to mid-log. Mitochondrial morphology was examined using fluorescence microscopy of
living cells. The left hand panel shows representative images of reticular or fragmented mitochondria are shown. Bar
= 10µM. The percent of cells (mean ± s.e.m.) within the population displaying mitochondrial fission is given *
p<0.05 difference from wild type.
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Figure A2-S4 (A) Quantification of Med13-HA degradation following 0.4mM H2O2 stress for the experiments
shown in Figure A2-6 (A) and Figure A2-7 (B) (C) Wild type (RSY10) cultures harboring either wild type Gal4ADMed13742-844 or the various point mutations indicated were grown to mid-log phase (0 hr) then treated with 0.4 mM
H2O2 for the indicated times. Med13-HA levels were determined by Western blot analysis. Tub1 levels were used as
a loading control. (D) Med12 is not destroyed in H2O2 stress. A strain harboring endogenous Med12-myc
(RSY1787) was treated with 0.4 mM H2O2 for the timepoints indicated and Med12 levels analyzed by Western blot.
Tub1 levels were used as loading controls.
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Figure A2-S5 (A) IUPred and ANCHOR plot analysis of Med13 These programs generates a plot with the profiles
calculated by IUPred [242], a general disorder prediction method (in red), and ANCHOR [243], a prediction of
disordered binding regions (in blue). Underneath the profile, predicted binding regions are indicated by the
horizontal bars. The bar is shaded according to the prediction score. Regions that are filtered out are marked by
empty bars. Grr1 and cyclin C binding domains identified in this work are also shown. In addition, the domain of
Med13 that does not interact with cyclin C is marked as well as the CCR4-NOT4 complex and TFIIS interaction
domains [245, 246]. (B) Phyre2 [244] plot analysis of yeast Med13.
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